Bicyclic peptide ligands specific for EPHA2
By developing bicyclic polypeptide ligand and drug conjugates specific to EphA2, the bleeding events and coagulation system impact of existing anti-EphA2 drugs were solved, and effective inhibition of overexpression of EphA2 in tumors and safe anti-tumor treatment was achieved.
Patent Information
- Application Number
- CN202410970988.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-14
- Filing Date
- 2018-12-19
- Publication Date
- 2024-11-08
AI Technical Summary
Existing anti-EphA2 drugs have bleeding events and coagulation system effects in clinical applications, and it is difficult to effectively inhibit the diseases caused by overexpression of EphA2 in tumors.
A polypeptide ligand containing EphA2 specific for this polypeptide ligand forms a covalent bond with cysteine residues through non-aromatic molecular scaffolds, forms a bicyclic structure, and binds to drug conjugates for prevention Or treat diseases related to overexpression of EphA2 in tumors.
The bicyclic drug conjugate showed high antitumor activity, was able to significantly inhibit tumor growth, and did not cause bleeding events or changes in coagulation parameters in animal models, providing a safe and effective treatment regimen.
Smart Images

Figure BDA0004953201500000141 
Figure BDA0004953201500000142 
Figure BDA0004953201500000151
Abstract
Description
Technical Field
[0001] The present invention relates to polypeptides covalently bound to a non-aromatic molecular scaffold such that two or more peptide loops are subtended between the points of attachment to the scaffold. Specifically, the present invention describes peptides that are high-affinity binders of Eph receptor tyrosine kinase A2 (EphA2). The present invention also includes drug conjugates comprising the peptide conjugated to one or more effectors and / or functional groups, pharmaceutical compositions comprising the peptide ligand and the drug conjugate, and the use of the peptide ligand and the drug conjugate in preventing, inhibiting or treating a disease or condition characterized by overexpression of EphA2 in diseased tissues (e.g., tumors). Background Art
[0002] Cyclic peptides can bind to protein targets with high affinity and target specificity, and are therefore an attractive class of molecules for the development of therapeutics. In fact, several cyclic peptides have been successfully used clinically, such as the antimicrobial peptide vancomycin, the immunosuppressant drug cyclosporin or the anticancer drug octreotide (Driggers et al. (2008), Nat Rev Drug Discov 7 (7), 608-24). The good binding properties come from the relatively large interaction surface formed between the peptide and the target and the reduced conformational flexibility of the cyclic structure. Typically, macrocycles bind to surfaces of hundreds of square angstroms, such as the cyclic peptide CXCR4 antagonist CVX15 ( Wu et al. (2007), Science 330, 1066-71), Cyclic peptide with Arg-Gly-Asp motif that binds to integrin αVb3 (Xiong et al. (2002), Science 296(5565), 151-5), or the cyclic peptide inhibitor upain-1 ( Zhao et al. (2007), J Struct Biol 160(1), 1-10).
[0003] Due to their cyclic configuration, peptide macrocycles are less flexible than linear peptides, resulting in less entropic loss when binding to a target and resulting in higher binding affinity. Reduced flexibility also results in locking of a target-specific conformation, increasing binding specificity compared to linear peptides. This effect has been exemplified by a potent, selective inhibitor of matrix metalloproteinase 8 (MMP-8) that loses selectivity for other MMPs when its ring is opened (Cherney et al. (1998), J Med Chem 41 (11), 1749-51). The favorable binding properties obtained by macrocyclization are more pronounced in polycyclic peptides having more than one peptide ring, such as in vancomycin, nisin, and actinomycin.
[0004] Different research groups have previously attached polypeptides with cysteine residues to synthetic molecular structures (Kemp and McNamara (1985), J. Org. Chem; Timmerman et al. (2005), ChemBioChem). Meloen and colleagues have used tri(bromomethyl)benzene and related molecules to rapidly and quantitatively cyclize multiple peptide rings to synthetic scaffolds for structural mimicry of protein surfaces (Timmerman et al. (2005), ChemBioChem). Methods for producing candidate drug compounds are disclosed, wherein the compounds are produced by attaching cysteine-containing polypeptides to molecular scaffolds such as TATA (1,1',1"-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one, Heinis et al. Angew Chem, Int Ed. 2014; 53:1602-1606).
[0005] Combinatorial methods based on phage display have been developed to generate and screen large libraries of bicyclic peptides against target targets (Heinis et al. (2009), Nat Chem Biol 5(7), 502-7 and WO2009 / 098450). Briefly, a combinatorial library of linear peptides containing two regions of three cysteine residues and six random amino acids (Cys-(Xaa)6-Cys-(Xaa)6-Cys) is displayed on phage and cyclized by covalently linking the cysteine side chains to a small molecule scaffold. Summary of the invention
[0006] According to a first aspect of the present invention, a peptide ligand specific for EphA2 is provided, which comprises a polypeptide and a non-aromatic molecular scaffold, wherein the polypeptide comprises at least three cysteine residues separated by at least two ring sequences, and the non-aromatic molecular scaffold forms a covalent bond with the cysteine residues of the polypeptide, so that at least two polypeptide rings are formed on the molecular scaffold.
[0007] According to another aspect of the present invention, there is provided a drug conjugate comprising a peptide ligand as defined herein conjugated to one or more effectors and / or functional groups.
[0008] According to another aspect of the present invention, there is provided a pharmaceutical composition comprising the peptide ligand or drug conjugate as defined herein and one or more pharmaceutically acceptable excipients.
[0009] According to another aspect of the present invention, there is provided a peptide ligand or drug conjugate as defined herein for use in preventing, inhibiting or treating a disease or disorder characterized by overexpression of EphA2 in diseased tissues (eg, tumors). BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 : Body weight changes after administration of BCY6031 to female Balb / C nude mice bearing LU-01-0046 tumors. Data points represent the mean body weight of the group.
[0011] Figure 2 : Tumor volume tracking after administration of BCY6031 to female Balb / C nude mice bearing LU-01-0046 tumors. Data points represent the mean of the groups. Treatment was stopped from day 28.
[0012] Figure 3 : General schematic diagram showing the concept of preparing bicyclic drug conjugates (BDCs).
[0013] Figure 4 : A plot of mean tumor volume versus time of BCY6136 in HT1080 xenograft mice. Doses (2, 3, and 5 mg / kg) were administered on days 0 and 7. The upper right inset shows changes in body weight during treatment, indicating tumor burden, drug-related toxicology, and overall animal health.
[0014] Figure 5 : A graph of mean tumor volume versus time of BCY6136 in NCI-H1975 xenograft mice. Doses (1, 2, and 3 mg / kg) were administered on days 0, 7, 14, 21, 28, and 35. The upper right inset shows changes in body weight during treatment, indicating tumor burden, drug-related toxicology, and overall animal health.
[0015] Figure 6 : A graph of the time of mean tumor volume and BCY6136 in MDA-MB-231 xenograft mice. Doses (1, 2 and 3 mg / kg) were administered on days 0, 7, 14, 21, 28, 35 and 45. The upper right inset shows changes in body weight during treatment, indicating tumor load, drug-related toxicology and overall animal health.
[0016] Figures 7 to 9 : BCY6136 ( Figure 7 )、ADC( Figure 8 ) and BCY6033( Fig. 9 ) were followed for body weight changes and tumor volumes. Data points represent the mean body weight of the groups.
[0017] Fig.10 : Body weight changes and tumor volume tracking after administration of BCY6136, EphA2-ADC or Docetaxel to male Balb / c nude mice bearing PC-3 xenografts. Data points represent the mean body weight of the groups.
[0018] Figures 11 to 13 : BCY6033 ( Fig.11 )、BCY6136( Fig.12 ) and BCY6082( Fig.13 ) were followed for changes in body weight and tumor volume. Data points represent the mean tumor volume and body weight of the groups.
[0019] Fig.14 and Fig.15 : Body weight change and tumor volume tracking after administration of BCY6136 and ADC to female Balb / c nude mice bearing LU-01-0251 xenografts. Data points represent the mean body weight of the group.
[0020] Fig.16 : Body weight change and tumor volume tracking after administration of BCY6033, BCY6136, BCY6082 and BCY6031 to female Balb / c nude mice bearing LU-01-0046. Data points represent the mean body weight of the group.
[0021] Fig.17 : Body weight change and tumor volume tracking after administration of BCY6136 or ADC to female Balb / c nude mice bearing LU-01-0046 NSCLC PDX. Data points represent the mean body weight of the group.
[0022] Figures 18 to 22 : BCY6033 ( Fig.18 )、BCY6136( Fig.19 )、BCY6082( Fig. 20 )、BCY6173( Fig.21 ) and BCY 6175 and 6031( Fig. 22 ) were followed for body weight changes and tumor volumes. Data points represent the mean body weight of the groups.
[0023] Fig.23 : BCY6136 was administered to female BALB / c nude mice bearing LU-01-0412 xenografts ( Fig.23 Body weight changes and tumor volume were followed after treatment with BCY8245 or BCY8781. Data points represent the mean tumor volume (left panel) and body weight (right panel) of the groups.
[0024] Fig.24 : Body weight change and tumor volume tracking after administration of BCY6136 to female Balb / c nude mice bearing LU-01-0486 xenografts. Data points represent the mean body weight of the group.
[0025] Figure 25 to Figure 27 : BCY6033 ( Fig.25 )、BCY6136( Fig.26 ) and BCY6082( Fig. 27 ) were followed for changes in body weight and tumor volume. Data points represent the mean tumor volume and body weight of the groups.
[0026] Fig.28 : Body weight change and tumor volume tracking after administration of BCY6136 to female BALB / c mice carrying EMT-6 syngeneic genes. Data points represent the mean body weight of the group. From day 14, the dose of groups 3 and 4 was changed to 5 mpk and 3 mpk.
[0027] Fig.29 : Body weight change and tumor volume tracking after administration of BCY6136 to female Balb / c nude mice bearing NCI-N87 xenografts. Data points represent the mean body weight of the group.
[0028] Fig.30 : Body weight change and tumor volume tracking after administration of BCY6136 to female Balb / c nude mice bearing SK-OV-3 xenografts. Data points represent the mean body weight of the group.
[0029] Fig.31 : Body weight change and tumor volume tracking after administration of BCY6136 to female Balb / c nude mice bearing OE21 xenografts. Data points represent the mean body weight of the group.
[0030] Fig.32 : Body weight change and tumor volume tracking after administration of BCY6136 to female CB17-SCID mice bearing MOLP-8 xenografts. Data points represent the mean body weight of the group.
[0031] Fig.33 : Body weight change and tumor volume tracking after administration of BCY6082 to female CB17-SCID mice bearing MOLP-8 xenografts. Data points represent the mean body weight of the group.
[0032] Figures 34 to 42 : BCY6082 ( Fig.34 )、BCY6031( Fig.35 )、BCY6173( Fig.36 )、BCY6135( Fig.37 )、BCY6033( Fig.38 )、BCY6136( Fig.39 )、BCY6174( Fig.40)、BCY6175( Fig.41 ) and ADC( Fig.42 ) were followed for body weight changes and tumor volumes. Data points represent the mean body weight of the groups.
[0033] Error bars are shown in the upper graph and represent the standard error of the mean (SEM). DETAILED DESCRIPTION
[0034] In one embodiment, the loop sequence comprises 2, 3, 5, 6 or 7 amino acids.
[0035] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, one consisting of 2 amino acids and the other consisting of 7 amino acids (such as those listed in Table 4).
[0036] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences each consisting of 5 amino acids (eg, those listed in Tables 3 and 4).
[0037] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, each consisting of 6 amino acids (eg, those listed in Tables 3 to 5).
[0038] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, wherein both loop sequences consist of 6 amino acids (such as those listed in Table 10).
[0039] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, one of which consists of 7 amino acids and the other of which consists of 3 amino acids (such as those listed in Table 4).
[0040] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, one of which consists of 6 amino acids and the other of which consists of 7 amino acids (such as those listed in Table 5).
[0041] In one embodiment, the peptide ligand comprises an amino acid sequence selected from the group consisting of:
[0042] C i -X1-C ii -X2-C iii
[0043] wherein X1 and X2 represent amino acid residues between the cysteine residues listed in Tables 3 to 5, C i , C iiand C iii represent the first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.
[0044] In another embodiment, the peptide ligand comprises an amino acid sequence selected from one or more peptide ligands listed in one or more of Tables 3 to 5.
[0045] In another embodiment, the peptide ligand comprises an amino acid sequence selected from the group consisting of:
[0046] C i -X1-C ii -X2-C iii
[0047] wherein X1 and X2 represent amino acid residues between the cysteine residues listed in Table 10, C i , C ii and C iii represent the first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.
[0048] In another embodiment, the peptide ligand comprises an amino acid sequence selected from one or more peptide ligands listed in Table 10.
[0049] In one embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 6 amino acids, and the peptide ligand has an amino acid sequence selected from the group consisting of:
[0050] C i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 1); and
[0051] C i PLVNPLC ii LHPGWTC iii (SEQ ID NO: 97);
[0052] HyP is hydroxyproline, HArg is homoarginine, C i , C ii and C iii represent the first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.
[0053] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 6 amino acids, and the peptide ligand has the following amino acid sequence:
[0054] C i(HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 1);
[0055] HyP is hydroxyproline, HArg is homoarginine, C i , C ii and C iii represent the first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.
[0056] In one embodiment, the peptide ligand of the invention is a peptide ligand other than the following amino acid sequence:
[0057] C i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 1).
[0058] In one embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 6 amino acids, and the peptide ligand has an amino acid sequence selected from the group consisting of:
[0059] (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 2) (BCY6099; Compound 66); and
[0060] (β-Ala)-Sar 10 -A(HArg)DC i PLVNPLC ii LHPGWTC iii ((β-Ala)-Sar 10 -(SEQ ID NO: 11))(BCY6014; Compound 67);
[0061] Among them, Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline.
[0062] In another embodiment, the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 6 amino acids, and the peptide ligand has the following amino acid sequence:
[0063] (β-Ala)-Sar 10 -A(HArg)DCi (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 2) (BCY6099; Compound 66);
[0064] Among them, Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline.
[0065] In one embodiment, the peptide ligand of the invention is a peptide ligand other than the following amino acid sequence:
[0066] (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 2) (BCY6099; Compound 66).
[0067] In one embodiment, the molecular scaffold is selected from 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA), and the peptide ligand is selected from any one of the peptide ligands listed in Tables 3 to 5.
[0068] In an alternative embodiment, the molecular scaffold is selected from 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA), and the peptide ligand is selected from any one of the peptide ligands listed in Table 10.
[0069] In one embodiment, the molecular scaffold is selected from 1,1',1"-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA), and the peptide ligand is selected from:
[0070] (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii
[0071] (SEQ ID NO: 2) (BCY6099; Compound 66); and
[0072] (β-Ala)-Sar 10 -A(HArg)DC i PLVNPLC ii LHPGWTC iii ((β-Ala)-Sar10 -(SEQ ID NO: 11))(BCY6014; Compound 67);
[0073] Among them, Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline.
[0074] In another embodiment, the molecular scaffold is selected from 1,1',1"-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA), and the peptide ligand is:
[0075] (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 2); wherein Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline.
[0076] In one embodiment, the peptide ligand is selected from any one of Compounds 1-113 or a pharmaceutically acceptable salt thereof.
[0077] In another embodiment, the peptide ligand is Compound 66 (BCY6099) or Compound 67 (BCY6014) or a pharmaceutically acceptable salt thereof.
[0078] In another embodiment, the peptide ligand is Compound 66 (BCY6099) or a pharmaceutically acceptable salt thereof.
[0079] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art, e.g., in the fields of peptide chemistry, cell culture and phage display, nucleic acid chemistry, and biochemistry. Standard techniques are used for molecular biology, genetic, and biochemical methods (see Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al., Short Protocols in Molecular Biology (1999) 4th edition, John Wiley & Sons, Inc.), which are incorporated herein by reference.
[0080] Nomenclature
[0081] serial number
[0082] When referring to amino acid residue positions within the peptides of the invention, cysteine residues are omitted from the numbering since they are invariant (C i , C ii and C iii ), therefore, the numbering of the amino acid residues in the peptides of the present invention is as follows:
[0083] -C i -HyP1-L2-V3-N4-P5-L6-C ii -L7-H8-P9-(D-Asp) 10 -W 11 -(HArg) 12 -C iii - (SEQ ID NO: 1).
[0084] For the purposes of this description, it is assumed that all bicyclic peptides are cyclized with 1,1',1"-(1,3,5-triazinane-1,3,5-triyl)tripropan-2-en-1-one (TATA) to produce a trisubstituted 1,1',1"-(1,3,5-triazinane-1,3,5-triyl)tripropan-1-one structure. Cyclization with TATA occurs at C i , C ii and C iii superior.
[0085] Molecular form
[0086] The N- or C-terminal extension of the bicyclic core sequence is added to the left or right side of the sequence and separated by a hyphen. For example, N-terminal (β-Ala)-Sar 10 The -Ala tail will be represented as:
[0087] (β-Ala)-Sar 10 -A- (SEQ ID NO: X).
[0088] Reverse peptide sequence
[0089] According to Nair et al. (2003) J Immunol 170 (3), 1362-1373, it is envisaged that the peptide sequences disclosed herein will also be used in their inverse form. For example, the order is reversed (i.e., the N-terminus becomes the C-terminus and vice versa) and their stereochemistry is also inverted (i.e., D-amino acids become L-amino acids and vice versa).
[0090] Peptide ligand
[0091] Peptide ligands as referred to herein refer to peptides, peptides or peptidomimetics that are covalently bound to a molecular scaffold. Typically, such peptides, peptides or peptidomimetics include peptides with natural or non-natural amino acids, two or more reactive groups (i.e., cysteine residues) that can form covalent bonds with the scaffold, and sequences (referred to as loop sequences) relative to the reactive groups, which are referred to as loop sequences because when the peptide, peptide or peptidomimetics are bound to the scaffold, they form a ring. In the case of the present application, a peptide, peptide or peptidomimetics comprises at least three cysteine residues (referred to herein as C i , C ii and C iii ), which form at least two rings on the support.
[0092] Advantages of peptide ligands
[0093] Certain bicyclic peptides of the present invention have many favorable properties that make them considered as drug-like molecules suitable for injection, inhalation, nasal, ocular, oral or topical administration. These favorable properties include:
[0094] - Species cross-reactivity. This is a typical requirement for preclinical efficacy and pharmacokinetic evaluations;
[0095] - Protease stability. The bicyclic peptide ligands should in most cases show stability against plasma proteases, epithelial ("membrane-anchored") proteases, gastric and intestinal proteases, lung surface proteases, intracellular proteases, etc. Protease stability should be maintained across species so that bicyclic peptide lead candidates can be developed in animal models and reliably administered to humans;
[0096] - Ideal solubility profile. This is a function of the ratio of charged hydrophilic residues to hydrophobic residues and intra / inter-molecular H-bonds, which is important for formulation and absorption purposes;
[0097] - Optimal plasma half-life in circulation. Depending on the clinical indication and treatment regimen, it may be desirable to develop bicyclic peptides with short or prolonged in vivo exposure times to manage chronic or acute disease states. The optimal exposure duration depends on the requirement for sustained exposure (to achieve maximum therapeutic efficacy) versus the requirement for short exposure (to minimize toxicological effects due to sustained exposure to the agent);
[0098] - Selectivity. Certain peptide ligands of the present invention show good selectivity for other Eph receptor tyrosine kinases such as EphA1, EphA3, EphA4, EphA5, EphA6, EphA7 and EphB1 and factor XIIA, carbonic anhydrase 9 and CD38 (selectivity data for selected peptide ligands of the present invention can be found in Tables 7 and 14). It should also be noted that the selected peptide ligands of the present invention show cross-reactivity with other species (e.g., mice and rats) to allow testing in animal models (Tables 3 to 6 and 15); and
[0099] -Safety. Bleeding events have been reported in preclinical in vivo models and clinical trials using EphA2 antibody-drug conjugates. For example, a Phase 1 open-label study using MEDI-547 was suspended due to bleeding and coagulation events in 5 of 6 patients (Annunziata et al., Invest New Drugs (2013) 31: 77-84). The bleeding events observed in patients are consistent with the effects on the coagulation system observed in preclinical studies in rats and monkeys: increased activated partial thromboplastin time and increased fibrinogen / fibrin degradation products (Annunziata et al., IBID). Significant bleeding events were reported in toxicology studies in monkeys (Annunziata et al., IBID). Together, these results suggest that MEDI-547 causes disseminated intravascular coagulation (DIC) in preclinical species and patients. The BDC reported herein has a short in vivo half-life (<30 minutes) and is therefore inherently unlikely to cause DIC in patients. The results presented herein (see Biological Data Sections 5 and 6 and Table 20) demonstrate that selected bicyclic drug conjugates of the present invention have no effect on coagulation parameters and did not cause bleeding events in preclinical studies.
[0100] Pharmaceutically acceptable salts
[0101] It will be understood that salt forms are within the scope of the present invention and reference to a peptide ligand includes salt forms of the ligand.
[0102] The salts of the present invention can be synthesized from parent compounds containing a base or acid moiety by conventional chemical methods, such as those described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (ed.), Camille G. Wermuth (ed.), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. Typically, these salts can be prepared by reacting the free acid or base forms of these compounds with an appropriate base or acid in water or in an organic solvent or in a mixture of the two.
[0103] Acid addition salts (mono or di-salts) can be formed with various acids (inorganic and organic). Examples of acid addition salts include mono or di-salts formed with acids selected from the group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfonic acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactonic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (e.g., D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-oxoglutaric acid, ethanol Acid, hippuric acid, hydrohalic acid (such as hydrobromic acid, hydrochloric acid, hydroiodic acid), isethionic acid, lactic acid (such as (+)-L-lactic acid, (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, pyruvic acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid and valeric acid, as well as acylated amino acids and cation exchange resins.
[0104] One group of specific salts includes salts formed from acetic acid, hydrochloric acid, hydroiodic acid, phosphoric acid, nitric acid, sulfuric acid, citric acid, lactic acid, succinic acid, maleic acid, malic acid, isethionic acid, fumaric acid, benzenesulfonic acid, toluenesulfonic acid, sulfuric acid, methanesulfonic acid (mesylate), ethanesulfonic acid, naphthalenesulfonic acid, valeric acid, propionic acid, butyric acid, malonic acid, glucuronic acid and lactobionic acid. One specific salt is hydrochloride. Another specific salt is acetate.
[0105] If the compound is anionic or has a functional group that can be anionic (e.g., -COOH can be -COO - ), then a salt may be formed with an organic or inorganic base that generates an appropriate cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Li + 、Na + and K + , alkaline earth metal cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ or Zn + Examples of suitable organic cations include, but are not limited to, ammonium ions (i.e., NH4 + ) and substituted ammonium ions (e.g., NH3R+ NH2R2 + 、NHR3 + NR4 + ). Some examples of suitable substituted ammonium ions are those derived from methylamine, ethylamine, diethylamine, propylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH3)4 + .
[0106] When the peptides of the present invention contain amine functional groups, they can form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to those skilled in the art. Such quaternary ammonium compounds are within the scope of the peptides of the present invention.
[0107] Modified derivatives
[0108] It should be understood that modified derivatives of the peptide ligands as defined herein are within the scope of the present invention. Examples of such suitable modified derivatives include one or more modifications selected from the following: N-terminal and / or C-terminal modification; replacement of one or more amino acid residues with one or more non-natural amino acid residues (e.g., replacement of one or more polar amino acid residues with one or more isosteric or isoelectronic amino acids; replacement of one or more non-polar amino acid residues with other non-natural isosteric or isoelectronic amino acids); addition of spacer groups; replacement of one or more oxidation-sensitive amino acid residues with one or more oxidation-resistant amino acid residues; replacement of one or more amino acid residues with one or more replacement amino acids (e.g., alanine), replacement of one or more L-amino acid residues with one or more D-amino acid residues; N-alkylation of one or more amide bonds in the bicyclic peptide ligand; replacement of one or more surrogate bonds (surrogate bonds); replacement of one or more amino acid residues with one or more surrogate bonds (surrogate bonds); replacement of ... bond); peptide backbone length modification; substitution of a hydrogen on the α-carbon of one or more amino acid residues with another chemical group, modification of amino acids such as cysteine, lysine, glutamate / aspartate and tyrosine with suitable amine, thiol, carboxylic acid and phenol reactive reagents to functionalize the amino acids, and introduction or replacement of amino acids to introduce orthogonal reactivity suitable for functionalization, for example, amino acids carrying azide or alkyne groups allow functionalization with alkyne or azide bearing moieties, respectively.
[0109] In one embodiment, the modified derivative comprises an N-terminal and / or C-terminal modification. In a further embodiment, wherein the modified derivative comprises an N-terminal modification using a suitable amino-reactive chemistry, and / or a C-terminal modification using a suitable carboxyl-reactive chemistry. In a further embodiment, the N-terminal or C-terminal modification comprises the addition of an effector group, including but not limited to a cytotoxic agent, a radiochelator, or a chromophore.
[0110] In a further embodiment, the modified derivative comprises an N-terminal modification. In a further embodiment, the N-terminal modification comprises an N-terminal acetyl group. In this embodiment, during peptide synthesis, the N-terminal residue is blocked by acetic anhydride or other suitable reagents to produce an N-terminal acetylated molecule. This embodiment provides the advantage of removing the potential recognition site of aminopeptidase and avoiding the possibility of bicyclic peptide degradation.
[0111] In an alternative embodiment, the N-terminal modification comprises the addition of a molecular spacer group that facilitates the conjugation of the effector group and maintains the potency of the bicyclic peptide to its target.
[0112] In a further embodiment, the modified derivative comprises a C-terminal modification. In a further embodiment, the C-terminal modification comprises an amide group. In this embodiment, the C-terminal residue is synthesized as an amide during peptide synthesis, producing a C-terminal amidated molecule. This embodiment provides the advantage of removing the potential recognition site of carboxypeptidase and reducing the proteolytic degradation possibility of the bicyclic peptide.
[0113] In one embodiment, the modified derivative comprises replacing one or more amino acid residues with one or more non-natural amino acid residues. In this embodiment, non-natural amino acids can be selected that have isosteric / isoelectronic side chains that are not recognized by degradative proteases and do not produce any side effects on target efficacy.
[0114] Alternatively, unnatural amino acids with constrained amino acid side chains can be used so that proteolysis of adjacent peptide bonds is conformationally and sterically hindered. Specifically, these involve proline analogs, bulky side chains, C -disubstituted derivatives (eg, aminoisobutyric acid, Aib), and cyclic amino acids, simple derivatives of amino-cyclopropylcarboxylic acids.
[0115] In one embodiment, the modified derivative comprises the addition of a spacer group. In a further embodiment, the modified derivative comprises the addition of a spacer group to the N-terminal cysteine (C i ) and / or C-terminal cysteine (C iii )Add a spacer group.
[0116] In one embodiment, the modified derivative comprises replacing one or more oxidation-sensitive amino acid residues with one or more oxidation-tolerant amino acid residues. In a further embodiment, the modified derivative comprises replacing a tryptophan residue with naphthylalanine or an alanine residue. This embodiment provides the advantage of improving the drug stability spectrum of the resulting bicyclic peptide ligand.
[0117] In one embodiment, the derivative of modification comprises replacing one or more charged amino acid residues with one or more hydrophobic amino acid residues. In an alternative embodiment, the derivative of modification comprises replacing one or more hydrophobic amino acid residues with one or more charged amino acid residues. The correct balance of charged amino acid residues and hydrophobic amino acid residues is an important feature of bicyclic peptide ligands. For example, hydrophobic amino acid residues affect the degree of plasma protein binding, therefore affecting the concentration of available free fractions in blood plasma, and charged amino acid residues (specifically arginine) can affect the interaction of peptide with the phospholipid membrane on the cell surface. Both combinations can affect the half-life, distribution volume and exposure of peptide drugs, and can be adjusted according to clinical endpoints. In addition, the correct combination and quantity of charged amino acid residues and hydrophobic amino acid residues can reduce the stimulation of injection site (if peptide drugs have been subcutaneously administered).
[0118] In one embodiment, the modified derivative comprises replacing one or more L-amino acid residues with one or more D-amino acid residues. This embodiment is believed to increase proteolytic stability by steric hindrance and stabilize the protein by the tendency of D-amino acids to -Conformation of the turn (Tugyi et al. (2005) PNAS, 102(2), 413-418).
[0119] In one embodiment, the modified derivatives include removal of any amino acid residues and substitution with alanine (eg, D-alanine).This embodiment provides the advantage of identifying key binding residues and removing potential proteolytic attack sites.
[0120] It should be noted that each of the modifications mentioned above is used to intentionally improve the potency or stability of the peptide. Further potency improvements based on modifications can be achieved through the following mechanisms:
[0121] - Incorporation of hydrophobic moieties that exhibit a hydrophobic effect and lead to a reduced off-rate, thereby achieving higher affinity;
[0122] - incorporation of charged groups that exhibit long-range ionic interactions, resulting in faster on-rates and higher affinities (see, e.g., Schreiber et al., Rapid, electrostatically assisted association of proteins (1996), Nature Struct. Biol. 3, 427-31); and
[0123] - Incorporating additional constraints into the peptide, for example by properly constraining the side chains of the amino acids to minimize entropy loss upon target binding; constraining the torsion angles of the backbone to minimize entropy loss upon target binding; and introducing additional cyclizations into the molecule for the same reason.
[0124] (For review, see Gentilucci et al., Curr. Pharmaceutical Design, (2010), 16, 3185-203 and Nestor et al., Curr. Medicinal Chem (2009), 16, 4399-418).
[0125] Isotope variation
[0126] The present invention includes all pharmaceutically acceptable (radioactive) isotope-labeled peptide ligands of the present invention, in which one or more atoms are replaced by atoms with the same atomic number, but the atomic mass or mass number is different from the atomic mass or mass number usually found in nature, and a metal chelating group (referred to as "effector") capable of accommodating the relevant (radioactive) isotope is linked to the peptide ligand of the present invention, and certain functional groups in the peptide ligand of the present invention are covalently replaced with relevant (radioactive) isotopes or isotope-labeled functional groups.
[0127] Examples of isotopes suitable for inclusion in the peptide ligands of the present invention include isotopes of hydrogen, such as 2 H(D) and 3 H(T), isotopes of carbon, such as 11 C. 13 C and 14 C, isotopes of chlorine, such as 36 Cl, isotopes of fluorine, such as 18 F, isotopes of iodine, such as 123 I. 125 I and 131 I, isotopes of nitrogen, such as 13 N and 15 N, isotopes of oxygen, such as 15 O. 17 O and 18 O, isotopes of phosphorus, such as 32 P, isotopes of sulfur, such as 35S, isotopes of copper, such as 64 Cu, gallium isotopes, such as 67 Ga or 68 Ga, an isotope of yttrium, such as 90 Y, and isotopes of lutetium, such as 177 Lu, and isotopes of bismuth, such as 213 Bi.
[0128] Certain isotope-labeled peptide ligands of the invention, such as those incorporating radioactive isotopes, can be used for drug and / or substrate tissue distribution studies and clinical assessment of the presence and / or absence of the EphA2 target in diseased tissues. The peptide ligands of the invention may further have valuable diagnostic properties because they can be used to detect or identify the formation of complexes between labeled compounds and other molecules, peptides, proteins, enzymes or receptors. Detection or identification methods may use compounds labeled with labeling agents such as radioactive isotopes, enzymes, fluorescent substances, luminescent substances (e.g., luminol, luminol derivatives, fluorescein, luminescent proteins and luciferases), etc. The radioactive isotope tritium, i.e. 3 H(T) and carbon-14, i.e. 14 C is particularly useful for this purpose due to its ease of incorporation and convenient means of detection.
[0129] Using heavier isotopes such as deuterium (i.e. 2 Substitution of H(D)) may offer certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and thus may be preferred in some circumstances.
[0130] Using positron emitting isotopes (such as 11 C. 18 F. 15 O and 13 N) substitutions can be used in positron emission tomography (PET) studies to examine target occupancy.
[0131] Isotopically-labeled compounds of the peptide ligands of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
[0132] Non-aromatic molecular scaffolds
[0133] The term "non-aromatic molecular scaffold" referred to herein refers to any molecular scaffold as defined herein which does not contain an aromatic (ie unsaturated) carbocyclic or heterocyclic ring system.
[0134] Examples of suitable non-aromatic molecular scaffolds are described in Heinis et al. (2014) Angewandte Chemie, International Edition 53(6) 1602-1606.
[0135] As described in previous documents, the molecular scaffold may be a small molecule, such as an organic small molecule.
[0136] In one embodiment, the molecular scaffold may be a macromolecule. In one embodiment, the molecular scaffold is a macromolecule composed of amino acids, nucleotides or carbohydrates.
[0137] In one embodiment, the molecular scaffold comprises reactive groups capable of reacting with functional groups of the polypeptide to form covalent bonds.
[0138] The molecular scaffold may include chemical groups that form linkages with the peptide, such as amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, olefins, alkynes, azides, anhydrides, succinimides, maleimides, alkyl halides, and acyl halides.
[0139] An example of a compound containing an α-unsaturated carbonyl group is 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA) (Angewandte Chemie, International Edition (2014), 53(6), 1602-1606).
[0140] Effectors and functional groups
[0141] According to a further aspect of the present invention, there is provided a drug conjugate comprising a peptide ligand as defined herein conjugated to one or more effectors and / or functional groups.
[0142] Effectors and / or functional groups can be attached, for example, to the N- and / or C-terminus of a polypeptide, to amino acids within a polypeptide, or to a molecular scaffold.
[0143] Suitable effector groups include antibodies and parts or fragments thereof. For example, the effector group may include an antibody light chain constant region (CL), an antibody CH1 heavy chain domain, an antibody CH2 heavy chain domain, an antibody CH3 heavy chain domain, or any combination thereof, and one or more constant domains. The effector group may also include the hinge region of an antibody (usually found between the CH1 and CH2 domains of an IgG molecule).
[0144] In a further embodiment of this aspect of the invention, the effector group according to the invention is the Fc region of an IgG molecule. Advantageously, the peptide ligand-effector group according to the invention comprises or consists of a peptide ligand Fc fusion having a tβ half-life of one day or more, two days or more, three days or more, four days or more, five days or more, six days or more, or seven days or more. Most advantageously, the peptide ligand according to the invention comprises or consists of a peptide ligand Fc fusion having a tβ half-life of one day or more.
[0145] Functional groups typically include binding groups, drugs, reactive groups for linking other entities, functional groups that facilitate uptake of the macrocyclic peptide into cells, and the like.
[0146] The ability of peptides to penetrate cells will allow peptides to effectively target intracellular targets. Targets that can be approached by peptides with the ability to penetrate cells include transcription factors, intracellular signaling molecules such as tyrosine kinases, and molecules involved in apoptosis pathways. Functional groups that can penetrate cells include peptides or chemical groups that have been added to peptides or molecular scaffolds. Peptides, such as those derived from homeobox proteins such as VP22, HIV-Tat, Drosophila (Antennapedia), for example, as Chen and Harrison, Biochemical Society Transactions (2007) Vol. 35, Part 4, p. 821; Gupta et al., Advanced Drug Discovery Reviews (2004) Vol. 57, 9637. The example of short peptides that has been shown to be effective in the translocation of plasma membrane includes 16 amino acid penetrating peptides (Derossi et al. (1994) J Biol.Chem. Vol. 269, p. 10444), 18 amino acid " model amphipathic peptides " (Oehlke et al. (1998) Biochim Biophys Acts Vol. 1414, p. 127) and HIV TAT protein arginine-rich regions. Non-peptide methods include using small molecule mimics or SMOC (Okuyama et al. (2007) Nature Methods Vol. 4, p. 153) that can be easily connected to biomolecules. Other chemical strategies by which guanidine groups are added to molecules also enhance cell penetration (Elson-Scwab et al. (2007) J Biol Chem Vol. 282, p. 13585). Small molecular weight molecules (such as steroids) can be added to molecular scaffolds to enhance cellular uptake.
[0147] One type of functional group that can be linked to a peptide ligand includes antibodies and binding fragments thereof, such as Fab, Fv or single domain fragments. In particular, antibodies that bind to proteins that can increase the half-life of the peptide ligand in vivo can be used.
[0148] In one embodiment, the peptide ligand-effector group according to the invention has a tβ half-life selected from 12 hours or more, 24 hours or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, 14 days or more, 15 days or more, or 20 days or more. Advantageously, the peptide ligand-effector group or composition according to the invention will have a tβ in the range of 12 to 60 hours. In a further embodiment, it will have a tβ half-life of one day or more. In a further embodiment, it will be in the range of 12 to 26 hours.
[0149] In a particular embodiment of the invention, the functional group is selected from metal chelators, which are suitable for complexing metal radioisotopes of pharmaceutical relevance.
[0150] Possible effector groups also include enzymes such as carboxypeptidase G2 for enzyme / prodrug therapy, where the peptide ligand replaces the antibody in ADEPT.
[0151] In a specific embodiment of the invention, the functional group is selected from drugs, such as cytotoxic agents for cancer treatment. Suitable examples include: alkylating agents such as cisplatin and carboplatin, as well as oxaliplatin, nitrogen mustard, cyclophosphamide, chlorambucil, ifosfamide; antimetabolites, including purine analogs azathioprine and mercaptopurine or pyrimidine analogs; plant alkaloids and terpenoids, including vinca alkaloids, such as vincristine, vinblastine, vinorelbine and vindesine; podophyllotoxin and its derivatives etoposide and teniposide; taxanes, including paclitaxel, originally known as Taxol; topoisomerase inhibitors including camptothecins: irinotecan and topotecan, and type II inhibitors, including amridine, etoposide, etoposide phosphate and teniposide. Other agents may include antitumor antibiotics, which include immunosuppressants actinomycin D (used in kidney transplantation), doxorubicin, epirubicin, bleomycin, calicheamicin, etc.
[0152] In a further specific embodiment of the present invention, the cytotoxic agent is selected from maytansinoids (such as DM1) or monomethyl auristatins (such as MMAE).
[0153] DM1 is a cytotoxic agent that is a thiol-containing derivative of maytansinoid and has the following structure:
[0154]
[0155] Monomethyl auristatin E (MMAE) is a synthetic antitumor agent and has the following structure:
[0156]
[0157] In yet another specific embodiment of the invention, the cytotoxic agent is selected from maytansinoids (eg DM1).Data are shown in Table 6 herein, which demonstrate the effects of peptide ligands conjugated to DM1 containing toxins.
[0158] In one embodiment, the cytotoxic agent is linked to the bicyclic peptide via a cleavable bond (e.g., a disulfide bond or a protease-sensitive bond). In a further embodiment, the groups adjacent to the disulfide bond are modified to control the hindrance of the disulfide bond and thereby control the rate of cleavage and the release of the accompanying cytotoxic agent.
[0159] Published work has identified the potential to alter the sensitivity of disulfide bonds to reduction by introducing steric hindrance on either side of the disulfide bond (Kellogg et al. (2011) Bioconjugate Chemistry, 22, 717). Greater degrees of steric hindrance reduce the rate of reduction by intracellular glutathione and extracellular (systemic) reducing agents, thereby reducing the ease of toxin release inside and outside the cell. Thus, an optimal choice of disulfide stability in circulation (which minimizes adverse side effects of the toxin) versus efficient release in the intracellular environment (which maximizes therapeutic effect) can be achieved by carefully selecting the degree of hindrance on either side of the disulfide bond.
[0160] The obstruction of either side of the disulfide bond is modulated by the introduction of one or more methyl groups on the targeting entity (here the bicyclic peptide) or toxin side of the molecular construct.
[0161] In one embodiment, the drug conjugate further comprises a linker between the peptide ligand and the cytotoxic agent.
[0162] In one embodiment, the cytotoxic agent and linker are selected from any combination of those cytotoxic agents and linkers described in WO 2016 / 067035 (which cytotoxic agents and linkers are incorporated herein by reference).
[0163] In one embodiment, the cytotoxic agent is selected from DM1 or MMAE.
[0164] In one embodiment, the linker between the cytotoxic agent and the bicyclic peptide comprises one or more amino acid residues. Thus, in one embodiment, the cytotoxic agent is MMAE and the linker is selected from: -Val-Cit-, -Trp-Cit-, -Val-Lys-, -D-Trp-Cit-, -Ala-Ala-Asn-, D-Ala-Phe-Lys- or -Glu-Pro-Cit-Gly-hPhe-Tyr-Leu- (SEQ ID NO: 98). In another embodiment, the cytotoxic agent is MMAE and the linker is selected from: -Val-Cit-, -Trp-Cit-, -Val-Lys- or -D-Trp-Cit-. In another embodiment, the cytotoxic agent is MMAE and the linker is -Val-Cit- or -Val-Lys-. In another embodiment, the cytotoxic agent is MMAE and the linker is -Val-Cit-.
[0165] In another embodiment, the linker between the cytotoxic agents comprises a disulfide bond, such as a cleavable disulfide bond. Thus, in another embodiment, the cytotoxic agent is DM1 and the linker is selected from: -SS-, -SS(SO3H)-, -SS-(Me)-, -(Me)-SS-(Me)-, -SS-(Me2)- or -SS-(Me)-SO3H-. In another embodiment, the cytotoxic agent is DM1 and the linker comprises a -SS- portion, such as (N-succinimidyl 3-(2-pyridyldithio) propionate (SPDB), or a -SS(SO3H)- portion, such as SO3H-SPDB.
[0166] In another embodiment, the cytotoxic agent comprises a non-cleavable cytotoxic agent. Thus, in one embodiment, the cytotoxic agent is non-cleavable MMAE (such as the cytotoxic agent in BCY6063) or non-cleavable DM1 (such as the cytotoxic agent in BCY6064).
[0167] In one embodiment, the cytotoxic agent is DM1 and the drug conjugate comprises a compound of formula (A):
[0168]
[0169] The bicyclic ring is selected from any one of BCY6099 and BCY6014 defined herein.
[0170] In an alternative embodiment, the cytotoxic agent is DM1 and the drug conjugate comprises a compound of formula (B):
[0171]
[0172] The bicyclic ring is selected from any one of BCY6099 and BCY6014 defined herein.
[0173] In another embodiment, the cytotoxic agent is DM1 and the drug conjugate comprises a compound of formula (A), wherein the bicyclic is selected from BCY6099 as defined herein. This BDC is referred to herein as BCY6027. The data provided herein demonstrate the excellent competitive binding of BCY6027 in the EphA2 competition binding assay, as shown in Table 6.
[0174] In another embodiment, the cytotoxic agent is DM1 and the drug conjugate comprises a compound of formula (B), wherein the bicyclic is selected from BCY6099 as defined herein. The BDC is referred to herein as BCY6028. The data provided herein demonstrate the excellent competitive binding of BCY6028 in the EphA2 competition binding assay, as shown in Table 6.
[0175] In another embodiment, the cytotoxic agent is DM1 and the drug conjugate comprises a compound of formula (A), wherein the bicyclic ring is selected from BCY6014 as defined herein. This BDC is referred to herein as BCY6031. The data provided herein demonstrate the excellent competitive binding of BCY6031 in the EphA2 competition binding assay, as shown in Table 6. In Tables 11 and 12 herein, Figure 1 and Figure 2 Data were also presented in the study, which showed that BCY6031 treatment completely eliminated non-small cell lung cancer from day 32, with no tumor regrowth occurring at day 28 after dosing was suspended.
[0176] In an alternative embodiment, the cytotoxic agent is DM1 and the drug conjugate comprises a compound of formula (B), wherein the bicyclic ring is selected from BCY6014 as defined herein. This BDC is referred to herein as BCY6032. The data provided herein demonstrate the excellent competitive binding of BCY6032 in the EphA2 competition binding assay, as shown in Table 6.
[0177] In another embodiment, the cytotoxic agent is MMAE or DM1 and the drug conjugate is selected from any of the BDCs listed in Table 11. The data presented herein show that these BDCs exhibit excellent cross-reactivity between human, mouse and rodent EphA2, as shown in Table 11.
[0178] In another embodiment, the cytotoxic agent is MMAE or DM1 and the drug conjugate is selected from any BDC listed in Table 13.
[0179] In another embodiment, the cytotoxic agent is MMAE or DM1, and the drug conjugate is selected from BCY6033, BCY6082, BCY6136, and BCY6173. The data presented herein indicate that these four bicyclic drug conjugates do not show significant binding to the closely related human homologs EphA1, EphA3, EphA4, EphA5, EphA6, EphA7, and EphB4; mouse EphA3 and EphA4; and rat EphA3 and EphB1, as shown in Tables 14 and 15.
[0180] In another embodiment, the drug conjugate is selected from any one of the following: BCY6031, BCY6033, BCY6082, BCY6135, BCY6136, BCY6173, BCY6174 and BCY6175:
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188]
[0189] In one embodiment, the drug conjugate is not BCY6027, BCY6028, BCY6135, BCY6136, BCY6173, BCY6174 and BCY6175.
[0190] In another embodiment, the drug conjugate is BCY6136. The data presented herein in Study 7 and Study 8 demonstrate that BCY6136 exhibits significant and potent antitumor activity in the PC-3 xenograft prostate cancer model (see Figures 7 to 10 Also presented herein are data showing that BCY6136 exhibits potent antitumor activity in the NCI-H1975 xenograft lung cancer (NSCLC) model (see Figures 11 to 13and Tables 25 to 30). The data presented in Study 10 and Study 11 herein demonstrate that BCY6136 exhibits potent antitumor effects in both large and small tumor size LU-01-0251 PDX lung cancer (NSCLC) models (see Fig.14 and Fig.15 and Tables 31 to 34), where complete tumor regression was observed. The data presented in Study 12 herein showed that BCY6136 exhibited significant anti-tumor effects in the LU-01-0046 PDX lung cancer (NSCLC) model (see Fig.16 and Tables 35 and 36), where complete tumor regression was observed with BCY6136. Data are also provided in Study 13 herein, which demonstrates that BCY6136 exhibits dose-dependent antitumor activity in the LU-01-0046 PDX lung cancer (NSCLC) model (see Fig.17 Also presented in Study 14 herein are data demonstrating that BCY6136 eliminates tumors in the LU-01-0046 PDX lung cancer (NSCLC) model (see Figures 18 to 22 and Tables 39 to 42). Data are also presented in Study 15 and Study 16 herein, which demonstrate the effect of BCY6136 in two models using cell lines with low / negligible EphA2 expression (i.e., Lu-01-0412 and Lu-01-0486). The data are shown in Fig.23 and Fig.24 As shown in Tables 43 to 46, BCY6136 had no effect on tumor regression in either of these cell lines, but BCY (BCY8245 and BCY8781) (which bind to targets highly expressed in the Lu-01-0412 cell line) completely eliminated the tumors. The data presented in Study 17 herein show that BCY6136 exhibits potent antitumor activity in the MDA-MB-231 xenograft breast cancer model (see Figure 25 to Figure 27 and Tables 47 to 50). Data are also presented in Study 18 herein, which demonstrate the effect of BCY6136 in a breast cancer model utilizing a cell line with low / negligible EphA2 expression (i.e., EMT6). The data are shown in Fig.28 In Tables 51 and 52, it was demonstrated that BCY6136 had no effect on tumor regression in this cell line. Data were also provided in Study 19 herein, which showed that BCY6136 exhibited significant antitumor activity in the NCI-N87 xenograft gastric cancer model (see Fig.29 and Tables 53 and 54). Study 20 herein also provides data demonstrating that BCY6136 exhibits significant anti-tumor activity in the SK-OV-3 xenograft ovarian cancer model (see Fig.30 and Tables 55 and 56), while ADC MEDI-547 showed moderate antitumor activity in comparison. Data were also provided in Study 21 herein, which showed that BCY6136 showed significant antitumor activity in the OE-21 xenograft esophageal cancer model (see Fig.31 Also provided in Study 22 herein are data showing that BCY6136 exhibited dose-dependent antitumor activity in the MOLP-8 xenograft multiple myeloma model, and that BCY6082 exhibited significant antitumor activity (see Fig.32 and Fig.33 Also presented in Study 23 herein are data demonstrating that BCY6136 exhibits potent antitumor activity in the HT-1080 xenograft fibrosarcoma model (see Figures 34 to 41 and Tables 61 and 62).
[0191] synthesis
[0192] The peptides of the present invention can be prepared by standard technology synthesis, and then reacted with molecular scaffolds in vitro. When this operation is performed, standard chemical methods can be used. This enables rapid large-scale preparation of soluble materials for further downstream experiments or verification. Such methods can be realized using conventional chemical methods disclosed in, for example, Timmerman et al. (supra).
[0193] Therefore, the present invention also relates to the preparation of a selected polypeptide or conjugate as described herein, wherein the preparation comprises the optional further steps as described below. In one embodiment, these steps are performed on a final product polypeptide / conjugate prepared by chemical synthesis.
[0194] When preparing conjugates or complexes, amino acid residues in the target polypeptide may optionally be substituted.
[0195] The peptides may also be extended to incorporate, for example, another loop, thereby introducing multispecificity.
[0196] To extend the peptide, standard solid phase or solution phase chemistry can be used, using orthogonally protected lysine (and analogs), simply chemically extended at its N-terminus or C-terminus or within a ring. Standard (bio) conjugation techniques can be used to introduce activated or activatable N- or C-termini. Alternatively, addition can be carried out by fragment condensation or native chemical ligation (for example, as described in (Dawson et al. 1994. Synthesis of Proteins by Native Chemical Ligation. Science 266: 776-779)), or by enzymes, for example using subtiligase as described in (Chang et al. Proc Natl Acad Sci US A. 1994 Dec 20; 91 (26): 12544-8 or Hikari et al. Bioorganic & Medicinal Chemistry Letters Volume 18, Issue 22, 15 November 2008, pages 6000-6003).
[0197] Alternatively, the peptides may be extended or modified by further conjugation via disulfide bonds. This has the additional advantage of allowing the first and second peptides to be separated from each other once in the reducing environment of the cell. In this case, a molecular scaffold may be added during the chemical synthesis of the first peptide so as to react with the three cysteine groups; an additional cysteine or thiol may then be attached to the N or C terminus of the first peptide so that the cysteine or thiol reacts only with the free cysteine or thiol of the second peptide to form a disulfide-linked bicyclic peptide-peptide conjugate.
[0198] Similar techniques are also applicable to the synthesis / coupling of two bicyclic and bispecific macrocycles, potentially leading to tetraspecific molecules.
[0199] Furthermore, the addition of other functional groups or effector groups can be accomplished in the same manner, using appropriate chemistry, at the N- or C-terminus or through side chain coupling. In one embodiment, coupling is performed in a manner that does not block the activity of either entity.
[0200] Pharmaceutical composition
[0201] According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising the peptide ligand or drug conjugate as defined herein and one or more pharmaceutically acceptable excipients.
[0202] Generally, the peptide ligands of the present invention will be used in purified form together with a pharmacologically suitable excipient or carrier. Typically, these excipients or carriers include aqueous or alcohol / water solutions, emulsions or suspensions, including physiological saline and / or buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's reagent. If necessary, a suitable physiologically acceptable adjuvant is maintained in suspension with the polypeptide complex, and the adjuvant can be selected from thickeners such as carboxymethylcellulose, polyvinyl pyrrolidone, gelatin and alginate.
[0203] Intravenous carriers include fluid and nutrient replenishers and electrolyte replenishers such as those based on Ringer's dextrose. Preservatives and other additives may also be present, such as antimicrobials, antioxidants, chelating agents and inert gases (Mack (1982) Remington's Pharmaceutical Sciences, 16th ed.).
[0204] The peptide ligands of the present invention can be used as compositions for single administration, or can be administered in combination with other agents. These can include antibodies, antibody fragments and various immunotherapeutic drugs, such as cyclosporine, methotrexate, doxorubicin or cisplatin and immunotoxins. Pharmaceutical compositions can include a "cocktail mixture" of various cytotoxins or other agents combined with the protein ligands of the present invention, or even a combination of polypeptides selected according to the present invention with different specificities, such as polypeptides selected using different target ligands, whether or not combined before administration.
[0205] The route of administration of the pharmaceutical composition according to the present invention can be those generally known to those of ordinary skill in the art. For therapeutic methods, the peptide ligands of the present invention can be administered to any patient according to standard techniques. Administration can be by any appropriate mode, including parenteral, intravenous, intramuscular, intraperitoneal, transdermal, pulmonary route, or appropriately by direct catheter infusion. Preferably, the pharmaceutical composition according to the present invention is administered by inhalation. The dosage and frequency of administration depend on the age, sex and condition of the patient, the simultaneous administration of other drugs, contraindications and other parameters to be considered by the clinician.
[0206] The peptide ligands of the present invention can be lyophilized for storage and reconstituted in a suitable carrier before use. This technique has been shown to be effective, and lyophilization and reconstitution techniques known in the art can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution may result in varying degrees of loss of activity, and levels may have to be adjusted upwards to compensate.
[0207] Compositions containing peptide ligands of the present invention or cocktails thereof can be administered for preventive and / or therapeutic treatments. In certain therapeutic applications, a sufficient amount to achieve at least partial inhibition, suppression, regulation, killing or some other measurable parameter of a selected cell population is defined as a "therapeutically effective dose". The amount required to achieve this dose will depend on the severity of the disease and the general state of the patient's own immune system, but typically 0.005 to 5.0 mg of the selected peptide ligand per kilogram of body weight, more commonly 0.05 to 2.0 mg / kg / dose. For preventive applications, compositions containing peptide ligands of the present invention or cocktails thereof can also be administered at similar or slightly lower doses.
[0208] Compositions comprising peptide ligands according to the present invention can be used to help alter, inactivate, kill or remove selective target cell populations in mammals in preventive and therapeutic settings. In addition, peptide ligands as described herein can be selectively used to kill, consume or otherwise effectively remove target cell populations from heterogeneous collections of cells in vitro (extracorporeally) or in vitro (in vitro). Blood from mammals can be combined with selected peptide ligands in vitro, thereby killing or otherwise removing undesirable cells from the blood and returning to the mammal according to standard techniques.
[0209] Therapeutic Uses
[0210] The bicyclic peptides of the present invention have particular use as EphA2 binding agents.
[0211] Eph receptor tyrosine kinase (Eph) belongs to a large group of receptor tyrosine kinases (RTKs) that phosphorylate proteins on tyrosine residues. Eph and its membrane-bound ephrin ligand (ephrin) control the localization of cells and the organization of tissues (Poliakov et al. (2004) Dev Cell 7, 465-80). Functional and biochemical Eph responses occur in higher ligand oligomerization states (Stein et al. (1998) Genes Dev 12, 667-678).
[0212] Among other model functions, it is shown that various Eph and ephrin play a role in vascular development. Knockout of EphB4 and ephrin-B2 results in a lack of the ability to remodel capillary beds into blood vessels (Poliakov et al., supra), and leads to embryonic lethality. Persistent expression of some Eph receptors and ephrins has also been observed in newborn adult microvessels (Brantley-Sieders et al. (2004) Curr Pharm Des 10, 3431-42; Adams (2003) J Anat 202, 105-12).
[0213] It has also been observed that unregulated regeneration of some ephrins and their receptors in adults promotes tumor invasion, metastasis and angiogenesis (Nakamoto et al. (2002) Microsc Res Tech 59, 58-67; Brantley-Sieders et al., supra). In addition, some Eph family members have been found to be overexpressed on tumor cells from a variety of human tumors (Brantley-Sieders et al., supra) Marme (2002) Ann Hematol 81 Suppl 2, S66; Booth et al. (2002) Nat Med 8, 1360-1).
[0214] EPH receptor A2 (ephrin receptor type A 2) is a protein that in humans is encoded by the EPHA2 gene.
[0215] EphA2 is upregulated in many human cancers and is often associated with disease progression, metastasis and poor prognosis, such as breast cancer (Zelinski et al. (2001) Cancer Res. 61, 2301-2306; Zhuang et al. (2010) Cancer Res. 70, 299-308; Brantley-Sieders et al. (2011) PLoS One 6, e24426), lung cancer (Brannan et al. (2009) Cancer Prev Res (Phila) 2, 1039-1049; Kinch et al. (2003) Clin Cancer Res. 9, 613-618; Guo et al. (2013) J Thorac Oncol. 8, 301-308), gastric cancer (Nakamura et al. (2005) Cancer Sci. 96, 42-47; Yuan et al. (2009) Dig Dis Sci 54, 2410-2417), pancreatic cancer (Mudali et al. (2006) Clin Exp Metastasis 23, 357-365), prostate cancer (Walker-Daniels et al. (1999) Prostate 41, 275-280), liver cancer (Yang et al. (2009) Hepatol Res. 39, 1169-1177) and glioblastoma (Wykosky et al. (2005) Mol Cancer Res. 3, 541-551; Li et al. (2010) Tumour Biol. 31, 477-488).
[0216] The full role of EphA2 in cancer progression remains to be determined, although there is evidence of interactions at many stages of cancer progression, including tumor cell growth, survival, invasion, and angiogenesis. Downregulation of EphA2 expression inhibits tumor cancer cell proliferation (Binda et al. (2012) Cancer Cell 22, 765-780), while blockade of EphA2 inhibits VEGF-induced cell migration (Hess et al. (2001) Cancer Res. 61, 3250-3255), sprouting and angiogenesis (Cheng et al. (2002) Mol Cancer Res. 1, 2-11; Lin et al. (2007) Cancer 109, 332-40) and metastatic progression (Brantley-Sieders et al. (2005) FASEB J. 19, 1884-1886).
[0217] Antibody drug conjugates directed against EphA2 have been shown to significantly reduce tumor growth in rat and mouse xenograft models (Jackson et al. (2008) Cancer Research 68, 9367-9374), and a similar approach has been attempted in humans, although treatment has been terminated due to treatment-related side effects (Annunziata et al. (2013) Invest New drugs 31, 77-84).
[0218] Polypeptide ligands selected according to the methods of the present invention can be used for in vivo therapeutic and prophylactic applications, in vitro and in vivo diagnostic applications, in vitro assays and reagent applications, etc. Ligands with selected specificity levels are useful in applications involving testing in non-human animals where cross-reactivity is required, or in diagnostic applications where cross-reactivity with homologs or paralogs needs to be carefully controlled. In some applications, such as vaccine applications, the ability to elicit an immune response to a predetermined range of antigens can be used to customize vaccines against specific diseases and pathogens.
[0219] For mammalian administration, substantially pure peptide ligands of at least 90 to 95% homogeneity are preferred, and for pharmaceutical use, particularly when the mammal is a human, 98 to 99% or greater homogeneity is most preferred. Once purified (partially purified or purified to homogeneity) as desired, the selected polypeptide can be used in diagnosis or therapy (including in vitro) or in the development and performance of assay procedures, immunofluorescence staining, etc. (Lefkovite and Pernis, (1979 and 1981) Immunological Methods, Vols. I and II, Academic Press, NY).
[0220] According to another aspect of the present invention, there is provided a peptide ligand or drug conjugate as defined herein for use in preventing, inhibiting or treating a disease or disorder characterized by overexpression of EphA2 in diseased tissues (eg tumors).
[0221] According to another aspect of the present invention, there is provided a method for preventing, inhibiting or treating a disease or disorder characterized by overexpression of EphA2 in diseased tissues (eg tumors), comprising administering to a patient in need thereof an effector group of a peptide ligand as defined herein and a drug conjugate.
[0222] In one embodiment, the EphA2 is mammalian EphA2. In another embodiment, the mammalian EphA2 is human EphA2.
[0223] In one embodiment, the disease or disorder characterized by overexpression of EphA2 in diseased tissue is selected from cancer.
[0224] Examples of cancers (and their benign counterparts) that may be treated (or inhibited) include, but are not limited to, tumors of epithelial origin (adenomas and various types of carcinomas, including adenocarcinomas, squamous cell carcinomas, transitional cell carcinomas, and others), such as bladder and urinary tract cancer, breast cancer, gastrointestinal cancer (including esophageal cancer, stomach (gastric) cancer, small intestine cancer, colon cancer, rectal cancer, and anal cancer), liver cancer (hepatocellular carcinoma), gallbladder and biliary system cancer, exocrine pancreatic cancer, kidney cancer, lung cancer (e.g., adenocarcinoma, small cell lung cancer, non-small cell lung cancer, bronchoalveolar carcinoma, and mesothelioma), head and neck cancer (e.g., tongue cancer, buccal cancer, laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, tonsil cancer, salivary gland cancer, nasal cavity cancer, and paranasal sinus cancer), ovarian cancer, fallopian tube cancer, peritoneal cancer, vaginal cancer, vulvar cancer , penile cancer, cervical cancer, uterine fibroids, endometrial cancer, thyroid cancer (e.g., follicular thyroid cancer), renal cancer, prostate cancer, skin and appendage cancer (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dysplastic nevus); hematologic malignancies (i.e., leukemias, lymphomas) and premalignant hematologic conditions and borderline malignancies, including hematologic malignancies and related conditions of the lymphoid lineage (e.g., acute lymphocytic leukemia [ALL], chronic lymphocytic leukemia [CLL], B-cell lymphomas such as diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, Burkitt's lymphoma, mantle cell lymphoma, T-cell lymphomas and leukemias, natural killer [NK ] cell lymphoma, Hodgkin lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma, and post-transplant lymphoproliferative disorder), and hematologic malignancies and myeloid-related disorders (e.g., acute myeloid leukemia [AML], chronic myeloid leukemia [CML], chronic myelomonocytic leukemia [CMML], hypereosinophilic syndrome, myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, myeloproliferative syndrome, myelodysplastic syndrome, and promyelocytic leukemia); tumors of mesenchymal origin, such as soft tissue sarcomas, bone or chondrosarcomas, such as osteosarcoma, fibrosarcoma, chondrosarcoma, Sarcomas, rhabdomyosarcomas, leiomyosarcomas, liposarcoma, angiosarcomas, Kaposi's sarcoma, Ewing's sarcoma, synovial sarcomas, epithelioid sarcomas, gastrointestinal stromal tumors, benign and malignant histiosarcomas, and dermatofibrosarcoma protuberans; tumors of the central or peripheral nervous system (e.g., astrocytomas, gliomas and glioblastomas, meningiomas, ependymomas, pinealomas, and schwannomas); endocrine tumors (e.g., pituitary tumors, adrenal tumors, islet cell tumors, parathyroid tumors, carcinoids, and medullary thyroid carcinoma); tumors of the eye and adnexa (e.g., retinoblastoma); germ cell and trophoblastic tumors (e.g., teratomas, seminoma, dysgerminoma, hydatidiform mole, and choriocarcinoma);Pediatric and embryonal tumors (e.g., medulloblastoma, neuroblastoma, Wilms tumor, and primitive neuroectodermal tumor); or congenital or other forms of syndromes that predispose the patient to malignancy (e.g., xeroderma pigmentosum).
[0225] In a further embodiment, the cancer is selected from the group consisting of breast cancer, lung cancer, gastric cancer, pancreatic cancer, prostate cancer, liver cancer, glioblastoma, and angiogenesis.
[0226] In another embodiment, the cancer is selected from prostate cancer, lung cancer (eg, non-small cell lung cancer (NSCLC)), breast cancer (eg, triple-negative breast cancer), gastric cancer, ovarian cancer, esophageal cancer, multiple myeloma, and fibrosarcoma.
[0227] In another embodiment, the cancer is prostate cancer. The data presented in Study 7 and Study 8 herein show that BCY6033 and BCY6136 exhibit significant and potent antitumor activity in the PC-3 xenograft prostate cancer model (see Figures 7 to 10 and Tables 21 to 24).
[0228] In yet another embodiment, the drug conjugates can be used to prevent, inhibit or treat solid tumors, such as fibrosarcoma and breast cancer and non-small cell lung cancer.
[0229] In another embodiment, the cancer is selected from lung cancer, such as non-small cell lung cancer (NSCLC). The data provided herein demonstrate that from the 32nd day, the BDC of the present invention (BCY6031) completely eliminated non-small cell lung cancer, and no tumor regrowth occurred on the 28th day after suspending administration. The data clearly demonstrate the clinical application of the BDC of the present invention in cancers such as lung cancer, specifically non-small cell lung cancer. Data are also provided in Study 9 herein, which show that in the NCI-H1975 xenograft lung cancer (NSCLC) model, BCY6033 showed dose-dependent anti-tumor activity, BCY6082 showed significant anti-tumor activity, and BCY6136 showed effective anti-tumor activity (see Figures 11 to 13 and Tables 25 to 30). Data are also presented in Study 10 and Study 11 herein, which demonstrate that BCY6136 exhibits potent antitumor effects in the LU-01-0251 PDX lung cancer (NSCLC) model of both large and small tumor sizes (see Fig.14 and Fig.15 and Tables 31 to 34), where complete tumor regression was observed. Data are also provided in Study 12 herein, which show that BCY6033, BCY6136, BCY6082, and BCY6031 exhibit significant anti-tumor effects in the LU-01-0046 PDX lung cancer (NSCLC) model (see Fig.16 and Tables 35 and 36), where complete tumor regression was observed for BCY6033 and BCY6136. Data are also provided in Study 13 herein, which shows that BCY6136 exhibits dose-dependent antitumor activity in the LU-01-0046 PDX lung cancer (NSCLC) model (see Fig.17 Also provided in Study 14 herein are data showing that in the LU-01-0046 PDX lung cancer (NSCLC) model, BCY6082 exhibited dose-dependent antitumor activity, BCY6031 and BCY6173 exhibited antitumor activity, and BCY6033, BCY6136, and BCY6175 eliminated tumors (see Figures 18 to 22 and Tables 39 to 42). Data are also presented in Study 15 and Study 16 herein, which demonstrate the effect of BCY6136 in two models using cell lines with low / negligible EphA2 expression (i.e., Lu-01-0412 and Lu-01-0486). The data are shown in Fig.23 and Fig.24 and Tables 43 to 46, and demonstrate that BCY6136 had no effect on tumor regression in either of these two cell lines, but BCY (BCY8245 and BCY8781) (which bind to targets highly expressed in the Lu-01-0412 cell line) completely regressed tumors. In another embodiment, the cancer is breast cancer. In another embodiment, the breast cancer is triple-negative breast cancer. The data provided in Study 17 herein show that in the MDA-MB-231 xenograft breast cancer model, BCY6082 exhibited anti-tumor activity, BCY6033 exhibited dose-dependent anti-tumor activity, and BCY6136 exhibited potent anti-tumor activity (see Figure 25 to Figure 27 and Tables 47 to 50). Data are also provided in Study 18 herein demonstrating the effect of BCY6136 in a breast cancer model utilizing a cell line with low / negligible EphA2 expression (i.e., EMT6). The data are shown in Fig.28 As well as in Tables 51 and 52, it is demonstrated that BCY6136 has no effect on tumor regression in this cell line. In an alternative embodiment, the breast cancer is Herceptin-resistant breast cancer. Without being bound by theory, EphA2 is believed to be associated with resistance to Herceptin, and therefore, entities targeting EphA2 have potential utility in patients who do not respond to Herceptin.
[0230] In another embodiment, the cancer is gastric cancer. The data presented in Study 19 herein show that BCY6136 exhibits significant anti-tumor activity in the NCI-N87 xenograft gastric cancer model (see Fig.29and Tables 53 and 54).
[0231] In another embodiment, the cancer is ovarian cancer. The data presented in Study 20 herein indicate that BCY6136 exhibits significant anti-tumor activity in the SK-OV-3 xenograft ovarian cancer model (see Fig.30 and Tables 55 and 56), while ADC MEDI-547 showed moderate anti-tumor activity in comparison.
[0232] In another embodiment, the cancer is esophageal cancer. The data presented in Study 21 herein indicate that BCY6136 exhibits significant anti-tumor activity in the OE-21 xenograft esophageal cancer model (see Fig.31 and Tables 57 and 58).
[0233] In another embodiment, the cancer is multiple myeloma. The data presented in Study 22 herein indicate that BCY6136 exhibits dose-dependent antitumor activity in the MOLP-8 xenograft multiple myeloma model, while BCY6082 exhibits significant antitumor activity (see Fig.32 and Fig.33 and Tables 59 and 60).
[0234] In another embodiment, the cancer is fibrosarcoma. The data presented in Study 23 herein showed that in the HT-1080 xenograft fibrosarcoma model, BCY6173, BCY6135, BCY6174, and BCY6175 showed dose-dependent antitumor activity, while BCY6082, BCY6031, BCY6033, and BCY6136 showed potent antitumor activity (see Figures 34 to 41 and Tables 61 and 62).
[0235] The term "prevention" as referred to herein involves administration of a protective composition prior to disease induction. "Suppression" refers to administration of a composition after the induction event but prior to clinical manifestation of the disease. "Treatment" involves administration of a protective composition after disease symptoms become apparent.
[0236] Animal model systems are available for screening peptide ligands for effectiveness in preventing or treating disease. The present invention allows the development of polypeptide ligands that can cross-react with human and animal targets, thereby allowing the use of animal models, which facilitates the use of animal model systems.
[0237] In addition, the data provided herein demonstrate the correlation between copy number variation (CNV) and gene expression of EphA2 in multiple tumor types. Therefore, according to another aspect of the present invention, a method for preventing, inhibiting or treating cancer is provided, the method comprising administering to a patient in need thereof an effector group and a drug conjugate of a peptide ligand defined herein, wherein the patient is identified as having an increased copy number variation (CNV) of EphA2.
[0238] In one embodiment, the cancer is selected from those cancers identified herein as having increased CNV of EphA2. In another embodiment, the cancer is breast cancer.
[0239] The present invention is further described below with reference to the following examples.
[0240] Example
[0241]
[0242]
[0243]
[0244] Materials and methods
[0245] Peptide synthesis
[0246] The peptide was synthesized by solid phase synthesis. Rink Amide MBHA resin was used. DMF was added to a mixture containing Rink Amide MBHA (0.4-0.45mmol / g) and Fmoc-Cys(Trt)-OH (3.0eq), followed by DIC (3eq) and HOAt (3eq) and mixed for 1 hour. Deblocking was performed using a 20% piperidine solution in DMF. Each subsequent amino acid was coupled with 3eq using an activating reagent, DIC (3.0eq) and HOAT (3.0eq) in DMF. The reaction was monitored by ninhydrin colorimetric reaction or tetrachloroethylene colorimetric reaction. After the synthesis was completed, the peptide resin was washed with DMF x 3, MeOH x 3, and then dried overnight under N2 bubbles. The peptide resin was then treated with 92.5% TFA / 2.5% TIS / 2.5% EDT / 2.5% H2O for 3h. The peptide was precipitated with cold isopropyl ether and centrifuged (3000rpm for 3 minutes). The precipitate was washed twice with isopropyl ether and the crude peptide was dried under vacuum for 2 hours and then lyophilized. The lyophilized powder was dissolved in ACN / H2O (50:50) and 100mM TATA in ACN was added, followed by a solution of ammonium bicarbonate in H2O (1M) and the solution was mixed for 1 hour. Once the cyclization was complete, the reaction was quenched with 1M aq. Cysteine hydrochloride (10eq relative to TATA) was then mixed and allowed to stand for one hour. The solution was lyophilized to give a crude product. The crude peptide was purified by preparative HPLC and lyophilized to give the product.
[0247] Unless otherwise stated, all amino acids were used in the L-configuration.
[0248] BCY6099 (Compound 66)
[0249]
[0250] Sequence: (β-Ala)-Sar 10 -(SEQ ID NO:2)-CONH2
[0251] 8.0 g of resin was used to generate 2.1 g of BCY6099 as a white solid (99.2% purity; 16.3% yield).
[0252]
[0253] BCY6014 (Compound 67)
[0254]
[0255] Sequence: (β-Ala)-Sar 10 -(SEQ ID NO: 11)-CONH2
[0256] 4.79 g of resin was used to produce 1.07 g of BCY6014 as a white solid (Q1: 131.9 mg, 97.99% purity; Q2: 141.7 mg, 99.04% purity; Q3: 800.7 mg, 92.35% purity; 16.9% yield).
[0257]
[0258] BCY6104 (Compound 99)
[0259]
[0260] Sequence (β-Ala)-Sar 10 -A(HArg)DC(HyP)(Hse(Me))VNPLCLHP(D-Asp)W(HArg)C((β-Ala)-Sar 10 -(SEQ ID NO: 85))
[0261] 4.44 g of resin was used to produce 700 mg of BCY6104 (95.87% purity, 10.5% yield) as a white solid.
[0262]
[0263] BCY6103 (Compound 100)
[0264]
[0265] Sequence: Sequence: (β-Ala)-Sar 10 -A(HArg)DC(HyP)(Hse(Me))VNPLCLHP(D-Asp)WTC((β-Ala)-Sar 10 -(SEQ ID NO:86))
[0266] 4.44 g of resin was used to produce 700 mg of BCY6103 (98.9% purity, 11.1% yield) as a white solid.
[0267]
[0268] BCY6101 (Compound 101)
[0269] Sequence: (β-Ala)-Sar 10 -A(HArg)DC(HyP)LVNPLCLHP(D-Ala)WTC((β-Ala)-Sar 10 -(SEQ ID NO: 87))
[0270]
[0271] 4.44 g of resin was used to produce 700 mg of BCY6101 (95.9% purity, 10.9% yield) as a white solid.
[0272]
[0273] BCY6102 (Compound 102)
[0274] Sequence: (β-Ala)-Sar 10 -A(HArg)DCPLVNPLCLHP(D-Ala)WTC((β-Ala)-Sar 10 -(SEQ ID NO: 88)))
[0275] 4.44 g of resin was used to produce 900 mg of BCY6102 (95.9% purity, 14.1% yield) as a white solid.
[0276]
[0277] BCY6139 (Compound 103)
[0278] Sequence: (β-Ala)-Sar 10 -ARDC(HyP)LVNPLCLHPGWTC((β-Ala)-Sar 10 -(SEQ IQ NO: 89))
[0279]
[0280] 4.44 g of resin was used to produce 900 mg of BCY6139 (97.4% purity, 11.2% yield) as a white solid.
[0281]
[0282] BCY6138 (Compound 104)
[0283] Sequence: (β-Ala)-Sar 10 -ARDCPLVVPLCL(D-3,3-DPA)PGWTC((β-Ala)-Sar 10 -(SEQ ID NO:90))
[0284]
[0285] 1.11 g of resin was used to produce 200 mg of BCY6138 (95.2% purity, 12.2% yield) as a white solid.
[0286]
[0287] BCY6137 (Compound 105)
[0288] Sequence: (β-Ala)-Sar 10 -ARDCPLVNPLCLHPGWTCLH((β-Ala)-Sar 10 -(SEQ IQ NO:91))
[0289] 4.44 g of resin was used to produce 600 mg of BCY6137 (98.9% purity, 9.06% yield) as a white solid.
[0290]
[0291] BCY6042 (Compound 91)
[0292]
[0293] Sequence: Ac-(SEQ ID NO: 14)-Sar6-(DK)
[0294] 1.11 g of resin was used to produce 99.2 mg of BCY6042 (99.2% purity, 7.0% yield) as a white solid.
[0295]
[0296] BCY6019 (Compound 77)
[0297]
[0298] Sequence: Ac(SEQ ID NO:12)-Sar6-(DK)
[0299] 4.79 g of resin was used to produce 732.0 mg of BCY6019 (92.82% purity, 12.2% yield) as a white solid.
[0300]
[0301] BCY6059 (Compound 106)
[0302]
[0303] Sequence: Ac-(SEQ ID NO: 12)-Sar6-(DK[Ac])
[0304] The aqueous solution of BCY6019 (0.05 g, 17.82 μmol, 1.00 eq) (3 mL) was adjusted to pH = 11 by Na2CO3 (aq), and acetic acid ester (5.46 mg, 53.46 μmol, 5.01 μL, 3.00 eq) was added. The mixture was stirred at 15 ° C for 1 hour. LC-MS showed that BCY6019 was completely consumed and a main peak with the expected MS was detected. The reaction was adjusted to pH = 7 by 1N HCl and directly purified by preparative HPLC (TFA conditions). Compound BCY6059 (18.1 mg, 6.36 μmol, yield 35.67%) was obtained as a white solid.
[0305]
[0306] BCY6160 (Compound 107)
[0307]
[0308]
[0309] Sequence: (β-AlaSO3H)-Sar4-(Cya)-Sar4-(Cya)-A(HArg)DCPLVNPLCLHP(D-Cya)WTC((β-AlaSO3H)-Sar4-(Cya)-Sar4-(Cya)-(SEQ ID NO: 92))
[0310] 1.11 g of resin was used to produce 45.2 mg of BCY6160 (95.5% purity, 2.5% yield) as a white solid.
[0311]
[0312] BCY6009 (Compound 108)
[0313]
[0314] Sequence: (β-Ala)-Sar 10 -ARDCPLVNPLCLHPGWTC((β-Ala)-Sar 10 -(SEQ ID NO: 10))
[0315] 4.79 g of resin was used to produce 2.42 g of BCY6009 as a white solid (>88.92% purity, 36.0% yield).
[0316]
[0317]
[0318] BCY6017 (Compound 109)
[0319]
[0320] Sequence: A(HArg)DCPLVNPLCLHPGWTC (SEQ ID NO: 11)
[0321] 1.19 g of resin was used to produce 189.9 mg of BCY6017 (95.05% purity, 16.8% yield) as a white solid.
[0322]
[0323] BCY6018 (Compound 110)
[0324]
[0325] Sequence: (β-Ala)-Sar5- (SEQ ID NO: 11)
[0326] 1.19 g of resin was used to produce 289.1 mg of BCY6018 (97.92% purity, 21.0% yield) as a white solid.
[0327]
[0328] BCY6152 (Compound 111)
[0329]
[0330] Sequence: (β-AlaSO3H)-Sar 10 -(SEQ ID NO:11)
[0331] 1.11 g of resin was used to produce 150.0 mg of BCY6152 as a white solid (98.75% purity; 9.5% yield).
[0332]
[0333] BCY6141 (Compound 112)
[0334]
[0335] Sequence: (β-Ala)-Sar 10-A(D-Arg)DC(HyP)LVNPLCL(D-3,3-DPA)P(D-Asp)W(HArg)C((β-Ala)-Sar 10 -(SEQ ID NO:93))
[0336] 1.11 g of resin was used to produce 120.0 mg of BCY6141 (97.91% purity; 7.3% yield) as a white solid.
[0337]
[0338] BCY6026 (Compound 87)
[0339]
[0340] Sequence: ACPLVNPLCLHPGWSCRGQ (SEQ ID NO: 77)
[0341] 1.11 g of resin was used to produce 285.0 mg of BCY6026 as a white solid (97.7% purity; 24.2% yield).
[0342]
[0343] BCY6153 (Compound 113)
[0344]
[0345]
[0346] Sequence: (β-AlaSO3H)-Sar5- (SEQ ID NO: 11)
[0347] 1.11 g of resin was used to produce 140.0 mg of BCY6153 as a white solid (98.59% purity; 9.9% yield).
[0348]
[0349] Preparation of Bicyclic Peptide Drug Conjugates
[0350] A general scheme for preparing bicyclic drug conjugates (BDCs) is shown in Figure 3 As shown, Table A describes the components of the targeting bicyclic and linker / toxin composition in each BDC.
[0351] Table A
[0352]
[0353]
[0354] The synthesis of the bicyclic peptide drug conjugates BCY6027, BCY6028, BCY6031 and BCY6032 listed in Table 6 was performed using the protocol disclosed in WO 2016 / 067035.
[0355] The activated bicyclic peptides of formula (C) and (D) were synthesized by the following method:
[0356]
[0357] The free amino groups of the bicyclic precursors were reacted with SPP (N-succinimidyl 4-(2-pyridyldithio)pentanoate, Annova Chem) and SPDB (N-succinimidyl 3-(2-pyridyldithio)propionate, Annova Chem) in DMSO, respectively. The concentration of the bicyclic precursor was 10 mM or higher, SPP or SPDB was in 1.3-fold excess, and diisopropylethylamine was in 20-fold excess at room temperature. After 1 hour, the reaction was judged to be complete by LCMS. Purification was performed by reverse phase as described above. The appropriate fractions were lyophilized.
[0358] Under semi-aqueous conditions (50% dimethylacetamide and 50% 100 mM sodium acetate pH 5.0, supplemented with 2 mM EDTA), activated bicyclic peptides having formula (C) and (D) were subjected to disulfide exchange with 1.15 equivalents of DM1 (as free sulfhydryl groups) at room temperature under nitrogen protection for 21 hours. The concentration of the activated bicyclic peptides having structures C and D in the reaction was 10 mM or higher.
[0359] Standard reverse phase purification was then performed using a C18 column. Fractions with a purity greater than 95% were isolated and lyophilized. This material did not contain measurable amounts of free toxin.
[0360] MMAE Series
[0361] Val-Cit-MMAE Series
[0362] Val-Cit-MMAE Connectors
[0363]
[0364]
[0365] Compound 2
[0366]
[0367] The peptide was synthesized by solid phase synthesis. 50 g of CTC resin (sub: 1.0 mmol / g) was used. DCM (400 mL) was added to a mixture containing CTC resin (50 mmol, 50 g, 1.0 mmol / g) and Fmoc-Cit-OH (19.8 g, 50 mmol, 1.0 eq), followed by DIEA (6.00 eq) and mixing for 3 hours. MeOH (50 mL) was then added and mixed for 30 minutes for end-capping. Deblocking was performed using 20% piperidine dissolved in DMF. Boc-Val-OH (32.5 g, 150 mmol, 3 eq) was coupled to 3 eq using a DMF (400 mL) solution of HBTU (2.85 eq) and DIPEA (6.0 eq). The reaction was monitored by the ninhydrin color reaction test. After the synthesis was completed, the peptide resin was washed with DMF X 3, MeOH X 3, and then dried overnight under N2 bubbles. Afterwards, the peptide resin was treated with 20% HFIP / DCM for 30 minutes twice. The solution was removed on a rotary evaporator to obtain a crude product. The crude peptide was dissolved in ACN / H2O and then lyophilized twice to obtain the peptide product (17.3 g crude product).
[0368] LCMS (ESI): <![CDATA[m / z 374.9[M+H] + ]]> Molecular weight 374.44
[0369] Compound 3
[0370]
[0371] A solution of compound 2 (4.00 g, 10.68 mmol, 1.00 eq) in DCM (40.00 mL) and MeOH (20.00 mL) was stirred at room temperature, then (4-aminophenyl) methanol (1.58 g, 12.82 mmol, 1.20 eq) and EEDQ (5.28 g, 21.37 mmol, 2.00 eq) were added, and the mixture was stirred in the dark for 9 hours. TLC (dichloromethane / methanol=5 / 1, Rf=0.56) showed that a new spot had formed. The reaction mixture was concentrated under reduced pressure to remove the solvent. By flash silica gel chromatography ( 120g The resulting residue was purified using a Silica Flash Column, eluting with 0 to 20% MeOH / DCM @ 80 mL / min).
[0372] Compound 3 (3.00 g, 6.26 mmol, yield 58.57%) was obtained as a white solid.
[0373] LCMS (ESI): <![CDATA[m / z 480.1[M+H] + ]]> Molecular weight 479.58
[0374] Compound 4
[0375]
[0376] To a solution of compound 3 (3.00 g, 6.26 mmol, 1.00 eq) in anhydrous THF (35.00 mL) and anhydrous DCM (15.00 mL) was added (4-nitrophenyl) chloroformate (6.31 g, 31.30 mmol, 5.00 eq) and pyridine (2.48 g, 31.30 mmol, 2.53 mL, 5.00 eq), and the mixture was stirred at 25 ° C for 5 hours. TLC (dichloromethane / methanol=10 / 1, Rf=0.55) showed that a new spot had formed. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography ( 120g Silica Flash Column, 0 to 10% DCM / MeOH elution @ 80 mL / min). Compound 4 (2.00 g, 3.10 mmol, 49.56% yield) was obtained as a white solid.
[0377] LCMS (ESI): <![CDATA[m / z 667.3[M+Na] + ]]> Molecular weight 644.68
[0378] Compound 5
[0379]
[0380] A mixture of compound 4 (278.43 mg, 387.80 μmol, 1.00 eq) and DIEA (501.19 mg, 3.88 mmol, 677.29 μL, 10.00 eq) was stirred in DMF (5.00 mL) under nitrogen for 10 minutes. MMAE (250.00 mg, 387.80 μmol, 1.00 eq) and HOBt (52.40 mg, 387.80 μmol, 1.00 eq) were added, and the mixture was stirred at 0 ° C under nitrogen for 20 minutes, and stirred for another 18 hours at 30 ° C. LC-MS showed that a main peak with the expected mass was detected. The resulting mixture was purified by rapid C18 gel chromatography ( 130g C18 Flash Column, 0 to 50% MeCN / H2O elution @ 75 mL / min). Compound 5 (190.00 mg, 155.29 μmol, 40.04% yield) was obtained as a white solid.
[0381] LCMS (ESI): <![CDATA[m / z 1223.4[M+H] + ]]> Molecular weight 1223.57
[0382] Compound 6
[0383]
[0384] 2,2,2-trifluoroacetic acid (413.32 mg, 3.62 mmol, 268.39 μL, 26.09 eq) was added to a solution of compound 5 (170.00 mg, 138.94 μmol, 1.00 eq) in DCM (2.70 mL), and the mixture was stirred at 25 ° C for 1 hour. LC-MS showed that compound 5 was completely consumed. The mixture was concentrated under reduced pressure to obtain a residue. The residue was dissolved in THF (10.00 mL), and K2CO3 (192.03 mg, 1.39 mmol, 10.00 eq) was added, and the mixture was stirred at room temperature for another 3 hours. LC-MS showed that a main peak with the expected mass was detected. The reaction mixture obtained was concentrated under reduced pressure to remove the solvent to obtain a residue. The residue was purified by rapid C18 gel chromatography ( 130g C18 Flash Column, 0 to 50% MeCN / H2O elution @ 75 mL / min). Compound 6 (110.00 mg, 97.92 μmol, 70.48% yield) was obtained as a white solid.
[0385] LCMS (ESI): <![CDATA[m / z 1123.4[M+H] + ]]> Molecular weight 1123.45
[0386] Compound 7
[0387]
[0388] To a solution of compound 6 (110.00 mg, 97.92 μmol, 1.00 eq) in DMA (5 mL), DIEA (25.31 mg, 195.83 μmol, 34.20 μL, 2.00 eq) and tetrahydropyran-2,6-dione (22.34 mg, 195.83 μmol, 2.00 eq) were added. The mixture was stirred at room temperature for 18 hours. LC-MS showed that compound 6 was completely consumed and a main peak with the expected mass was detected. The reaction mixture was purified by fast C18 gel chromatography ( 130g C18 Flash Column, 0 to 50% MeCN / H2O elution @ 75 mL / min). Compound 7 (100.00 mg, 80.81 μmol, 82.53% yield) was obtained as a white solid.
[0389] LCMS (ESI): <![CDATA[m / z 1237.4[M+H] + ]]> Molecular weight 1236.74
[0390] Compound 8 (MMAE-PABC-Cit-Val-glutarate-NHS)
[0391]
[0392] 1-Hydroxypyrrolidine-2,5-dione (27.90 mg, 242.42 μmol, 3.00 eq) was added to a solution of compound 7 (100.00 mg, 80.81 μmol, 1.00 eq) in DMA (4.5 mL) and DCM (1.5 mL) under N2, and the mixture was stirred at 0°C for 30 minutes. EDCI (46.47 mg, 242.43 μmol, 3.00 eq) was added to the mixture, and the mixture was stirred at 25°C for another 16 hours. LC-MS showed that compound 7 was completely consumed, and a major peak with the expected mass was detected. The reaction mixture was purified by flash C18 gel chromatography ( 130g C18 Flash Column, 0 to 50% MeCN / H2O elution @ 75 mL / min). Compound 8 (90.00 mg, 60.69 μmol, 75.11% yield) was obtained as a white solid.
[0393] LCMS (ESI): <![CDATA[m / z 1334.5[M+H] + ]]> Molecular weight 1334.62
[0394] General procedure for coupling MMAE-PABC-Cit-Val-glutarate-NHS to targeted bicyclic rings
[0395] To a solution of the bicyclic (1.0-1.3 eq) in DMA was added DIEA (3 eq) and MMAE-PABC-Cit-Val-glutarate-NHS (1 eq). The mixture was stirred at 25°C for 18 hours. The reaction was monitored by LC-MS and once complete, it was directly purified by preparative HPLC.
[0396] BCY6136
[0397]
[0398] BCY6099 (71.5 mg, 22.48 μmol) was used as the bicyclic reagent. Compound BCY6136 (40.9 mg, 9.05 μmol, 40.27% yield, 97.42% purity) was obtained as a white solid.
[0399]
[0400] BCY6033
[0401]
[0402]
[0403] BCY6014 (70.00 mg, 22.47 μmol, 1.00 eq) was used as the bicyclic reagent. Compound BCY6033 (33.90 mg, 7.96 μmol, 34.57% yield) was obtained as a white solid.
[0404]
[0405] BCY6029
[0406]
[0407] BCY6009 (70.0 mg, 22.47 μmol, 1 eq) was used as a bicyclic reagent to obtain compound BCY6029 (32.9 mg, 7.75 μmol, 33.49% yield) as a white solid.
[0408]
[0409] BCY6122
[0410]
[0411] BCY6104 (71.59 mg, 22.48 μmol, 1.00 eq) was used as a bicyclic reagent to obtain compound BCY6122 (38.30 mg, 8.57 μmol, 38.14% yield, 98.58% purity) as a white solid.
[0412]
[0413] BCY6053
[0414]
[0415] BCY6018 (72.40 mg, 26.97 μmol, 1.2 eq) was used as the bicyclic reagent. Compound BCY6053 (38.3 mg, 9.81 μmol, 43.65% yield) was obtained as a white solid.
[0416]
[0417]
[0418] BCY6049
[0419]
[0420] BCY6017 (50.75 mg, 22.48 μmol, 1.2 eq) was used as the bicyclic reagent. Compound BCY6049 (22.5 mg, 6.47 μmol, 34.54% yield) was obtained as a white solid.
[0421]
[0422] BCY6037
[0423]
[0424] BCY6019 (65.00 mg, 22.47 μmol, 1.00 eq) was used as a bicyclic reagent to obtain compound BCY6037 (26.80 mg, 6.66 μmol, 28.74% yield) as a white solid.
[0425]
[0426] Trp-Cit-MMAE Series
[0427] Trp-Cit-MMAE connector
[0428]
[0429]
[0430] General procedure for preparation of 3
[0431]
[0432] To a DMF (30.00 mL) solution of compound 2 (4.00 g, 8.67 mmol, 1.00 eq), DIC (1.61 g, 12.78 mmol, 1.97 mL, 9.00 eq) and HOBt (10.54 g, 78.00 mmol, 9.00 eq) was added (4-aminophenyl)methanol (9.61 g, 78.00 mmol, 9.00 eq). The mixture was stirred at 15 ° C for 1 hour. LC-MS showed that compound 2 was completely consumed and a main peak with the expected MS was detected. The mixture was purified by preparative HPLC. Compound 3 (4.20 g, 7.41 mmol, 85.49% yield) was obtained as a white solid.
[0433] LCMS (ESI): <![CDATA[m / z 566.9[M+H] + ]]> Molecular weight 566.66
[0434] General procedure for the preparation of 4
[0435]
[0436] To compound 3 (4.20g, 6.30mmol, 1.00eq), DIPEA (1.09g, 8.40mmol, 1.47mL, 7.00eq) in DMF (30.00mL) solution, one part of bis(4-nitrophenyl) carbonate (11.50g, 37.79mmol, 6.00eq) was added. The mixture was stirred at 0-15°C for 1.5 hours. LC-MS showed that compound 3 was completely consumed, and a main peak with the expected MS was detected. Direct purification by preparative HPLC (TFA conditions). Compound 4 (2.00g, 2.40mmol, 38.16% yield) was obtained as a white solid.
[0437] LCMS (ESI): <![CDATA[m / z 732.0[M+H] + ]]> Molecular weight 731.76
[0438] General procedure for the preparation of 5
[0439]
[0440] MMAE (233.03 mg, 324.57 μmol, 0.90 eq) and HOBt (48.73 mg, 360.63 μmol, 1.00 eq) were added to a DMF (10.00 mL) solution of compound 4 (300.00 mg, 360.63 μmol, 1.00 eq) and DIEA (93.22 mg, 721.27 μmol, 125.97 μL, 3.00 eq) at 0 ° C. The mixture was stirred at 30 ° C for 18 hours. LC-MS showed that compound 4 was completely consumed and a main peak with a desired MS was detected. Direct purification by preparative HPLC (neutral conditions). Compound 5 (250.00 mg, 190.75 μmol, 52.89% yield) was obtained as a yellow solid.
[0441] LCMS (ESI): <![CDATA[m / z 1310.5[M+H] + ]]> Molecular weight 1310.65
[0442] General procedure for the preparation of 6
[0443]
[0444]
[0445] TFA (1.54 g, 13.51 mmol, 1.00 mL, 73.76 eq) was added to a DCM (10.00 mL) solution of compound 5 (240.00 mg, 183.12 μmol, 1.00 eq). The mixture was stirred at 15 ° C for 2 hours. The mixture was then concentrated under reduced pressure to remove the solvent to obtain a residue, which was dissolved in THF, and K2CO3 was added and stirred at 15 ° C for 2 h. LC-MS showed that compound 5 was completely consumed, and a main peak with the desired MS was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue. The residue was purified by preparative HPLC (neutral conditions). The crude product 6 (125.00 mg, 94.37 μmol, 51.53% yield, TFA) was used in the next step without further purification.
[0446] LCMS (ESI): <![CDATA[m / z 1210.4[M+H] + ]]> Molecular weight 1209.53
[0447] General procedure for the preparation of 7
[0448]
[0449] To a solution of compound 6 (125.00 mg, 94.37 μmol, 1.00 eq, TFA) in DMA (5.00 mL) was added DIEA (24.39 mg, 188.75 μmol, 32.96 μL, 2.00 eq), tetrahydropyran-2,6-dione (21.54 mg, 188.75 μmol, 2.00 eq). The mixture was stirred at 15 ° C for 2 hours. LC-MS showed that compound 6 was completely consumed, and a main peak with the expected MS was detected. Direct purification by preparative HPLC (neutral conditions). Compound 7 (100.00 mg, 75.49 μmol, 80.00% yield) was obtained as a white solid.
[0450]
[0451]
[0452] General procedure for the preparation of 8 (MMAE-PABC-Cit-Trp-glutarate-NHS)
[0453]
[0454] To compound 7 (100.00 mg, 75.49 μmol, 1.00 eq), 1-hydroxypyrrolidine-2,5-dione (26.07 mg, 226.48 μmol, 3.00 eq) in DMA (3.00 mL) and DCM (1.00 mL) solution, EDCI (43.42 mg, 226.48 μmol, 3.00 eq) was added. The mixture was stirred at 15 ° C for 4 hours. LC-MS showed that compound 7 was completely consumed, and a main peak with a desired MS was detected. Remove DCM. Purify directly by preparative HPLC (neutral conditions). Compound 8 (60.00 mg, 42.20 μmol, 55.91% yield) was obtained as a white solid.
[0455] LCMS (ESI): <![CDATA[m / z 711.2[M+2H] 2+ ]]> Molecular weight 1421.7
[0456] General procedure for coupling MMAE-PABC-Cit-Trp-glutarate-NHS to targeted bicyclic
[0457] To a solution of the bicyclic (1.0-1.3 eq) in DMA was added DIEA (3 eq) and MMAE-PABC-Cit-Trp-glutarate-NHS (1 eq). The mixture was stirred at 25°C for 18 hours. The reaction was monitored by LC-MS and once complete, it was directly purified by preparative HPLC.
[0458] BCY6030
[0459]
[0460] BCY6009 (47.29 mg, 14.07 μmol, 1.00 eq) was used as the bicyclic reagent. Compound BCY6030 (0.0156 g, 3.51 μmol, 24.93% yield, 97.41% purity) was obtained as a white solid.
[0461]
[0462]
[0463] BCY6034
[0464]
[0465] BCY6014 (88.21 mg, 23.21 μmol, 1.10 eq) was used as the bicyclic reagent. Compound BCY6034 (27.70 mg, 6.05 μmol, 28.70% yield, 95.02% purity) was obtained as a white solid.
[0466]
[0467] BCY6050
[0468]
[0469] BCY6017 (57.17 mg, 25.32 μmol, 1.2 eq) was used as the bicyclic reagent. Compound BCY6050 (0.0519 g, 14.56 μmol, 69.01% yield) was obtained as a white solid.
[0470]
[0471] BCY6054
[0472]
[0473] BCY6018 (67.97 mg, 25.32 μmol, 1.2 eq) was used as a bicyclic reagent to obtain compound BCY6054 (40.10 mg, 10.05 μmol, 47.62% yield) as a white solid.
[0474]
[0475] BCY6038
[0476]
[0477] BCY6019 (81.39 mg, 23.21 μmol, 1.10 eq) was used as the bicyclic reagent. Compound BCY6038 (34.10 mg, 8.02 μmol, 38.00% yield, 96.68% purity) was obtained as a white solid.
[0478]
[0479] Val-Lys-MMAE Series
[0480] Val-Lys-MMAE Connector
[0481]
[0482] General procedure for the preparation of compound 2
[0483]
[0484] In the dark under nitrogen, to a mixture of compound 1 (3.00 g, 5.89 mmol, 1 eq) and (4-aminophenyl) methanol (869.93 mg, 7.06 mmol, 1.2 eq) in DCM (35 mL) and MeOH (18 mL) solution was added EEDQ (2.91 g, 11.77 mmol, 2 eq), and the mixture was stirred at 25 ° C for 5 hours. LC-MS showed that compound 1 was completely consumed and a main peak with the expected MS was detected. The resulting reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by flash silica gel chromatography ( 120g Silica Flash Column, 0 to 20% MeOH / DCM elution @ 80 mL / min). Compound 2 (2.2 g, 3.58 mmol, 60.79% yield) was obtained as a white solid.
[0485] LCMS (ESI): <![CDATA[m / z 615.0[M+H] + ]]> Molecular weight 614.78
[0486] General procedure for the preparation of compound 3
[0487]
[0488] To a solution of compound 2 (500 mg, 813.31 μmol, 1 eq) in THF (10 mL) was added DIEA (630.69 mg, 4.88 mmol, 849.98 μL, 6 eq) and stirred for 30 minutes at 0 ° C under nitrogen. Then bis (4-nitrophenyl) carbonate (1.48 g, 4.88 mmol, 6 eq) was added thereto and the mixture was stirred for another 21 hours at 25 ° C under nitrogen. LC-MS showed that a main peak with the expected MS was detected. The resulting reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by flash silica gel chromatography ( 40g Silica Flash Column, 0 to 20% MeOH / DCM elution @40 mL / min). Compound 3 (500 mg, 641.13 μmol, 78.83% yield) was obtained as a yellow solid.
[0489] LCMS (ESI): <![CDATA[m / z 780.0[M+H] + ]]> Molecular weight 779.89
[0490] General procedure for the preparation of compound 4
[0491]
[0492] To a DMF (8 mL) solution of a mixture of compound 3 (500 mg, 512.90 μmol, 1.23 eq) was added DIEA (135.01 mg, 1.04 mmol, 181.95 μL, 2.5 eq) and stirred at 0 ° C for 30 minutes. Then MMAE (300 mg, 417.84 μmol, 1 eq) and HOBt (84.69 mg, 626.76 μmol, 1.5 eq) were added thereto, and the mixture was stirred at 40 ° C for 15 hours. LC-MS showed that compound 3 was completely consumed, and a main peak with the expected MS was detected. The residue was purified by fast C18 gel chromatography ( 130g C18 Flash Column, 0 to 60% MeCN / H2O elution @ 75 mL / min). Compound 4 (330 mg, 242.87 μmol, 58.13% yield) was obtained as a white solid.
[0493] LCMS (ESI): <![CDATA[m / z 679.7[M+2H] 2+ ]]> Molecular weight 1358.77
[0494] General procedure for the preparation of compound 5
[0495]
[0496] To a solution of compound 4 (325 mg, 239.19 μmol, 1 eq) in DCM (18 mL) was added TFA (3.03 g, 26.60 mmol, 1.97 mL, 111.22 eq) at 0°C, and the mixture was stirred at 25°C for 2 hours. LC-MS showed that compound 4 was completely consumed. The reaction mixture was then concentrated under reduced pressure to obtain a residue, which was dissolved in THF (10 mL), and K2CO3 (661.16 mg, 4.78 mmol, 20 eq) was added thereto. The mixture was stirred at 25°C for 15 hours. LC-MS showed that a main peak with the expected MS was detected. The obtained reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by flash C18 gel chromatography ( 130g C18 Flash Column, 0 to 60% MeCN / H2O elution @ 75 mL / min). Compound 5 (170 mg, 135.07 μmol, 56.47% yield) was obtained as a white solid.
[0497] LCMS (ESI): <![CDATA[m / z 629.7[M+2H] 2+ ]]> Molecular weight 1258.65
[0498] General procedure for the preparation of compound 6
[0499]
[0500] A round bottle containing a DMA (5 mL) solution of compound 5 (140 mg, 111.23 μmol, 1 eq) was purged using a nitrogen balloon, and DIEA (28.75 mg, 222.46 μmol, 38.75 μL, 2 eq) was added at 0°C, stirred for 10 minutes, and a DMA solution of tetrahydropyran-2,6-dione (25.38 mg, 222.46 μmol, 2 eq) was added. The mixture was stirred at 25°C for 12 hours. LC-MS showed that compound 5 was completely consumed, and a main peak with the expected MS was detected. The resulting reaction mixture was purified by rapid C18 gel chromatography ( 43g C18 Flash Column, 0 to 60% MeCN / H2O elution @ 40 mL / min). Compound 6 (120 mg, 87.42 μmol, 78.59% yield) was obtained as a white solid.
[0501] LCMS (ESI): <![CDATA[m / z 686.7[M+2H] 2+ ]]> Molecular weight 1372.75
[0502] General procedure for the preparation of compound 7 (MMAE-PABC-Lys(Dde)-Val-glutarate-NHS)
[0503]
[0504]
[0505] 1-Hydroxypyrrolidine-2,5-dione (30.18 mg, 262.25 μmol, 3 eq) was added to a solution of compound 6 (120 mg, 87.42 μmol, 1 eq) in DMA (9 mL) and DCM (3 mL), stirred, and EDCI (50.27 mg, 262.25 μmol, 3 eq) was added thereto, and the mixture was stirred at 0 ° C for 30 minutes and at 25 ° C for another 19 hours. LC-MS showed that compound 6 was completely consumed and a main peak with the expected MS was detected. The resulting reaction mixture was concentrated under reduced pressure to remove DCM. The mixture was purified by flash C18 gel chromatography ( 43g C18 Flash Column, 0 to 60% MeCN / H2O elution @ 40 mL / min). Compound 7 (60 mg, 40.82 μmol, 46.70% yield) was obtained as a white solid.
[0506] LCMS (ESI): <![CDATA[m / z 735.3[M+2H] 2+ ]]> Molecular weight 1469.83
[0507] General procedure for the coupling of MMAE-PABC-Lys(Dde)-Val-glutarate-NHS with targeted bicyclic
[0508]
[0509] To a solution of the bicyclic (1.0-1.3 eq) in DMA was added DIEA (3 eq) and MMAE-PABC-Lys(Dde)-Val-glutarate-NHS (1 eq). The mixture was stirred at 25°C for 18 hours. The reaction was monitored by LC-MS and once complete, it was directly purified by preparative HPLC.
[0510] General procedure for Dde deprotection
[0511]
[0512] To a solution of the Dde protected peptide (1 eq) in DMF was added hydrazine hydrate (6500 eq) and the mixture was stirred for 1 hour at 25° C. The reaction was monitored by LC-MS and once complete the mixture was purified by preparative HPLC and the clean fractions were lyophilized.
[0513] BCY6061
[0514]
[0515] BCY6014 (124.12 mg, 40.82 μmol, 1.2 eq) was used as the bicyclic reagent. Dde-BCY6038 (80 mg, 18.20 μmol, 53.51% yield) was obtained as a white solid.
[0516]
[0517]
[0518] Dde-BCY6061 (78 mg, 17.75 μmol) was deprotected with hydrazine according to the general procedure to give BCY6061 (47.1 mg, 11.13 μmol, 62.73% yield) as a white solid.
[0519]
[0520] BCY6174
[0521]
[0522] BCY6099 (389.77 mg, 122.47 μmol, 1.2 eq) was used as the bicyclic reagent. Dde-BCY6174 (0.250 g, 55.10 μmol, 53.99% yield) was obtained as a white solid.
[0523]
[0524]
[0525] Dde-BCY6174 (0.250 g, 55.10 μmol, 1.0 eq) was deprotected with hydrazine according to the general procedure to give BCY6174 (0.1206 g, 27.45 μmol, 49.82% yield) as a white solid.
[0526]
[0527] D-Trp-Cit-MMAE Series
[0528] D-Trp-Cit-MMAE connector
[0529]
[0530]
[0531] General procedure for the preparation of compound 3
[0532]
[0533] To a DMF (30.00 mL) solution of compound 1 (2 g, 4.33 mmol, 1.00 eq), DIC (4.92 g, 39.00 mmol, 6.00 mL, 9.00 eq), HOBt (5.27 g, 39.00 mmol, 9.00 eq) was added (4-aminophenyl)methanol (4.80 g, 39.00 mmol, 9.00 eq). The mixture was stirred at 15 ° C for 1 hour. LC-MS showed that compound 1 was completely consumed and a main peak with the expected MS was detected. Direct purification by preparative HPLC (neutral conditions). Compound 2 (2 g, 3.53 mmol, 81.45% yield) was obtained as a white solid.
[0534] LCMS (ESI): <![CDATA[m / z 666.9[M+H] + ]]> Molecular weight 666.78
[0535] General procedure for the preparation of compound 4
[0536]
[0537] To a DMF (20 mL) solution of compound 2 (2 g, 3.00 mmol, 1 eq), DIEA (2.71 g, 21.00 mmol, 3.66 mL, 7 eq) was added a portion of bis (4-nitrophenyl) carbonate (5.48 g, 18.00 mmol, 6 eq) at 0 ° C. The mixture was stirred at 0-15 ° C for 2 hours. LC-MS showed that compound 2 was completely consumed and a main peak with the expected MS was detected. Direct purification by preparative HPLC (neutral conditions). Compound 3 (0.9 g, 1.08 mmol, 36.07% yield) was obtained as a yellow solid.
[0538] LCMS (ESI): <![CDATA[m / z 832.0[M+H] + ]]> Molecular weight 831.88
[0539] General procedure for the preparation of compound 5
[0540]
[0541] MMAE (302.08 mg, 420.74 μmol, 1 eq) was added to a DMF (10 mL) solution of compound 3 (350 mg, 420.74 μmol, 1.00 eq), HOBt (56.85 mg, 420.74 μmol, 1 eq) and DIEA (163.13 mg, 1.26 mmol, 219.86 μL, 3 eq) at 0 ° C. The mixture was stirred at 40 ° C for 18 hours. LC-MS showed that compound 4 was completely consumed and a main peak with the expected MS was detected. Direct purification by preparative HPLC (neutral conditions). Compound 4 (0.22 g, 155.95 μmol, 37.06% yield) was obtained as a yellow solid.
[0542] LCMS (ESI): <![CDATA[m / z 1410.5[M+H] + ,705.7[M+2H] 2+ <!-- 72 --> ]]> Molecular weight 1410.76
[0543] General procedure for the preparation of compound 6
[0544]
[0545] TFA (1.54 g, 13.51 mmol, 1 mL, 90.73 eq) was added to a DCM (9 mL) solution of compound 4 (0.21 g, 148.86 μmol, 1 eq). The mixture was stirred at 15 ° C for 4 h and concentrated under reduced pressure to give a residue, which was dissolved in THF, then K2CO3 (s) was added and stirred at 15 ° C for 16 h. LC-MS showed that compound 4 was completely consumed and a main peak with the desired MS was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (neutral conditions). Compound 5 (0.13 g, 102.02 μmol, 68.54% yield, 95% purity) was obtained as a white solid.
[0546] LCMS (ESI): <![CDATA[m / z 1210.4[M+H] + ,605.8[M+2H] 2+ ]]> Molecular weight 1210.53
[0547] General procedure for the preparation of compound 7
[0548]
[0549] DIEA (38.44 mg, 297.40 μmol, 51.80 μL, 3 eq) and tetrahydropyran-2,6-dione (22.62 mg, 198.26 μmol, 2 eq) were added to a solution of compound 5 (0.12 g, 99.13 μmol, 1 eq) in DMA (5 mL). The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that compound 5 was completely consumed and a main peak with the expected MS was detected. Direct purification by preparative HPLC (neutral conditions). Compound 6 (0.09 g, 67.94 μmol, 68.54% yield) was obtained as a white solid.
[0550] LCMS (ESI): <![CDATA[m / z 662.7[M+2H] 2+ ]]> Molecular weight 1324.63
[0551] General procedure for the preparation of compound 8
[0552]
[0553] EDCI (39.08 mg, 203.84 μmol, 3 eq) was added to a solution of compound 6 (0.09 g, 67.95 μmol, 1 eq), HOSu (23.46 mg, 203.84 μmol, 3 eq) in DMA (6 mL) and DCM (2 mL). The mixture was stirred at 15 ° C for 16 h. LC-MS showed that compound 6 was completely consumed, and a main peak with the expected MS was detected. DCM was removed and directly purified by preparative HPLC (neutral conditions). Compound 7 (0.06 g, 40.09 μmol, 59.01% yield, 95% purity) was obtained as a white solid.
[0554] LCMS (ESI): <![CDATA[m / z 711.2[M+2H] 2+ ]]> Molecular weight 1421.7
[0555] BCY6062
[0556] To a solution of BCY6014 (76.99 mg, 25.32 μmol, 1.2 eq) in DMA (5 mL) was added DIEA (8.18 mg, 63.31 μmol, 11.03 μL, 3 eq), compound 7 (0.03 g, 21.10 μmol, 1 eq). The mixture was stirred at 15 ° C for 16 hours. The reaction was monitored by LC-MS, and once completed, the mixture was purified by preparative HPLC. BCY6062 (0.0255 g, 5.70 μmol, 27.01% yield, 97.15% purity) was obtained as a white solid.
[0557]
[0558] DM1 Series
[0559] DM1-SS-Series
[0560] DM1-SPDP-TFP Connector
[0561]
[0562] SPDB
[0563]
[0564] 4-sulfanylbutyric acid (4.50 g, 37.45 mmol, 1.00 eq) was added to a solution of 2-(2-pyridyldisulfanyl)pyridine (12.37 g, 56.18 mmol, 1.50 eq) in EtOH (100.00 mL). The mixture was stirred at 15 ° C for 18 hours under N2. LC-MS showed that compound 1 was completely consumed and a major peak with the expected mass was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue. The residue was purified by preparative HPLC (C18360 g, neutral conditions). Compound SPDB (1.9 g, 8.29 mmol, 22.12% yield) was obtained as a yellow solid.
[0565] 1 H NMR:ES6446-8-P1A 400MHz CDCl3
[0566] δppm 1.98(q,J=7.09Hz,2H),2.45(t,J=7.15Hz,2H),2.79(t,J=7.03Hz,2H),7.03(d d,J=7.15,4.89Hz,1H),7.19(s,1H),7.56-7.65(m,2H),8.41(d,J=4.52Hz,1H).
[0567] LCMS (ESI): <![CDATA[m / z 230.0[M+H] + ]]> Molecular weight 229.31
[0568] DM1-SPDB
[0569]
[0570] A mixture of DM1 (250.00 mg, 338.62 μmol, 1.00 eq) and 4-(2-pyridyldisulfanyl)butanoic acid (100.95 mg, 440.21 μmol, 1.30 eq) was added to a 50 mL flask under nitrogen, and the flask containing DMF (10.00 mL) was purged with N2 for 30 minutes. The mixture was stirred at room temperature for 1 hour. LC-MS showed that DM1 was completely consumed and a major peak with the expected mass was detected. The residue was purified by flash C18 gel chromatography ( 120g C18 Flash Column, 0 to 60% MeCN / H2O elution @ 85 mL / min). DM1-SPDB (120.00 mg, 140.11 μmol, 41.38% yield) was obtained as a white solid.
[0571] LCMS (ESI): <![CDATA[m / z 838.0[M+H-H2O] + ]]> Molecular weight 856.44
[0572] DM1-SPDB-TFP
[0573]
[0574] EDCI (80.58 mg, 420.34 μmol, 3.00 eq) was added to a solution of DM1-SPDB (120.00 mg, 140.11 μmol, 1.00 eq) and 2,3,5,6-tetrafluorophenol (69.81 mg, 420.34 μmol, 3.00 eq) in DCM (1.00 mL) and DMA (3.00 mL). The mixture was stirred at 15 ° C for 4 hours. LC-MS showed that DM1-SPDB was completely consumed and a main peak with the expected mass was detected. DCM was removed, and the residue and the mixture were directly purified by preparative HPLC (neutral conditions). The compound DM1-SPDB-TFP (60.00 mg, 59.73 μmol, 42.63% yield) was obtained as a white solid.
[0575] LCMS (ESI): <![CDATA[m / z 985.9[M+H-H2O] + ]]> Molecular weight 1004.5
[0576] General procedure for coupling DM1-SPDB-TFP to targeted bicyclic rings
[0577] To a solution of the targeted bicyclic (1.1-1.3 eq) in DMA was added DIEA (3 eq) and DM1-SPDB-TFP (1 eq). The mixture was stirred at 25°C for 18 hours. The reaction was monitored by LC-MS and once complete, the mixture was directly purified by preparative HPLC.
[0578] BCY6135
[0579]
[0580] BCY6099 (114.1 mg, 35.84 μmol) was used as the bicyclic reagent. 22.4 mg of compound BCY6135 (5.30 μmol, 17.74% yield, 95.14% purity) was obtained as a white solid.
[0581]
[0582]
[0583] BCY6031
[0584]
[0585] BCY6014 (121.07 mg, 39.82 μmol) was used as the bicyclic reagent. 59.90 mg of compound BCY6031 (14.67 μmol, 36.85% yield, 95.02% purity) was obtained as a white solid.
[0586]
[0587] BCY6134
[0588]
[0589] BCY6104 (95.11 mg, 29.87 μmol, 1 eq) was used as the bicyclic reagent. BCY6134 (0.0232 g, 5.64 μmol, 18.89% yield, 97.82% purity) was obtained as a white solid.
[0590]
[0591] BCY6027
[0592]
[0593] BCY6009 (60.24 mg, 19.91 μmol, 1.00 eq) was used as the bicyclic reagent. BCY6027 (20.40 mg, 5.11 μmol, 25.69% yield, 96.88% purity) was obtained as a white solid.
[0594]
[0595] BCY6047
[0596]
[0597] BCY6017 (61.81 mg, 27.38 μmol, 1.1 eq) was used as the bicyclic reagent. BCY6047 (0.032 g, 10.34 μmol, 41.53% yield) was obtained as a white solid.
[0598]
[0599] BCY6035
[0600]
[0601] BCY6019 (115.22 mg, 32.86 μmol, 1.10 eq) was used as the bicyclic reagent. BCY6035 (37.80 mg, 10.37 μmol, 34.73% yield) was obtained as a white solid.
[0602]
[0603] BCY6051
[0604]
[0605] BCY6018 (73.48 mg, 27.38 μmol, 1.1 eq) was used as the bicyclic reagent. BCY6051 (0.0582 g, 16.52 μmol, 66.39% yield) was obtained as a white solid.
[0606]
[0607] BCY6154
[0608]
[0609] BCY6152 (93.17 mg, 29.87 μmol, 1 eq) was used as the bicyclic reagent. BCY6154 (40.10 mg, 9.93 μmol, 33.27% yield, 98.06% purity) was obtained as a white solid.
[0610]
[0611] BCY6155
[0612]
[0613] BCY6153 (82.55 mg, 29.87 μmol, 1 eq) was used as the bicyclic reagent. BCY6155 (0.0312 g, 8.55 μmol, 28.62% yield, 98.69% purity) was obtained as a white solid.
[0614]
[0615] DM1-SS(SO3H)-Series
[0616] DM1-SPDP(SO3H)-NHS connector
[0617]
[0618] Compound 2
[0619]
[0620] To a solution of 4-sulfanylbutyric acid (2.0 g, 16.64 mmol, 1 eq) and 2-(2-pyridyldisulfanyl)pyridine (11.0 g, 49.93 mmol, 3 eq) in EtOH (50 mL) was added AcOH (1.05 g, 17.48 mmol, 1 mL, 1.05 eq). The mixture was stirred at 40 ° C for 16 hours under N2. LC-MS showed that a major peak with the expected mass was detected, and TLC showed that 4-sulfanylbutyric acid was completely consumed. The reaction mixture was concentrated under reduced pressure to remove the solvent to give a residue. The residue was purified by preparative HPLC (neutral conditions). Compound 2 (2.0 g, 8.72 mmol, 52.4% yield) was obtained as a yellow solid.
[0621] 1 H NMR: 400MHz CDCl3
[0622] δppm 2.03-2.11(m,2H),2.54(t,J=7.20Hz,2H),2.88(t,J=7.20Hz,2H),7.11-7.14(m,1H),7.67-7.74(m,2H),8.50(d,J=4.80Hz,1H).
[0623] LCMS (ESI): <![CDATA[230[M+H] + ]]> Molecular weight 229.31
[0624] Compound 3
[0625]
[0626] Add the chlorosulfonic acid (1.5g, 13.08mmol, 0.89mL, 6eq) that is divided into three portions and the DIEA (1.13g, 8.72mmol, 1.52mL, 4eq) that is divided into two portions to DCE (5mL) solution of compound 2 (0.5g, 2.18mmol, 1eq).The mixture is stirred 2 hours at 75 ℃.LC-MS shows that compound 2 is completely consumed, and a main peak with a desired quality is detected.By adding 3mL H2O quenching reaction mixture, and removing DCE.By residue, mixture by preparative HPLC direct purification (neutral conditions).Compound 3 (0.68g, 1.76mmol, 80.6% productive rate, 80% purity) that is obtained as light yellow oil.
[0627] 1 H NMR: 400MHz CDCl3
[0628] δppm 2.49-2.54(m,2H),3.63-3.67(m,2H),3.90(t,J=6.60Hz,2H),7.09-7.12 (m,1H),7.66-7.76(m,2H),8.47(dd,J=4.80Hz,0.80Hz,1H),8.56(s,1H).
[0629] LCMS (ESI): <![CDATA[310.0[M+H] + ]]> Molecular weight 309.37
[0630] DM1-SO3H-SPDB
[0631]
[0632] To a DMF (10 mL) solution of DM1 (1.0 g, 1.35 mmol, 1 eq) and compound 3 (502.9 mg, 1.63 mmol, 1.2 eq) was added NaHCO (aq) until pH reached 8. The mixture was stirred at 25 ° C for 1 hour. LC-MS showed that DM1 was completely consumed and a main peak with the expected mass was detected. The residue and the mixture were directly purified by preparative HPLC (neutral conditions). Compound DM1-SO H-SPDB (0.28 g, 299.0 μmol, 22.1% yield) was obtained as a white solid.
[0633] LCMS (ESI): <![CDATA[918.2[M+H-H2O] + ]]> Molecular weight 936.50
[0634] DM1-SO3H-SPDB-NHS
[0635]
[0636] EDCI (171.9 mg, 896.95 μmol, 3 eq) was added to a solution of DM1-SO3H-SPDB (103.2 mg, 896.95 μmol, 3 eq) in DMA (6 mL) and DCM (2 mL). The mixture was stirred at 25 ° C for 16 hours. LC-MS showed that DM1-SO3H-SPDB was completely consumed and a main peak with the expected mass was detected. DCM was removed. The residue and the mixture were directly purified by preparative HPLC (neutral conditions). The compound DM1-SO3H-SPDB-NHS (0.22 g, 212.85 μmol, 71.2% yield) was obtained as a white solid.
[0637] LCMS (ESI): <![CDATA[1015.2[M+H-H2O] + ]]> Molecular weight 1033.57
[0638] General procedure for the coupling of DM1-SO3H-SPDB-NHS with targeted bicyclic rings
[0639] To a solution of the targeted bicyclic (1.1-1.3 eq) in DMA was added DIEA (3 eq) and DM1-SO3H-SPDB-NHS (1 eq). The mixture was stirred at 25°C for 16 hours. The reaction was monitored by LC-MS and once complete, the mixture was directly purified by preparative HPLC.
[0640] BCY6173
[0641]
[0642] BCY6099 (200.15 mg, 62.89 μmol) was used as the bicyclic reagent to obtain 57.1 mg of compound BCY6173 (3.40 μmol, 22.79% yield, 95.80% purity) as a white solid.
[0643]
[0644]
[0645] BCY6082
[0646]
[0647] BCY6014 (711.9 mg, 234.14 μmol) was used as the bicyclic reagent. 308 mg of compound BCY6082 (74.97 μmol, 35.2% yield, 96.36% purity) were obtained as a white solid.
[0648]
[0649] BCY6150
[0650]
[0651] BCY6018 (77.91 mg, 29.03 μmol, 1 eq) was used as the bicyclic reagent. BCY6150 (0.0249 g, 6.61 μmol, 22.78% yield) was obtained as a white solid.
[0652]
[0653]
[0654] BCY6151
[0655]
[0656] BCY6104 (120.17 mg, 37.73 μmol, 1.3 eq) was used as the bicyclic reagent. BCY6151 (0.0256 g, 6.16 μmol, 21.22% yield) was obtained as a white solid.
[0657]
[0658] BCY6162
[0659]
[0660] BCY6138 (82.80 mg, 26.61 μmol, 1.1 eq) was used as the bicyclic reagent. BCY6162 (0.0362 g, 8.98 μmol, 37.13% yield) was obtained as a white solid.
[0661]
[0662] BCY6161
[0663]
[0664] BCY6137 (79.67 mg, 24.48 μmol, 1.1 eq) was used as the bicyclic reagent. BCY6161 (0.0232 g, 5.26 μmol, 21.76% yield) was obtained as a white solid.
[0665]
[0666] DM1-SS-Me Series
[0667] DM1-SS-Me connector
[0668]
[0669] SPP
[0670]
[0671] To a solution of 2-(2-pyridyldisulfanyl)pyridine (2.46 g, 11.18 mmol, 1.50 eq) and AcOH (1.05 g, 17.49 mmol, 1.00 mL, 2.35 eq) in EtOH (50.00 mL) was added 4-sulfanylpentanoic acid (1.00 g, 7.45 mmol, 1.00 eq). The mixture was stirred at 40 ° C for 18 hours under N2. LC-MS showed that compound 1 was completely consumed and a major peak with the expected mass was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent to give a residue. The residue was purified by preparative HPLC (neutral conditions). Compound SPP (1.61 g, 6.62 mmol, 88.81% yield) was obtained as a yellow solid.
[0672] 1 H NMR: 400MHz DMSO-d6
[0673] δppm 1.36(d,J=6.78Hz,3H),1.88-2.07(m,2H),2.56(td,J=7.53,1.76Hz,2H),3.00-3.09(m,1H),7.11(ddd,J= 7.34, 4.96, 1.00Hz, 1H), 7.66 (td, J = 7.78, 1.76Hz, 1H), 7.73-7.77 (m, 1H), 8.48 (dt, J = 4.02, 0.88Hz, 1H).
[0674] LCMS (ESI): <![CDATA[243.8[M+H] + ]]> Molecular weight 243.34
[0675] DM1-SPP
[0676]
[0677] A solution of DM1 (200 mg, 270.90 μmol, 1.00 eq) and 4-(2-pyridyldisulfanyl)pentanoic acid (98.89 mg, 406.35 μmol, 1.50 eq) in water (5.00 mL) was adjusted to pH = 8 using NaHCO3 (aq). The mixture was stirred at 15°C for 1 hour. LC-MS showed that DM1 was completely consumed, and a main peak with the expected mass was detected (main MS was M+1-18). The mixture was directly purified by preparative HPLC (neutral conditions). Compound DM1-SPP (120 mg, 137.86 μmol, 50.89% yield) was obtained as a white solid.
[0678] LCMS (ESI): <![CDATA[852.0[M+H-H2O] + ]]> Molecular weight 870.47
[0679] DM1-SPP-TFP
[0680]
[0681] EDCI (115.62 mg, 603.13 μmol, 3.0 eq) was added to a solution of DM1-SPP (0.175 g, 201.04 μmol, 1.0 eq), 2,3,5,6-tetrafluorophenol (100.16 mg, 603.13 μmol, 3.0 eq) in DCM (1.0 mL) and DMA (3.0 mL). The mixture was stirred at 15 ° C for 12 hours. LC-MS showed that DM1-SPP was completely consumed and a main peak with the expected MS was detected. DCM was removed and the residue was purified by preparative HPLC (neutral conditions). Compound DM1-SPP-TFP (0.123 g, 120.76 μmol, 60.07% yield) was obtained as a white solid.
[0682] LCMS (ESI): <![CDATA[999.9[M+H-H2O] + ]]> Molecular weight 1018.53
[0683] General procedure for coupling DM1-SPP-TFP to targeted bicyclic rings
[0684] To a solution of the targeted bicyclic (1.1-1.3 eq) in DMA was added DIEA (3 eq) and DM1-SPP-TFP (1 eq). The mixture was stirred at 25°C for 16 hours. The reaction was monitored by LC-MS and once complete, the mixture was directly purified by preparative HPLC.
[0685] BCY6032
[0686]
[0687] To a solution of DM1-SPP (30.00 mg, 34.46 μmol, 1.00 eq) in DMF (5.00 mL) was added DIEA (13.36 mg, 103.38 μmol, 18.05 μL, 3.00 eq) and HATU (13.10 mg, 34.46 μmol, 1.00 eq). After 1 hour, BCY6014 (104.79 mg, 34.46 μmol, 1.00 eq) was added, and the mixture was stirred at 15 ° C for 2 hours. LC-MS showed that 40% of DM1-SPP remained. Several new peaks were observed on LC-MS, and 20% of the desired compound was detected. The mixture was directly purified by preparative HPLC (TFA conditions). Compound BCY6032 (10.00 mg, 2.57 μmol, 7.45% yield) was obtained as a white solid.
[0688]
[0689]
[0690] BCY6052
[0691]
[0692] BCY6018 (86.96 mg, 32.40 μmol, 1.1 eq) was used as the bicyclic reagent. BCY6052 (32.30 mg, 9.13 μmol, 31.01% yield) was obtained as a white solid.
[0693]
[0694] BCY6048
[0695]
[0696] BCY6017 (66.50 mg, 29.45 μmol, 1.2 eq) was used as the bicyclic reagent. BCY6048 (40.80 mg, 13.12 μmol, 53.45% yield) was obtained as a white solid.
[0697]
[0698] BCY6036
[0699]
[0700]
[0701] BCY6019 (113.60 mg, 32.40 μmol, 1.10 eq) was used as the bicyclic reagent. (53.20 mg, 14.00 μmol, 47.54% yield, 96.26% purity) was obtained as a white solid.
[0702]
[0703] BCY6028
[0704]
[0705] BCY6009 (99.00 mg, 29.45 μmol, 1.00 eq) was used as the bicyclic reagent. BCY6028 (24.30 mg, 6.05 μmol, 20.56% yield, 96.61% purity) was obtained as a white solid.
[0706]
[0707] Disulfide linkers (various hindrances)
[0708] BCY6039(DM1-Me-SS-Me-Bicyclic)
[0709]
[0710]
[0711] Compound 2A
[0712]
[0713] To a solution of 2-(2-pyridyldisulfanyl)pyridine (2.46 g, 11.18 mmol, 1.50 eq) and AcOH (1.05 g, 17.49 mmol, 1.00 mL, 2.35 eq) in EtOH (50.00 mL) was added 4-sulfanylpentanoic acid (1A) (1.00 g, 7.45 mmol, 1.00 eq). The mixture was stirred at 40 °C for 18 hours under N2. LC-MS showed that 1A was completely consumed and a major peak with the expected mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue, which was purified by preparative HPLC (neutral conditions). Compound 2A (1.61 g, 6.62 mmol, 88.81% yield) was obtained as a light yellow solid.
[0714] LCMS (ESI): <![CDATA[243.9[M+H] + ]]> Molecular weight 243.34
[0715] Compound 3A
[0716]
[0717] EDCI (23.63 mg, 123.28 μmol, 3.00 eq) was added to a DMA (1 mL) solution of 2A (0.01 g, 41.09 μmol, 1.00 eq) and 1-hydroxypyrrolidine 2,5-dione (14.19 mg, 123.28 μmol, 3.00 eq). The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that 2A was completely consumed and a main peak with the expected mass was detected. The residue was purified by preparative HPLC (neutral conditions). Compound 3A (0.011 g, 32.31 μmol, 78.63% yield) was obtained as a white solid.
[0718] LCMS (ESI): <![CDATA[340.8[M+H] + ]]> Molecular weight 340.41
[0719] Compound 4A
[0720]
[0721] To a solution of BCY6014 (98.25 mg, 32.31 μmol, 1.00 eq) in DMA (3 mL) was added DIEA (8.26 mg, 64.62 μmol, 11.26 μL, 2.00 eq) and 3A (0.011 g, 32.31 μmol, 1.00 eq). The mixture was stirred at 15 ° C for 18 hours. LC-MS showed that 3A was completely consumed and a main peak with the expected mass was detected. The mixture was directly purified by preparative HPLC (neutral conditions). Compound 4A (0.04 g, 12.25 μmol, 37.90% yield) was obtained as a white solid.
[0722] LCMS (ESI): <![CDATA[1088.7[M+3H] 3+ ,816.5[M+4H] 4+ ]]> Molecular weight 3264.88
[0723] Compound 5A
[0724]
[0725] To a solution of 4A (0.04 g, 12.25 μmol, 1.00 eq) in MeCN (4 mL) and water (2 mL) was added TCEP (4.21 mg, 14.70 μmol, 4.05 μL, 1.20 eq). The mixture was stirred at 15 ° C for 1 hour. LC-MS showed that 4A was completely consumed and a main peak with the desired mass was detected. The residue was purified by preparative HPLC (neutral conditions). Compound 5A (0.035 g, 11.09 μmol, 90.53% yield) was obtained as a white solid.
[0726] LCMS (ESI): <![CDATA[1052.2[M+3H] 3+ ]]> Molecular weight 3155.73
[0727] DM3-SPy
[0728]
[0729] To a solution of 4-(2-pyridyldisulfanyl)pentanoic acid (2A) (22.46 mg, 92.29 μmol, 1.20 eq), HATU (35.09 mg, 92.29 μmol, 1.20 eq), DIEA (29.82 mg, 230.71 μmol, 40.19 μL, 3.00 eq) in DMF (5 mL) was added 1B (0.05 g, 76.90 μmol, 1.00 eq). The mixture was stirred at 15 °C for 1 hour. LC-MS showed that 1B was completely consumed and a major peak with the expected mass was detected. The residue was purified by preparative HPLC (neutral conditions). Compound DM3-SPy (0.025 g, 28.56 μmol, 37.13% yield) was obtained as a white solid.
[0730] LCMS (ESI): <![CDATA[875.1[M+H] + ]]> Molecular weight 875.49
[0731] BCY6039
[0732]
[0733] A solution of DM3-SPy (0.015 g, 17.13 μmol, 1.00 eq) and 5A (54.08 mg, 17.13 μmol, 1.00 eq) in DMF (3 mL) was adjusted to pH = 8 using NaHCO3 (aq). The mixture was stirred at 15 ° C for 1 hour. LC-MS showed that DM3-SPy was completely consumed and a main peak with the expected mass was detected. The mixture was directly purified by preparative HPLC (TFA conditions). Compound BCY6039 (0.0263 g, 6.58 μmol, 38.39% yield) was obtained as a white solid.
[0734]
[0735] BCY6055(DM1-SS-Me2-bicyclic)
[0736]
[0737]
[0738] Compound 2
[0739]
[0740] A solution of compound 1 (0.045 g, 126.96 μmol, 1 eq) in H2O (1 mL) was adjusted to pH = 13 using 1N NaOH solution. The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that compound 1 was completely consumed and a main peak with the expected mass was detected. The residue was purified by preparative HPLC (neutral conditions). Compound 2 (0.03 g, 116.56 μmol, 91.81% yield) was obtained as a yellow solid.
[0741] LCMS (ESI): <![CDATA[257.9[M+H] + ]]> Molecular weight 257.37
[0742] Compound 3
[0743]
[0744] A DMF (5 mL) solution of compound 2 (0.03, 116.56 μmol, 1.0 eq) and DM1 (111.87 mg, 151.53 μmol, 1.3 eq) was stirred at 15 ° C for 2 hours. LC-MS showed that DM1 was completely consumed and a main peak with a desired mass was detected. The mixture was directly purified by preparative HPLC (NH4HCO3 conditions). Compound 3 (0.05 g, 56.53 μmol, 48.50% yield) was obtained as a white solid.
[0745] LCMS (ESI): <![CDATA[866.0[M+H-H2O] + ]]> Molecular weight 884.49
[0746] Compound 4
[0747]
[0748] EDCI (32.51 mg, 169.59 μmol, 3 eq) was added to a DMA (3 mL) and DCM (1 mL) solution of compound 3 (0.05 g, 56.53 μmol, 1.0 eq) and 2,3,5,6-tetrafluorophenol (28.16 mg, 169.59 μmol, 3.0 eq). The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that compound 3 was completely consumed and a main peak with a desired mass was detected. DCM was removed and the mixture was directly purified by preparative HPLC (neutral conditions). Compound 4 (0.03 g, 29.05 μmol, 51.40% yield) was obtained as a white solid.
[0749] LCMS (ESI): <![CDATA[1014.0[M+H-H2O] + ]]> Molecular weight 1032.55
[0750] BCY6055
[0751]
[0752] DIEA (11.27 mg, 87.16 μmol, 15.18 μL, 3.0 eq) and compound 4 (0.03 g, 29.05 μmol, 1.0 eq) were added to a solution of BCY6014 (106.01 mg, 34.87 μmol, 1.2 eq) in DMA (3 mL). The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that compound 4 was completely consumed and a main peak with the expected mass was detected. The mixture was directly purified by preparative HPLC (TFA conditions).
[0753] Compound BCY6055 (0.0352 g, 9.01 μmol, 31.01% yield) was obtained as a white solid.
[0754]
[0755]
[0756] BCY6077(DM1-SS-Me-(SO3H)-bicyclic)
[0757]
[0758] General procedure for the preparation of compound 2
[0759]
[0760] Chlorosulfonic acid (0.86 g, 7.38 mmol, 491.43 μL, 17.96 eq) and DIEA (318.67 mg, 2.47 mmol, 429.47 μL, 6 eq) were added to a solution of compound 1 (0.1 g, 410.94 μmol, 1 eq) in 1,2-dichloroethane (3 mL) in three portions and two portions. The mixture was stirred at 75 ° C for 16 hours. LC-MS showed that compound 1 was completely consumed, and a main peak MS324 with the expected MS was detected, and a main peak of the by-product MS 221 was PySSPy. The solvent was removed and dissolved in H2O / MeCN=15 / 1. Direct purification by preparative HPLC (neutral conditions: MeCN / H2O). Compound 2 (0.055 g, 170.06 μmol, 41.38% yield) was obtained as a yellow oil.
[0761] LCMS (ESI): <![CDATA[323.6[M+H] + ]]> Molecular weight 323.4
[0762] General procedure for preparing DM1-SO3H-SPP
[0763]
[0764] A solution of DM1 (113.00 mg, 153.06 μmol, 1.1 eq) and compound 2 (0.045 g, 139.14 μmol, 1 eq) in DMF (2 mL) was adjusted to pH = 8 using NaHCO (aq). The mixture was stirred at 15 ° C for 1 hour. LC-MS showed that DM1 was completely consumed and a main peak with the expected MS was detected. Direct purification by preparative HPLC (neutral conditions). Compound DM1-SO H-SPP (0.075 g, 78.90 μmol, 56.71% yield) was obtained as a white solid.
[0765] LCMS (ESI): <![CDATA[931.9[M+H-H2O] + ]]> Molecular weight 950.52
[0766] General procedure for the preparation of DM1-SO3H-SPP-NHS
[0767]
[0768] EDCI (13.31 mg, 69.43 μmol, 1.1 eq) was added to a solution of DM1-SO3H-SPP (0.06 g, 63.12 μmol, 1 eq), 1-hydroxypyrrolidine-2,5-dione (7.99 mg, 69.43 μmol, 1.1 eq) in DMA (1.5 mL) and DCM (0.5 mL). The mixture was stirred at 15 ° C for 18 hours. LC-MS showed that DM1-SO3H-SPP was completely consumed and a main peak with the expected MS was detected. Direct purification by preparative HPLC (neutral conditions: MeCN / H2O). The compound DM1-SO3H-SPP-NHS (0.045 g, 42.96 μmol, 68.05% yield) was obtained as a white solid.
[0769] LCMS (ESI): <![CDATA[984[M-NHS+K] + ]]> Molecular weight 1047.6
[0770] General procedure for preparing BCY6077
[0771] DIEA (12.95 mg, 100.23 μmol, 17.46 μL, 3 eq) and DM1-SO3H-SPP-TFP (0.035 g, 33.41 μmol, 1 eq) were added to a solution of BCY6014 (101.58 mg, 33.41 μmol, 1 eq) in DMA (1 mL). The mixture was stirred at 15 °C for 16 hours. LC-MS showed that DM1-SO3H-SPP-TFP had been completely consumed and a main peak with the expected MS was detected. Direct purification by preparative HPLC (TFA conditions). Compound BCY6077 (41.30 mg, 10.03 μmol, 30.01% yield, 96.44% purity) was obtained as a white solid.
[0772]
[0773] Non-cleavable series
[0774] BCY6063(MMAE)
[0775]
[0776]
[0777] MMAE Glutarate
[0778]
[0779] DIEA (108.01 mg, 835.68 μmol, 145.56 μL, 3.0 eq) and tetrahydropyran-2,6-dione (63.57 mg, 557.12 μmol, 2.0 eq) were added to a solution of MMAE (0.2 g, 278.56 μmol, 1.0 eq) in DMA (3 mL). The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that MMAE was completely consumed and a main peak with a desired mass was detected. The mixture was directly purified by preparative HPLC (neutral conditions). Compound glutaric acid ester-MMAE (0.12 g, 144.22 μmol, 51.77% yield) was obtained as a white solid.
[0780] LCMS (ESI): <![CDATA[832.3[M+H] + ]]> Molecular weight 832.09
[0781] Glutarate-MMAE-NHS
[0782]
[0783]
[0784] To glutaric acid ester-MMAE (0.12g, 144.22μmol, 1.0eq), 1-hydroxypyrrolidine-2,5-dione (49.79mg, 432.65μmol, 3.0eq) DMA (3mL) and DCM (1mL) solution, add EDCI (82.94mg, 432.65μmol, 3.0eq). The mixture was stirred at 15 ℃ for 16 hours. LC-MS shows that glutaric acid ester-MMAE is completely consumed, and detects a main peak with a desired quality. The mixture is directly purified by preparative HPLC (TFA conditions). Obtained as the compound glutaric acid ester-MMAE-NHS (0.055g, 59.19μmol, 41.04% yield) of white solid.
[0785] LCMS (ESI): <![CDATA[929.2[M+H] + ]]> Molecular weight 929.17
[0786] BCY6063
[0787]
[0788] DIEA (10.43 mg, 80.72 μmol, 14.06 μL, 3 eq) and glutarate-MMAE-NHS (0.025 g, 26.91 μmol, 1 eq) were added to a DMA (2 mL) solution of BCY6014 (98.17 mg, 32.29 μmol, 1.2 eq). The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that glutarate-MMAE-NHS was completely consumed, and a main peak with a desired mass was detected. The mixture was directly purified by preparative HPLC (TFA conditions). Compound BCY6063 (32.10 mg, 8.33 μmol, 30.95% yield) was obtained as a white solid.
[0789]
[0790] BCY6064(DM1)
[0791]
[0792] Compound 1
[0793]
[0794] TEA (41.12 mg, 406.35 μmol, 56.56 μL, 3 eq) was added to a DMF (5 mL) solution of DM1 (0.1 g, 135.45 μmol, 1 eq) and 3-[(2-bromoacetyl)amino]propionic acid (34.14 mg, 162.54 μmol, 1.2 eq). The mixture was stirred at 15 ° C for 1 hour. LC-MS showed that DM1 was completely consumed and a main peak with the desired mass was detected. The mixture was directly purified by preparative HPLC (neutral conditions). Compound 1 (0.08 g, 92.23 μmol, 68.09% yield) was obtained as a white solid.
[0795] LCMS (ESI): <![CDATA[849.1[M+H-H2O] + ]]> Molecular weight 867.41
[0796] Compound 2
[0797]
[0798] EDCI (53.04 mg, 276.69 μmol, 3 eq) was added to a solution of compound 1 (0.08 g, 92.23 μmol, 1 eq) and 2,3,5,6-tetrafluorophenol (45.95 mg, 276.69 μmol, 3 eq) in DMA (3 mL) and DCM (1 mL). The mixture was stirred at 15 ° C for 4 hours. LC-MS showed that compound 1 was completely consumed and a main peak with the expected mass was detected. The mixture was directly purified by preparative HPLC (neutral conditions).
[0799] Compound 2 (0.06 g, 59.09 μmol, yield 64.06%) was obtained as a white solid.
[0800] LCMS (ESI): <![CDATA[997.0[M+H-H2O] + ]]> Molecular weight 1015.46
[0801] BCY6064
[0802]
[0803] DIEA (11.45 mg, 88.63 μmol, 15.44 μL, 3.0 eq) and compound 2 (0.030 g, 29.54 μmol, 1 eq) were added to a solution of BCY6014 (107.79 mg, 35.45 μmol, 1.2 eq) in DMA (3 mL). The mixture was stirred at 15 ° C for 16 hours. LC-MS showed that compound 2 was completely consumed and a main peak with the expected mass was detected. The mixture was directly purified by preparative HPLC (TFA conditions).
[0804] Compound BCY6064 (28.40 mg, 7.30 μmol, 24.71% yield) was obtained as a white solid.
[0805]
[0806] BCY6105
[0807]
[0808]
[0809] General procedure for the preparation of compound 2
[0810] To a solution of compound 1 (3.5 g, 5.68 mmol, 1.0 eq) in DCM (20 mL) and MeOH (10 mL) were added (4-aminophenyl)methanol (978.5 mg, 7.95 mmol, 1.4 eq) and EEDQ (2.81 g, 11.35 mmol, 2.0 eq) in the dark, and the mixture was stirred at 25 ° C. for 18 hours. LC-MS showed that compound 1 was completely consumed, and a major peak with the expected MS ([M+H + ]=722.0). The resulting reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by flash silica gel chromatography ( 220g Silica Flash Column, 0 to 10% methanol / dichloromethane elution @ 80 mL / min). Compound 2 (3.0 g, 4.16 mmol, 73.2% yield) was obtained as a yellow solid.
[0811] General procedure for the preparation of compound 3
[0812] To a solution of compound 2 (2.5 g, 3.46 mmol, 1.0 eq) in THF (30 mL) was added DIEA (2.69 g, 20.78 mmol, 3.62 mL, 6.0 eq) and di(4-nitrophenyl) carbonate (6.32 g, 20.78 mmol, 6.0 eq), and the mixture was stirred at 25 ° C for 16 hours. TLC indicated that compound 2 was completely consumed and a new spot was formed. According to TLC, the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by flash silica gel chromatography ( 220g Silica Flash Column, 0 to 5% methanol / dichloromethane elution @100 mL / min). Compound 3 (2.2 g, 2.48 mmol, 71.6% yield) was obtained as a yellow solid.
[0813] General procedure for the preparation of compound 4
[0814] To a solution of compound 3 (0.3 g, 338.24 umol, 1.0 eq) in DMF (5 mL) was added HOBt (50.3 mg, 372.06 umol, 1.1 eq), DIEA (131.1 mg, 1.01 mmol, 176.7 μL, 3.0 eq) and MMAE (218.6 mg, 304.42 umol, 0.9 eq). The mixture was stirred at 40 ° C for 16 hours. LC-MS showed a peak with the expected MS ([M+H + ]=1466.4,[M+2H +] / 2=733.2). The reaction mixture was then directly purified by preparative HPLC (neutral conditions) to give compound 4 (0.2 g, 136.44 umol, 40.3% yield) as a white solid.
[0815] General procedure for the preparation of compound 5
[0816] First, compound 4 (0.175 g, 119.39 umol, 1.0 eq) was dissolved in TFA (1.8 mL), and then triisopropylsilane (13.5 g, 85.20 mmol, 17.5 mL, 713.7 eq) was added. The mixture was stirred at 0°C for 30 minutes. LC-MS showed a peak with the expected MS ([M+H + ]=1123.4,[M+2H + ] / 2=562.2). The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue. The residue was purified by preparative HPLC (neutral conditions). Compound 5 (0.1 g, 89.02 umol, 74.6% yield) was obtained as a yellow solid.
[0817] General procedure for the preparation of compound 6
[0818] DIEA (24.2 mg, 186.94 umol, 32.6 μL, 3.0 eq) and tetrahydropyran-2,6-dione (14.2 mg, 124.62 umol, 2.0 eq) were added to a solution of compound 5 (0.07 g, 62.31 umol, 1.0 eq) in DMA (1.0 mL). The mixture was stirred at 25 ° C for 2 hours. LC-MS showed that compound 5 was completely consumed, and a main peak with the expected MS ([M+H + ]=1237.4,[M+2H + ] / 2=619.3). The reaction mixture was then directly purified by preparative HPLC (neutral conditions) to give compound 6 (0.04 g, 32.32 umol, 51.8% yield) as a light yellow solid.
[0819] General procedure for the preparation of compound 7
[0820] EDCI (18.6 mg, 96.97 umol, 3.0 eq) was added to a solution of compound 6 (0.04 g, 32.32 umol, 1.0 eq) in DMA (3.0 mL) and DCM (1.0 mL). The mixture was stirred at 25 ° C for 18 hours. LC-MS showed that compound 6 was completely consumed, and a main peak with the expected MS ([M+H+ ]=1334.5,[M+2H + ] / 2=667.7). The reaction mixture was then directly purified by preparative HPLC (TFA conditions) to give compound 7 (0.025 g, 18.73 umol, 57.9% yield) as a white solid.
[0821] General procedure for preparing BCY6105
[0822] DIEA (8.7 mg, 67.44 umol, 11.7 μL, 3.0 eq) and compound 7 (0.03 g, 22.48 umol, 1.0 eq) were added to a solution of BCY6014 (82.0 mg, 26.98 umol, 1.2 eq) in DMA (4 mL). The mixture was stirred at 25 ° C for 18 hours. LC-MS showed that compound 7 was completely consumed, and a main peak with the expected MS was detected ([M+4H + ] / 4=1065.2). The reaction mixture was then directly purified by preparative HPLC (TFA conditions). Compound BCY6105 (0.024 g, 5.41 umol, 24.1% yield, 96.06% purity) was obtained as a white solid.
[0823] BCY6106
[0824]
[0825]
[0826] General procedure for the preparation of compound 2
[0827] EEDQ (5.28 g, 21.34 mmol, 2.0 eq) and (4-aminophenyl) methanol (2.63 g, 21.34 mmol, 2.0 eq) were added to a solution of compound 1 (5.0 g, 10.67 mmol, 1.0 eq) in DCM (30 mL) and MeOH (10 mL). The mixture was stirred at 20 ° C for 18 hours. LC-MS showed that compound 1 was completely consumed, and a main peak with the expected MS was detected (expected m / z=574, while Boc group shedding and partial shedding corresponded to m / z=474 and 518, respectively). The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue. The residue was purified by preparative HPLC (neutral conditions). Compound 2 (3.7 g, 6.45 mmol, 60.4% yield) was obtained as a yellow solid.
[0828] General procedure for the preparation of compound 3
[0829] A portion of DIEA (5.36 g, 41.49 mmol, 7.23 mL, 7.0 eq) and di(4-nitrophenyl)carbonate (10.82 g, 35.56 mmol, 6.0 eq) were added to a solution of compound 2 (3.4 g, 5.93 mmol, 1.0 eq) in DMF (20 mL). The mixture was stirred at 25 ° C for 2 hours. LC-MS showed a peak with the desired MS (m / z=639 corresponds to the mass of the Boc group falling off during ESI). The reaction mixture was directly purified by preparative HPLC (neutral conditions). Compound 3 (3.0 g, 4.06 mmol, 68.5% yield) was obtained as a yellow solid.
[0830] General procedure for the preparation of compound 4
[0831] To a DMF (15mL) solution of compound 3 (707.4mg, 957.55umol, 1.0eq), HOBt (155.3mg, 1.15mmol, 1.2eq), DIEA (371.3mg, 2.87mmol, 500.4μL, 3.0eq) and MMAE (0.55g, 766.04umol, 0.8eq) were added. The mixture was stirred at 30°C for 16 hours. LC-MS showed a peak with the desired MS (m / z=1317 was expected, while m / z=609 corresponds to the mass with two protons and the Boc group falling off during ESI). The reaction mixture was then directly purified by preparative HPLC (neutral conditions). Compound 4 (0.53g, 402.23umol, 42.0% yield) was obtained as a yellow solid.
[0832] General procedure for the preparation of compound 5
[0833] To a DMF (4mL) solution of compound 4 (0.526g, 399.20umol, 1.0eq), piperidine (862.2mg, 10.13mmol, 1.0mL, 25.4eq) was added. The mixture was stirred at 25°C for 30 minutes. LC-MS showed that compound 4 was completely consumed, and a main peak with the expected MS was detected (expected m / z=1095, and m / z=265 corresponds to Fmoc-piperidine adduct). The reaction mixture was then directly purified by preparative HPLC (neutral conditions). Compound 5 (0.230g, 209.97umol, 52.6% yield) was obtained as a white solid.
[0834] General procedure for the preparation of compound 6
[0835] EDCI (52.5 mg, 273.87 umol, 1.2 eq), HOBt (37.0 mg, 273.87 umol, 1.2 eq) and compound 5 (0.25 g, 228.23 umol, 1 eq) were added to a DMF (10 mL) solution of Fmoc-(D-Ala)-Phe-OH (125.6 mg, 273.87 umol, 1.2 eq). The mixture was stirred at 25 ° C for 3 hours. LC-MS showed that compound 5 was completely consumed, and a peak with the expected MS was detected (m / z=718 corresponding to the mass with two protons and Boc group falling off during ESI). The reaction mixture was then directly purified by preparative HPLC (neutral conditions). Compound 6 (0.18 g, 117.20 umol, 51.3% yield) was obtained as a white solid.
[0836] General procedure for the preparation of compound 7
[0837] To a DMF (8 mL) solution of compound 6 (0.18 g, 117.20 umol, 1.0 eq), piperidine (1.72 g, 20.25 mmol, 2.0 mL, 172.8 eq) was added. The mixture was stirred at 25 ° C for 1 hour. LC-MS showed that compound 7 was completely consumed, and a main peak with the expected MS was detected (m / z=1314 and 657, corresponding to the expected mass, m / z=265 corresponding to the Fmoc-piperidine adduct). The reaction mixture was then directly purified by preparative HPLC (neutral conditions). Compound 7 (0.13 g, 98.96 umol, 84.4% yield) was obtained as a white solid.
[0838] General procedure for the preparation of compound 8
[0839] DIEA (31.0 mg, 239.79 umol, 41.8 μL, 3.0 eq) and tetrahydropyran-2,6-dione (27.4 mg, 239.79 umol, 3.0 eq) were added to a solution of compound 7 (0.105 g, 79.93 umol, 1.0 eq) in DMA (4 mL). The mixture was stirred at 25 ° C for 2 hours. LC-MS showed that compound 7 was completely consumed, and a main peak with the expected MS was detected (m / z 664.5 corresponds to the mass with two protons and the Boc group falling off during ESI). The reaction mixture was then directly purified by preparative HPLC (neutral conditions) to give compound 8 (0.09 g, 63.04 umol, 78.8% yield) as a white solid.
[0840] General procedure for the preparation of compound 9
[0841] To a solution of compound 8 (0.09 g, 63.04 umol, 1.0 eq), 1-hydroxypyrrolidine-2,5-dione (21.7 mg, 189.11 umol, 3.0 eq) in DMA (3 mL) and DCM (1 mL) was added EDCI (36.2 mg, 189.11 umol, 3.0 eq) dissolved in 1 mL of DCM. The mixture was stirred at 25 ° C for 18 hours. LC-MS showed that compound 8 was completely consumed, and a main peak with the expected MS was detected (expected m / z=1524 (one proton) and 763 (two protons), while m / z=713 corresponds to the mass of the Boc group falling off during ESI). The reaction mixture was directly purified by preparative HPLC (neutral conditions). Compound 9 (0.07 g, 45.91 umol, 72.8% yield) was obtained as a white solid.
[0842] General procedure for the preparation of compound 10
[0843] DIEA (11.8 mg, 91.81 umol, 16.0 μL, 2.0 eq) and compound 9 (0.07 g, 45.91 umol, 1.0 eq) were added to a DMF (3 mL) solution of BCY6014 (167.5 mg, 55.09 umol, 1.2 eq). The mixture was stirred at 25 ° C for 16 hours. LC-MS showed that compound 9 was completely consumed, and a main peak with the expected MS was detected ([M+4H+] / 4=1112.9, [M+5H+] / 5=890.5). The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue. The crude product 10 (0.220 g, crude product) was used in the next step without further purification.
[0844] General procedure for preparing BCY6106
[0845] To a solution of compound 10 (0.200 g, 44.95 umol, 1.0 eq) in DCM (4 mL) was added 1 mL of TFA. The mixture was stirred at 25 °C for 1 hour. LC-MS showed a major peak with the expected MS ([M+4H + ] / 4=1088.0, [M+5H + ] / 5=870.8). The reaction mixture was concentrated under reduced pressure to give a residue, which was then directly purified by preparative HPLC (TFA conditions). Compound BCY6106 (0.0297 g, 20.06 umol, 14.5% yield, 95.46% purity) was obtained as a white solid.
[0846] BCY6175
[0847]
[0848]
[0849] General procedure for the preparation of compound 9
[0850] The synthesis of compound 9 was performed in a manner similar to that described in BCY6106.
[0851] General procedure for the preparation of compound 10A
[0852] DIEA (21.61 mg, 167.23 μmol, 29.13 μL, 3 eq) and compound 9 (0.085 g, 55.74 μmol, 1.0 eq) were added to a solution of BCY6099 (195.15 mg, 61.32 μmol, 1.1 eq) in DMA (3 mL). The mixture was stirred at 25 ° C for 16 hours. LC-MS showed that compound 9 was completely consumed and a main peak with the desired m / z was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue (light yellow oil). The reactant was directly purified by preparative HPLC (neutral conditions). Compound 10A (0.160 g, 34.84 μmol, 62.50% yield) was obtained as a white solid.
[0853] General procedure for preparing BCY6175
[0854] TFA (4.5 mL) was added to a solution of compound 10A in DCM (4.5 mL). The mixture was stirred at 0 ° C for 30 minutes. LC-MS showed that compound 10A was completely consumed and a main peak with the desired m / z was detected. The reaction mixture was concentrated under reduced pressure to remove the solvent to give a residue, which was purified by preparative HPLC (TFA conditions). Compound BCY6175 (61.40 mg, 13.56 μmol, 31.13% yield) was obtained as a white solid.
[0855] BCY6107
[0856]
[0857] General procedure for the preparation of compound 2
[0858] To a solution of compound 1 (3.0 g, 8.49 mmol, 1.0 eq) in DCM (30 mL) and MeOH (10 mL) were added EEDQ (2.52 g, 10.19 mmol, 1.2 eq) and (4-aminophenyl)methanol (1.25 g, 10.19 mmol, 1.2 eq). The mixture was stirred at 25 °C for 16 hours. LC-MS showed that compound 1 was completely consumed and a major peak with the expected MS ([M+H]+ 459.5). In addition, TLC showed that compound 1 was completely consumed and a new spot was formed. The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue. The residue was purified by flash silica gel chromatography ( 120g SilicaFlash Column, 0 to 60% ethyl acetate / petroleum ether gradient elution, @80 mL / min). Compound 2 (3.5 g, 7.63 mmol, 89.9% yield) was obtained as a yellow solid.
[0859] General procedure for the preparation of compound 3
[0860] To a solution of compound 2 (3.3 g, 7.20 mmol, 1.0 eq) in THF (100 mL) was added DIEA (4.65 g, 35.98 mmol, 6.27 mL, 5.0 eq) and di(4-nitrophenyl) carbonate (8.76 g, 28.79 mmol, 4.0 eq). The mixture was stirred at 25 °C for 16 hours. LC-MS showed that compound 2 was completely consumed, and a major peak with the expected MS was detected ([M+H] + 624.0). In addition, TLC showed that compound 2 was completely consumed and a new spot was formed. The reaction mixture was concentrated under reduced pressure to remove the solvent to obtain a residue. The residue was purified by flash silica gel chromatography ( 120g Silica Flash Column, 0 to 15% ethyl acetate / petroleum ether gradient elution, @80 mL / min). Compound 3 (3.0 g, 4.81 mmol, 66.8% yield) was obtained as a yellow solid.
[0861] General procedure for the preparation of compound 4
[0862] To a DMF (5 mL) solution of compound 3 (124.09 mg, 198.97 umol, 1.0 eq) was added HOBt (32.3 mg, 238.77 umol, 1.2 eq), DIEA (77.1 mg, 596.92 μmol, 103.9 μL, 3.0 eq), and MMAE (0.1 g, 139.28 umol, 0.7 eq). The mixture was stirred at 25 ° C for 1 hour. LC-MS showed that compound 3 was completely consumed, and a main peak with the expected MS was detected ([M+H] + 1202.5, [M+Na] + 1224.5). The reaction mixture was then directly purified by preparative HPLC (neutral conditions). After freeze-drying, compound 4 (0.08 g, 66.53 umol, 33.4% yield) was obtained as a white solid.
[0863] General procedure for the preparation of compound 5
[0864] To a solution of compound 4 (0.08 g, 66.53 umol, 1.0 eq) in DMF (4 mL) was added piperidine (862.2 mg, 10.13 mmol, 1 mL, 152.2 eq). The mixture was stirred at 25 °C for 1 hour. LC-MS showed that compound 4 was completely consumed, and a main peak with the expected MS was detected ([M+H] + 981.5, [M+Na] + 1003.5, while m / z=264.0 corresponds to Fmoc-piperidine adduct). The reaction mixture was directly purified by preparative HPLC (neutral conditions). Compound 5 (0.055 g, 56.11 umol, 84.3% yield) was obtained as a white solid.
[0865] General procedure for the preparation of compound 6
[0866] To a DMF (4 mL) solution of Fmoc-Glu (t-Bu) -Pro-Cit-Gly-HPhe-Tyr (t-Bu) -OH (74.1 mg, 66.31 umol, 1.3 eq) was added EDCI (12.7 mg, 66.31 umol, 1.3 eq), HOBt (8.9 mg, 66.31 umol, 1.3 eq) and compound 5 (0.05 g, 51.01 umol, 1.0 eq). The mixture was stirred at 25 ° C for 30 minutes. LC-MS showed that 20% of compound 5 remained, several new peaks were formed, and 60% of the reaction mixture was the desired product ([M+2H + ] / 2=1040.4). The reaction mixture was directly purified by preparative HPLC (neutral conditions). Compound 6 (0.07 g, 33.66 umol, 66.0% yield) was obtained as a white solid.
[0867] General procedure for the preparation of compound 7
[0868] To a DMF (4 mL) solution of compound 6 (0.07 g, 33.66 umol, 1.0 eq) was added piperidine (2.9 mg, 33.66 umol, 3.3 μL, 1.0 eq). The mixture was stirred at 25 ° C for 15 minutes. LC-MS showed that compound 6 was completely consumed, and a main peak with the expected MS was detected ([M+2H +] / 2=929.1, and m / z=264.2 corresponds to Fmoc-piperidine adduct). The reaction mixture was directly purified by preparative HPLC (neutral conditions). Compound 7 (0.045 g, 24.23 umol, 72.0% yield) was obtained as a white solid.
[0869] General procedure for the preparation of compound 8
[0870] DIEA (8.3 mg, 64.61 umol, 11.2 μL, 3.0 eq) and tetrahydropyran-2,6-dione (7.4 mg, 64.61 umol, 3 eq) were added to a solution of compound 7 (0.04 g, 21.54 umol, 1.0 eq) in DMA (1 mL). The mixture was stirred at 25 ° C for 1 hour. LC-MS showed that compound 7 was completely consumed, and a main peak with the expected MS was detected ([M+2H + ] / 2=986.4). The reaction mixture was then directly purified by preparative HPLC (neutral conditions). Compound 8 (0.035 g, 17.75 umol, 82.4% yield) was obtained as a white solid.
[0871] General procedure for the preparation of compound 9
[0872] EDCI (10.2 mg, 53.26 umol, 3.0 eq) was added to a DMA (3 mL) and DCM (1 mL) solution of compound 8 (0.035 g, 17.75 umol, 1.0 eq), 1-hydroxypyrrolidine-2,5-dione (6.1 mg, 53.26 umol, 3.0 eq). The mixture was stirred at 25 ° C for 16 hours. LC-MS showed that compound 8 was partially retained, and a peak with the desired MS was detected ([M+2H+] / 2=1034.7). DCM was then removed and the mixture was subsequently purified by preparative HPLC (neutral conditions). Compound 9 (0.03 g, 14.50 umol, 81.7% yield) was obtained as a white solid.
[0873] General procedure for the preparation of compound 10
[0874] To a solution of BCY6014 (52.9 mg, 17.40 umol, 1.59 μL, 1.2 eq) in DMF (2 mL) were added DIEA (5.6 mg, 43.51 umol, 7.6 μL, 3.0 eq) and compound 9 (0.03 g, 14.50 umol, 1.0 eq). The mixture was stirred at 25 ° C for 16 hours. LC-MS showed a main peak with the expected MS ([M+4H+] / 4=1249.2, [M+5H+] / 5=999.3). The solvent was then removed and the resulting crude product 10 (0.06 g, crude) was used in the next step without further purification.
[0875] General procedure for preparing BCY6107
[0876] 1mL TFA is added to a DCM (1mL) solution of compound 10 (0.055g, 11.01umol, 1.0eq). The mixture is stirred at 0°C for 15 minutes. LC-MS shows that compound 10 is completely consumed, and a main peak ([M+4H+] / 4=1221.0, [M+5H+] / 5=977.0) with desired MS is detected. The reaction mixture is concentrated under reduced pressure to remove solvent, and residue is obtained, which is then directly purified by preparative HPLC (TFA conditions). Compound BCY6107 (20.4mg, 4.03umol, 36.6% yield, 96.36% purity) is obtained as a white solid.
[0877] Biological data
[0878] Study 1. Fluorescence polarization measurements
[0879] (a) Direct binding assay
[0880] Peptides with fluorescent tags (fluorescein, SIGMA or Alexa Fluor488 TM, Fisher Scientific) was diluted to 2.5 nM in PBS with 0.01% Tween 20 or in 50 mM HEPES, pH 7.4 with 100 mM NaCl and 0.01% Tween (both referred to as assay buffer). This was combined with the titrated protein in the same assay buffer as the peptide to give a total volume of 25 μL of 1 nM peptide in a black walled and bottomed low-binding low-volume 384-well plate, typically 5 μL assay buffer, 10 μL protein (Table 1), then 10 μL fluorescent peptide. Selectivity was determined using a two-part series of dilutions, giving 12 different concentrations, with the highest concentration ranging from 500 nM for a known high affinity binder to 10 μM for a low affinity binder. Measurements were performed on a BMG PHERAstar FS equipped with an "FP 485 520 520" optical module that excites at 485 nm and detects parallel and perpendicular emission at 520 nm. The PHERAstar FS was set at 25°C, 200 flashes per well, a positioning delay of 0.1 seconds, and each well was measured at intervals of 5 to 10 minutes for 60 minutes. At the end of 60 minutes, there was no protein in the wells and the gain for the analysis was determined for each tracer. The data were analyzed using Systat Sigmaplot version 12.0. The mP values were fitted to a user-defined quadratic equation to generate Kd values: f = ymin + (ymax - ymin) / Lig * ((x + Lig + Kd) / 2 - sqrt ((((x + Lig + Kd) / 2) ^ 2) - (Lig * x))). "Lig" is the defined value for the tracer concentration used.
[0881] (b) Competition Binding Assay
[0882] Peptides without fluorescent tags were tested for competition with peptides with fluorescent tags and known Kd (Table 2). Reference compound A has the sequence Fl-G-Sar5-ACPWGPAWCPVNRPGCA (Fl-G-Sar5-(SEQ ID NO: 94)). Reference compound B has the sequence Fl-G-Sar5-ACPWGPFWCPVNRPGCA (Fl-G-Sar5-(SEQ ID NO: 95)). Reference compound C has the sequence Fl-G-Sar5-ADVTCPWGPFWCPVNRPGCA (Fl-G-Sar5- (SEQ ID NO: 96). Each of reference compounds A, B and C comprises a TBMB molecular scaffold. As described for the direct binding assay, peptides were diluted to the appropriate concentration in assay buffer with a maximum concentration of 5% DMSO and then serially diluted 1 to 2. 5 μL of the diluted peptide was added to the plate, followed by 10 μL of human or mouse EphA2 (Table 1) at a fixed concentration (depending on the fluorescent peptide used (Table 2)), followed by 10 μL of the fluorescent peptide. Measurements were performed as in the direct binding assay, but the gain was determined before the first measurement. Data analysis was performed using Systat Sigmaplot version 12.0, where mP values were fitted to a user-defined cubic equation to generate Ki values:
[0883] f=ymin+(ymax-ymin) / Lig*((Lig*((2*((Klig+Kcomp+Lig+Comp-Prot*c)∧2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Pro t*c)+Klig*Kcomp))∧0.5*COS(ARCCOS((-2*(Klig+Kcomp+Lig+Comp-Prot*c)^3+9*(Klig+Kcomp+Lig+Comp-Prot*c)*(K comp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp)-27*(-1*Klig*Kcomp*Prot*c)) / (2*((((Klig+Kcomp+Lig+Com p-Prot*c)^2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp))^3)^0.5))) / 3))-(Klig+Kcomp+Lig+Comp-P rot*c))) / ((3*Klig)+((2*((Klig+Kcomp+Lig+Comp-Prot*c)^2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig* Kcomp))^0.5*COS(ARCCOS((-2*(Klig+Kcomp+Lig+Comp-Prot*c)^3+9*(Klig+Kcomp+Lig+Comp-Prot*c)*(Kcomp*(Lig- Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp)-27*(-1*Klig*Kcomp*Prot*c)) / (2*((((Klig+Kcomp+Lig+Comp-Prot*c)∧ 2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp))^3)^0.5))) / 3))-(Klig+Kcomp+Lig+Comp-Prot*c)))).
[0884] "Lig", "KLig" and "Prot" are defined values related to: fluorescent peptide concentration, Kd of fluorescent peptide and EphA2 concentration, respectively.
[0885] Table 1: Ephrin receptors and sources
[0886] Receptor (domain) Species Form / label supplier Catalog Number EphA1(Ecto) people Fc fusion R&D systems 7146-A1 EphA2 (Ecto) people C-terminal polyHis R&D systems 3035-A2 EphA2 (Ecto) people C-terminal polyHis self made N / A EphA2 (Ecto) Mouse Fc fusion R&D Systems 639-A2 EphA2 (Ecto) Mouse C-terminal polyHis Sino Biological 50586-M08H EphA2 (ligand binding) Rat C-terminal polyHis self made N / A EphA2 (ligand binding) dog C-terminal polyHis self made N / A EphA3 (Ecto) people Fc fusion R&D systems 6444-A3 EphA3 (Ecto) people N-terminal polyHis self made N / A EphA3 (Ecto) Rat C-terminal polyHis Sino Biological 80465-R08H EphA4 (Ecto) people Fc fusion R&D systems 6827-A4 EphA4 (Ecto) people C-terminal polyHis Sino Biological 11314-H08H EphA4 (Ecto) Rat C-terminal polyHis Sino Biological 80123-R08H EphA6 (Ecto) people Fc fusion R&D systems 5606-A6 EphA7 (Ecto) people Fc fusion R&D systems 6756-A7 EphB1(Ecto) Rat Fc fusion R&D systems 1596-B1 EphB4 (Ecto) people C-terminal polyHis R&D systems 3038-B4
[0887] Table 2: Final concentrations of fluorescent peptides and EphA2 used in competition binding assays
[0888]
[0889]
[0890] Certain peptide ligands of the present invention were tested in the above assays and the results are listed in Tables 3-7:
[0891]
[0892]
[0893]
[0894]
[0895]
[0896]
[0897]
[0898]
[0899]
[0900]
[0901]
[0902]
[0903] Study 2: Fluorescence polarization measurement (alternative approach)
[0904] (a) Competitive Binding
[0905] Peptides without fluorescent tags were tested for competition with peptides with fluorescent tags and known Kd (Table 9). 5 μL of increasing (2-fold) concentrations of test compounds were added to the plate, followed by 10 μL of a fixed concentration of EphA2 protein (Table 8) (the concentration depends on the fluorescent peptide used) (Table 9), followed by 10 μL of fluorescent peptide. The buffer was the assay buffer as described above, DMSO < 1%. Measurements were performed on a BMG PHERAstar FS equipped with an "FP 485 520 520" optical module that excites at 485 nm and detects parallel and perpendicular emission at 520 nm. The PHERAstar FS was set to 25°C, 200 flashes per well, a positioning delay of 0.1 seconds, and each well was measured at intervals of 5 to 10 minutes for 60 minutes. Alternatively, measurements were performed at similar time intervals on a PerkinElmer Envision equipped with a FITCFP dual mirror, FITC FP 480 excitation filter and FITC FP P-pol 535 and FITC FP S-pol emission filters, 30 flashes, and a G factor of 1.2. Data analysis was performed in Systat Sigmaplot version 12.0 or 13.0, where mP values at 60 minutes were fitted to a user-defined cubic equation to generate Ki values:
[0906] f=ymin+(ymax-ymin) / Lig*((Lig*((2*((Klig+Kcomp+Lig+Comp-Prot*c)^2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Pro t*c)+Klig*Kcomp))^0.5*COS(ARCCOS((-2*(Klig+Kcomp+Lig+Comp-Prot*c)^3+9*(Klig+Kcomp+Lig+Comp-Prot*c)*(K comp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp)-27*(-1*Klig*Kcomp*Prot*c)) / (2*((((Klig+Kcomp+Lig+Com p-Prot*c)^2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp))^3)^0.5))) / 3))-(Klig+Kcomp+Lig+Comp-P rot*c))) / ((3*Klig)+((2*((Klig+Kcomp+Lig+Comp-Prot*c)^2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig* Kcomp))^0.5*COS(ARCCOS((-2*(Klig+Kcomp+Lig+Comp-Prot*c)^3+9*(Klig+Kcomp+Lig+Comp-Prot*c)*(Kcomp*(Lig- Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp)-27*(-1*Klig*Kcomp*Prot*c)) / (2*((((Klig+Kcomp+Lig+Comp-Prot*c)^ 2-3*(Kcomp*(Lig-Prot*c)+Klig*(Comp-Prot*c)+Klig*Kcomp))^3)^0.5))) / 3))-(Klig+Kcomp+Lig+Comp-Prot*c)))).
[0907] "Lig", "KLig" and "Prot" are defined values, which are related to: fluorescent peptide concentration, Kd of fluorescent peptide and EphA2 concentration, respectively.
[0908] Table 8: Eph receptors and sources
[0909] Receptor (domain) Species Form / label supplier Catalog Number EphA2 (Ecto) people C-terminal polyHis R&D systems 3035-A2 EphA2 (Ecto) people C-terminal polyHis self made N / A EphA2 (Ecto) Mouse C-terminal polyHis Sino Biological 50586-M08H EphA2 (ligand binding) Rat C-terminal polyHis self made N / A
[0910] Table 9: Final concentrations of fluorescent peptides and EphA2 used in the competition binding assay
[0911]
[0912] Certain peptide ligands and bicyclic drug conjugates of the invention were tested in the above-described competitive binding assays, and the results are shown in Tables 10-11:
[0913] Table 10: Competition binding of selected bicyclic peptides
[0914]
[0915] The results of the competitive binding assays in Table 10 show that the bicyclic peptides targeting human EphA2 (BCY6014 and BCY6099) bind to mouse and rat EphA2 with high affinity. Similarly, BCY6019 binds to both human and mouse EphA2. These results show that certain peptides of the invention can be used in in vivo mouse and rat models of efficacy and toxicology.
[0916] Table 11: Competition binding of selected bicyclic drug conjugates (BDCs)
[0917]
[0918]
[0919] Table 11 shows that certain bicyclic drug conjugates of the present invention exhibit excellent cross-reactivity between human, mouse and rodent EphA2. Therefore, the peptides of the present invention can be used in mouse and rat in vivo efficacy and toxicology models.
[0920] (b) SPR measurement
[0921] Non-Fc fusion proteins were transferred to EZ-Link TMSulfo-NHS-LC-Biotin was biotinylated in 4 mM sodium acetate, 100 mM NaCl, pH 5.4 for 1 hour, with a 3-fold molar excess of biotin to protein. After dialyzing the reaction mixture into PBS, the extent of labeling was determined using a fluorescent biotin quantification kit (Thermo). For analysis of peptide binding, a Biacore T200 instrument was used, which utilizes a XanTec CMD500D chip. Streptavidin was immobilized on the chip using standard amine coupling chemistry at 25°C with HBS-N (10 mM HEPES, 0.15 M NaCl, pH 7.4) as the running buffer. Briefly, the carboxymethyl dextran surface was activated by injecting a 1:1 ratio of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) / 0.1 M N-hydroxysuccinimide (NHS) at a flow rate of 10 μl / min for 7 minutes. For capture of streptavidin, the protein was diluted to 0.2 mg / ml in 10 mM sodium acetate (pH 4.5) and captured by injecting 120 μl onto the activated chip surface. Residual activated groups were blocked by a 7 min injection of 1 M ethanolamine (pH 8.5):HBS-N (1:1). The buffer was exchanged to PBS / 0.05% Tween 20 and biotinylated EphA2 was captured to levels of 500-1500 RU using a 0.2 μM dilution of the protein in buffer. Serial dilutions of the peptide were prepared in this buffer with a final DMSO concentration of 0.5% and a maximum peptide concentration of 50 or 100 nM, followed by six 2-fold dilutions. SPR analysis was run at 25°C at a flow rate of 90 μl / min with 60 sec association and 900-1200 sec dissociation. Data were corrected for DMSO exclusion volume effects. All data were double referenced to blank injections and reference surfaces using standard processing procedures, and data processing and kinetic fitting were performed using Scrubber software version 2.0c (BioLogic Software). Data were fit using a simple 1:1 binding model to account for mass transport effects where appropriate.
[0922] For the binding of bicyclic drug conjugates, a Biacore 3000 instrument was used. For biotinylated proteins, the immobilization level was 1500RU and the maximum concentration was 100nM. Alternatively, a CMD500D or CM5 chip (GE Healthcare) was used, and the method was the same as described above. For Fc-tagged proteins, the CM5 chip was activated as described above, and then goat anti-human IgG antibody (Thermo-Fisher H10500) was diluted to 20μg / ml in 10mM sodium acetate pH5.0 and captured to about 3000RU. The surface was then blocked as described above. The capture of Fc-tagged proteins was then performed to obtain about 200-400RU of target protein. The proteins used are described below. All proteins were reconstructed according to the buffer and concentration recommended by the manufacturer and captured using a PBS / 0.05% Tween 20 solution of 5-10μg / ml protein.
[0923] Table 12
[0924]
[0925] Certain peptide ligands and bicyclic drug conjugates of the invention were tested in the above-described competitive binding assays, and the results are shown in Tables 13 to 15:
[0926] Table 13: SPR binding analysis of selected bicyclic peptide and bicyclic drug conjugates of the present invention
[0927]
[0928]
[0929] Table 13 details the binding affinities and kinetic parameters (Koff and Kon) of selected bicyclic drug conjugates for binding to human EphA2 as determined using the SPR assay.
[0930] Table 14: SPR binding analysis of selected bicyclic drug conjugates of the invention to human Eph homologs
[0931]
[0932] Table 14 illustrates the binding results of four bicyclic drug conjugates (BCY6033, BCY6082, BCY6136 and BCY6173) to closely related human Ephrin homologues in the SPR assay. The results show that the compounds of the present invention do not show significant binding to closely related human homologues (EphA1, EphA3, EphA4, EphA5, EphA6, EphA7 and EphB4).
[0933] Table 15: SPR binding analysis of selected bicyclic drug conjugates of the invention to mouse and rat Eph orthologs
[0934]
[0935] The results in Table 15 demonstrate that certain bicyclic drug conjugates of the invention (BCY6033, BCY6082, BCY6136, and BCY6173) are also selective for mouse and rat EphA2 and do not show significant binding to closely related homologs (mouse EphA3 and EphA4; and rat EphA3 and EphBl).
[0936] Studies 3 and 7-23
[0937] In each of Studies 3 and 7–23, the following methods were used in each study:
[0938] (a) Materials
[0939] (i) Animals and housing conditions
[0940] animal
[0941] Species: Mouse (Mus Musculus)
[0942] Strain: Balb / c nude or CB17-SCID
[0943] Age: 6-8 weeks
[0944] Weight: 18-22g
[0945] Number of animals: 9-90 mice
[0946] Animal supplier: Shanghai Lingchang Biotechnology Laboratory Animal Co., Ltd.
[0947] Rearing conditions
[0948] Mice were maintained in individual ventilated cages at constant temperature and humidity with 3–5 animals per cage.
[0949] Temperature: 20 to 26°C.
[0950] Humidity 40-70%.
[0951] Cage: Made of polycarbonate. Dimensions are 300 mm x 180 mm x 150 mm. Bedding material is corn cob, changed twice a week.
[0952] Diet: Animals had free access to irradiated sterilized dry pelleted food throughout the study.
[0953] Water: Animals had free access to sterile drinking water.
[0954] Cage Identification: Identification tags for each cage contained the following information: number of animals, sex, strain, date received, treatment, study number, group number, and start date of treatment.
[0955] Animal identification: Tagging animals with ear codes.
[0956] (ii) Test and Positive Control
[0957]
[0958] 1 Full details of MEDI-547, a fully human monoclonal antibody 1C1 (recognizing human and murine EphA2) conjugated to MMAF via an mc linker, are described in Jackson et al. (2008) Cancer Res 68, 9367-74.
[0959] (b) Experimental methods and procedures
[0960] (i) Observation
[0961] All steps related to animal manipulation, care, and handling in this study were performed in accordance with the guidelines approved by the WuXi AppTec Institutional Animal Care and Use Committee (IACUC) and followed the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). For routine monitoring, animals were examined daily for tumor growth and any effects of treatment on normal behavior, such as activity, food and water consumption (by visual inspection only), weight gain / loss, eye / hair matting, and any other abnormal effects, as specified in the protocol. Deaths and observed clinical signs were recorded according to the animal number in each subgroup.
[0962] (ii) Tumor measurements and endpoints
[0963] The primary endpoint was to see if tumor growth could be delayed or if the mice could be cured. Tumor volume was measured three times a week using a caliper in two dimensions, with volume in mm 3 Expressed using the following formula: V = 0.5axb 2 , where a and b are the long and short diameters of the tumor, respectively. The tumor size is then used to calculate the T / C value. The T / C value (percentage) represents an indicator of the anti-tumor effect; T and C are the average volumes of the treatment group and the control group, respectively, on a given day.
[0964] The TGI of each group was calculated using the following formula: TGI (%) = [1-(T i -T0) / (V i -V0)]×100;T iis the mean tumor volume of the treatment group on a given day, T0 is the mean tumor volume of the treatment group on the day treatment started, V i is with T i The mean tumor volume of the empty vector control group on the same day, V0 is the mean tumor volume of the empty vector group on the day the treatment started.
[0965] (iii) Sample collection
[0966] At the end of the study, tumors from all groups were collected for FFPE.
[0967] (iv) Statistical analysis
[0968] Summary statistics of tumor volume for each group at each time point are provided, including the mean and standard error of the mean (SEM).
[0969] The differences in tumor volume between the groups were statistically analyzed based on the data obtained at the optimal treatment time point after the final dose.
[0970] One-way ANOVA was performed to compare tumor volumes between groups, and when a significant F statistic (ratio of treatment variance to error variance) was obtained, the Games-Howell test was used for intergroup comparisons. All data were analyzed using GraphPad Prism 5.0. P < 0.05 was considered statistically significant.
[0971] Study 3: In vivo efficacy in the LU-01-0046 PDX model
[0972] Cancer cell lines (CCLs) are originally derived from patient tumors, but acquire the ability to proliferate in in vitro cell cultures. As a result of in vitro manipulation, CCLs traditionally used for cancer research are genetically transformed, and this genetic transformation cannot be restored when the cells are grown in vivo. Due to the cell culture process, cells that are more suitable for survival in culture are selected, so tumor-resident cells and proteins that interact with cancer cells are eliminated, and the culture becomes phenotypically homogenous. Researchers began to attribute the reason why only 5% of anticancer agents approved by the Food and Drug Administration after preclinical testing to the lack of tumor heterogeneity and the lack of a human stromal microenvironment. Specifically, CCL xenografts generally cannot predict drug responses in primary tumors because CCLs do not follow the drug tolerance pathways or microenvironment effects on drug response that exist in human primary tumors. To overcome these problems, the inventors have used PDX models to improve the predictive power of preclinical models.
[0973] PDXs are generated when cancerous tissue from a patient's primary tumor is implanted directly into immunodeficient mice. PDXs maintain the patient's histology, including the presence of non-tumor cells (e.g., stromal cells), and therefore better mimic the tumor microenvironment. Therefore, PDXs are often more reflective of the heterogeneity and histology of the primary tumor than CCL xenografts.
[0974] BCY6031 was screened in primary adenocarcinoma PDX xenografts (LU-01-0046) derived from patients with non-small cell lung cancer (NSCLC). Using RNA sequencing, it has been demonstrated that LU-01-0046 expresses high levels of EphA2. BCY6031 showed excellent efficacy in the LU-01-0046 model and is therefore a promising new therapy for the treatment of non-small cell lung cancer.
[0975] (a) Treatment group
[0976] This experiment was designed to compare tumor growth in empty vehicle treated animals and animals treated with 5 mg / kg, qw BCY6031 for 4 weeks.
[0977] Table 16
[0978]
[0979] Note: n: number of animals; Dosing volume: adjust the dosing volume according to body weight.
[0980] (b) Experimental methods
[0981] (i) PDX information
[0982] Table 17
[0983]
[0984] (ii) Tumor inoculation
[0985] Each mouse was inoculated subcutaneously on the right side with an area of approximately 30 mm 3 LU-01-0046 tumor fragments. When the average tumor volume reached 943mm 3 The test article, administration route, dosing frequency and number of animals in each group are described above.
[0986] (iii) Preparation of test article preparation
[0987] Table 18
[0988]
[0989] (c) Results
[0990] (i) Mortality, morbidity, and weight gain or loss
[0991] Animal body weights were monitored regularly as an indirect measure of toxicity. Figure 1 Shown are changes in body weight of female Balb / C nude mice bearing LU-01-0046 tumors to which BCY6031 was administered.
[0992] (ii) Tumor growth curve
[0993] Tumor growth curve Figure 2 shown.
[0994] (iii) Tumor growth inhibition analysis
[0995] Tumor growth inhibition by BCY6031 in the PDX model LU-01-0046 was calculated based on tumor volume measurements on day 7 after the start of treatment.
[0996] Table 19: Tumor Growth Inhibition Analysis (T / C and TGI) on Day 7
[0997]
[0998] a. Mean ± SEM.
[0999] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1000] (e) Discussion
[1001] This study evaluated the therapeutic efficacy of BCY6031 in the LU-01-0046 PDX model. Figure 1 The measured body weights are shown. Table 19 and Figure 2 Tumor volumes of treatment groups at different time points are shown.
[1002] The average tumor size of empty vector-treated mice reached 2191 mm on day 7. 3 BCY6031 at 5 mg / kg produced potent antitumor activity, with tumors measuring 463 mm on day 7. 3 (TGI = 138.6%, p < 0.05). Moreover, BCY6031 treatment completely eliminated the tumor from day 32, and no tumor regrowth occurred on day 28 after drug withdrawal. BCY6031 did not cause significant weight loss ( Figure 1 ), and no adverse clinical manifestations were observed in drug-treated mice throughout the study.
[1003] Study 4: In vivo efficacy of BCY6136 in the CDX xenograft model
[1004] The study evaluated the therapeutic efficacy of BCY6136 in three cancer cell-derived (CDX) models: the HT1080 fibrosarcoma line, the MDA-MB-231 triple-negative breast cancer line, and the NCI-H1975 non-small cell lung cancer (NSCLC) line.
[1005] (a) Experimental methods
[1006] Balb / c mice were inoculated subcutaneously with tumor cells on the right flank and the mice were plated when the average tumor volume reached 150 to 200 mm 3 Drug treatment was started at 1:10 p.m. Tumor measurements and statistical analysis were performed as described above. Tumor-bearing animals were treated weekly with BCY6136 or empty vector.
[1007] (b) Discussion
[1008] Figure 4-6 BCY6136 was shown to be effective in breast, lung, and fibrosarcoma xenograft models following once-weekly dosing.
[1009] HT1080 Fibrosarcoma Model:
[1010] In the HT1080 model, once-weekly administration of BCY6136 at doses of 3 and 5 mg / kg on days 0 and 7 achieved complete regression of tumor growth by day 14 ( Figure 4 ). BCY6136 administration at a dose of 2 mg / kg once weekly on days 0 and 7 resulted in tumor stasis (partial regression) ( Figure 4 BCY6136 treatment did not result in significant weight loss ( Figure 4 Inset), and no adverse clinical observations were observed in the drug-treated mice throughout the study.
[1011] NCI-H1975 NSCLC Model:
[1012] Complete regression of tumor growth was observed in the NCI-H1975 model around day 28 after weekly dosing of BCY6136 at 2 and 3 mg / kg ( Figure 5 After dosing was stopped on day 35, no tumor regrowth was observed in animals treated with 3 mg / kg from day 35 to day 72 at the end of the measurement period for the 3 mg / kg group ( Figure 5 In this model, BCY6136 administration at 2 mg / kg resulted in complete regression from around day 28. After dosing was stopped on day 35, tumor regrowth did not occur until around day 51 in the 2 mg / kg dose. At this dose level, moderate tumor regrowth was observed from around day 51 until study termination on day 77. Treatment with 1 mg / kg of BCY6136 resulted in tumor stasis (partial regression) ( Figure 5BCY6136 treatment did not result in significant weight loss ( Figure 5 ), and no adverse clinical observations were observed in the drug-treated mice throughout the study.
[1013] MDA-MB-231 Mammary Gland Model:
[1014] Tumor stasis (partial regression) was observed in the MDA-MB231 model after weekly dosing at 2 and 3 mg / kg from day 0 to day 45 ( Figure 6 Some weight loss (attributable to tumor burden) was observed in animals treated at 2 mg / kg ( Figure 6 illustration).
[1015] These results demonstrate that BCY6136 produced profound tumor growth inhibition in mice implanted with fibrosarcoma, breast, and lung CDX xenografts following once-daily dosing.
[1016] Study 5: Safety Study in Rats
[1017] Six (6) female rats were randomized into 3 groups of 2 to determine the toxicity of BCY6136, followed by intravenous bolus administration of 5, 7.5 and 10 mg / kg on days 1 and 8. The study was terminated on day 15.
[1018] No significant effects on coagulation parameters (prothrombin time (seconds), activated partial thromboplastin time (seconds) or fibrinogen levels (g / L)) were observed on days 2, 12 and 15 (data not shown). No bleeding events were reported during the survival period and no signs of internal bleeding were detected after pathological examination.
[1019] Study 6: Safety Study in Cynomolgus Monkeys
[1020] We conducted a 28-day toxicology study of BCY6136 in cynomolgus monkeys. BCY6136 was administered at doses of 1.0 and 2.0 mg / kg on days 1, 8, 15, and 22. Animals were euthanized and necropsied on day 29 (7 days after the final dose).
[1021] No significant effects on coagulation parameters relative to baseline were observed on days 18, 22 and 25 (data not shown) and day 29 (Table 20).No bleeding events were reported during the survival period and no signs of internal bleeding were detected after pathological examination.
[1022] Table 20: Coagulation parameters on day 29 after administration of 1.0 and 2.0 mg / kg BCY6136 to cynomolgus monkeys
[1023]
[1024] Study 7: In vivo efficacy of BCY6033 and BCY6136 and ADC in the treatment of PC-3 xenografts in Balb / c nude mice Research
[1025] (a) Research objectives
[1026] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6033 and BCY6136 in the treatment of PC-3 xenografts.
[1027] (b) Experimental design
[1028]
[1029] (c) Experimental methods and procedures
[1030] (i) Cell culture
[1031] PC-3 tumor cells were maintained in F12K medium supplemented with 10% heat-inactivated fetal bovine serum in an atmosphere of 5% CO2 in air at 37°C. Tumor cells were routinely subcultured twice a week. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1032] (ii) Tumor inoculation
[1033] Each mouse was inoculated subcutaneously with PC-3 (10*10 6 ) tumor cells to form a tumor. When the average tumor volume reaches about 150mm 3 At 1 , animals were randomized into groups and treatment was started. The administration of the test articles and the number of animals in each group are shown in the experimental design table below.
[1034] (iii) Preparation of test article preparation
[1035]
[1036]
[1037] (d) Results
[1038] (i) Body weight changes and tumor growth curves
[1039] Body weight and tumor growth curves Figures 7 to 9 shown.
[1040] (ii) Tumor volume tracking
[1041] Table 21 shows the mean tumor volume over time in female Balb / c nude mice bearing PC-3 xenografts.
[1042] Table 21: Tumor Volume Tracking Over Time
[1043]
[1044]
[1045] (iii) Tumor growth inhibition analysis
[1046] The tumor growth inhibition rate of the test substances in the PC-3 xenograft model was calculated based on the measured tumor volume on day 16 after the start of treatment.
[1047] Table 22: Tumor Growth Inhibition Analysis
[1048]
[1049] a. Mean ± SEM.
[1050] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1051] (e) Summary and discussion of results
[1052] In this study, the therapeutic efficacy of the test articles was evaluated in the PC-3 xenograft model. Figures 7 to 9 and Tables 21 and 22 show the body weight and tumor volume measured in all treatment groups at various time points.
[1053] The average tumor size of empty vector-treated mice reached 2070 mm on day 16. 3 BCY6136 at 1mg / kg, qw(TV=107mm 3 , TGI=102.2%, p<0.001), BCY6136 at 2mg / kg, qw (TV=79mm 3 , TGI=103.6%,p<0.001) and BCY6136 at 3mg / kg, qw (TV=70mm 3 , TGI=104.1%, p<0.001), showing effective anti-tumor effect.
[1054] BCY6033 at 3mg / kg, qw(TV=116mm 3 , TGI=101.8%,p<0.001) and ADC
[1055] At 3 mg / kg, qw(TV=124mm 3 , TGI=101.4%, p<0.001), showing a considerable anti-tumor effect.
[1056] During this study, the body weight of the animals was monitored regularly. All mice maintained a good body weight.
[1057] Study 8. In vivo efficacy of BCY6136 in the treatment of PC-3 xenografts in Balb / c nude mice
[1058] (a) Research objectives
[1059] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the treatment of PC-3 xenografts in Balb / c nude mice.
[1060] (b) Experimental design
[1061]
[1062]
[1063] aN, number of animals in each group.
[1064] b. After 4 weeks of treatment as shown in the experimental design table, mice in groups 3, 5 and 6 were treated with 1.5 mg / kg qw of BCY6136 from day 52 during the monitoring schedule.
[1065] c. Due to severe weight loss in docetaxel-treated mice after the first dose, the treatment was suspended for 2 weeks and then a lower dose of treatment (docetaxel, 10 mg / kg) was given on day 28. After that, mice were treated with 1.5 mg / kg qw of BCY6136 from day 42 to day 70.
[1066] (c) Experimental methods and procedures
[1067] (i) Cell culture
[1068] Tumor cells were maintained in F-12K medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in an atmosphere of 5% CO2 in air. Tumor cells were routinely subcultured twice a week. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1069] (ii) Tumor inoculation
[1070] Each mouse was inoculated subcutaneously on the right side of the lung with 0.2 ml of PC-3 tumor cells (10 x 10 6 ) of PBS to form tumors. When the average tumor volume reached 454 mm 3 At 1 , 52 animals were randomly divided into groups. The test article administration and the number of animals in each group are shown in the experimental design table.
[1071] (iii) Preparation of test article preparation
[1072]
[1073]
[1074] (c) Results
[1075] (i) Body weight changes and tumor growth curves
[1076] Body weight and tumor growth curves Fig.10 shown.
[1077] (ii) Tumor volume tracking
[1078] Table 23 shows the mean tumor volume over time in male Balb / c nude mice bearing PC-3 xenografts.
[1079] Table 23: Tumor volume tracking over time (Day 0 to Day 20)
[1080]
[1081] (iii) Tumor growth inhibition analysis
[1082] The tumor growth inhibition rate of the test substances in the PC-3 xenograft model was calculated based on the tumor volume measurements on day 20 after the start of treatment.
[1083] Table 24: Tumor Growth Inhibition Analysis
[1084]
[1085] a. Mean ± SEM.
[1086] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1087] (d) Summary and discussion of results
[1088] In this study, the therapeutic efficacy of the test articles was evaluated in the PC-3 xenograft model. Fig.10 Tables 23 and 24 show the measured body weights and tumor volumes for all treatment groups at various time points.
[1089] The average tumor size of empty vector-treated mice reached 2364 mm on day 20. 3 . BCY6136, 0.167mg / kg, qw (TV=1188mm 3 , TGI=61.4%, p<0.001), 0.5mg / kg, q2w (TV=530mm 3 , TGI=96.0%, p<0.001), 0.5mg / kg, qw (TV=234mm 3, TGI=111.4%, p<0.001) and 1.5mg / kg, qw (TV=131mm 3 , TGI = 117.2%, p < 0.001) produced significant antitumor activity on day 20 in a dose- or dose-frequency-dependent manner. BCY6136, 1.5 mg / kg, q2w (TV = 128 mm 3 , TGI=117.0%, p<0.001) produced antitumor activity comparable to that of BCY6136, 1.5mg / kg qw. Among them, mice treated with BCY6136, 0.5mg / kg, qw or BCY6136, 0.5mg / kg, q2w showed obvious tumor recurrence after cessation of treatment, and further treatment with BCY6136, 1.5mg / kg, qw from day 52 was effective in achieving tumor regression. After cessation of treatment, mice treated with BCY6136, 1.5mg / kg q2w also showed tumor recurrence, but further administration did not completely cause tumor regression. Mice treated with BCY6136, 1.5mpk, qw did not show any tumor recurrence until day 48.
[1090] EphA2-ADC, 0.33mg / kg, qw (TV=1637mm 3 , TGI=38.1%, p<0.001),
[1091] 1mg / kg, qw(TV=981mm 3 , TGI=72.2%, p<0.001) and 3mg / kg, qw (TV=184mm 3 , TGI=114.0%, p<0.001) produced significant antitumor activity in a dose-dependent manner on day 20. Mice treated with EphA2-ADC, 3 mg / kg, qw did not show any tumor recurrence until day 59.
[1092] Docetaxel, 15 mg / kg, qw (TV = 419 mm 3 , TGI = 101.8%, p < 0.001) produced significant antitumor activity, but caused severe weight loss in the animals. After stopping treatment, the mice showed obvious tumor recurrence. Starting from day 42, treatment with BCY6136, 1.5 mg / kg, qw achieved tumor regression in these mice.
[1093] Study 9. Effect of BCY6033, BCY6136, and BCY6082 on the treatment of NCI-H1975 xenografts in Balb / c nude mice Internal efficacy test
[1094] (a) Research objectives
[1095] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6033, BCY6136, and BCY6082 in the treatment of the NCI-H1975 xenograft model in Balb / c nude mice.
[1096] (b) Experimental design
[1097]
[1098] (c) Experimental methods and procedures
[1099] (i) Cell culture
[1100] Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1101] (ii) Tumor inoculation
[1102] Each mouse was subcutaneously inoculated with 0.2 ml of PBS containing NCI-H1975 tumor cells (10×10^6) on the right side to form tumors. When the average tumor volume reached 149 mm 3 At 1 , 36 animals were randomly divided into groups. The test article administration and the number of animals in each group are shown in the experimental design table.
[1103] (iii) Preparation of test article preparation
[1104]
[1105]
[1106] (iv) Sample collection
[1107] At PG-D23, we fixed tumors from group 1 for FFPE.
[1108] At PG-D44, we fixed Group 2 and Group 5 tumors for FFPE.
[1109] At the end of the study, we fixed group 6 tumors for FFPE.
[1110] (d) Results
[1111] (i) Body weight changes and tumor growth curves
[1112] Body weight and tumor growth Figures 11 to 13 shown.
[1113] (ii) Tumor volume tracking
[1114] The mean tumor volumes over time in female Balb / c nude mice bearing NCI-H1975 xenografts are shown in Tables 25 to 29.
[1115] Table 25: Tumor volume tracking (PG-D0 to PG-D17)
[1116]
[1117]
[1118] Table 26: Tumor Volume Tracking (PG-D18 to PG-D35)
[1119]
[1120] Table 27: Tumor Volume Tracking (PG-D37 to PG-D53)
[1121]
[1122]
[1123] Table 28: Tumor Volume Tracking (PG-D56 to PG-D74)
[1124]
[1125] Table 29: Tumor Volume Tracking (PG-D77 to PG-D98)
[1126]
[1127] (iii) Tumor growth inhibition analysis
[1128] Tumor growth inhibition rates of BCY6033, BCY6136, and BCY6082 in the NCI-H1975 xenograft model were calculated based on tumor volume measurements on day 21 after the start of treatment.
[1129] Table 30: Tumor Growth Inhibition Analysis
[1130]
[1131]
[1132] a. Mean ± SEM.
[1133] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1134] (e) Summary and discussion of results
[1135] In this study, the therapeutic efficacy of BCY6033, BCY6136, and BCY6082 was evaluated in the NCI-H1975 xenograft model. Figures 11 to 13 and Tables 25 to 30 show the body weights and tumor volumes measured in all treatment groups at various time points.
[1136] On day 21, the average tumor size in mice treated with empty vector reached 2371 mm 3 . BCY6033, 1mg / kg (TV=306mm 3 , TGI=92.9%, p<0.001), 2mg / kg (TV=95mm 3 , TGI = 102.5%, p < 0.001) and 3 mg / kg (TV = 29 mm 3 , TGI = 105.4%, p < 0.001) produced dose-dependent antitumor activity. 2mg / kg and 3mg / kg of BCY6033 eliminated tumors or caused tumors to regress to smaller sizes. Treatment was suspended from day 35, and the tumors did not show obvious regrowth during the subsequent 5-6 weeks of monitoring.
[1137] BCY6136, 1 mg / kg (TV = 205 mm 3 , TGI=97.5%, p<0.001), 2mg / kg (TV
[1138] =99mm 3 , TGI=102.3%, p<0.001) and 3mg / kg (TV=94mm 3 , TGI = 102.4%, p < 0.001) produced effective antitumor activity. 2mg / kg and 3mg / kg of BCY6136 eliminated tumors or caused tumors to regress to a smaller size. Treatment was suspended from day 35, and in the subsequent 5-6 weeks of monitoring, tumors in the 3mg / kg group did not show significant regrowth, but tumors in the 2mg / kg group showed significant regrowth, and no significant tumor inhibition was shown when dosing was resumed.
[1139] BCY6082, 2 mg / kg (TV=1528 mm3, TGI=37.9%, p>0.05) did not show obvious antitumor activity, while BCY6082, 5 mg / kg (TV=390 mm3, TGI=89.1%, p<0.001) produced significant antitumor activity.
[1140] In this study, one mouse treated with BCY6033, 3 mg / kg, lost more than 15% of its body weight during monitoring, while the other mouse maintained its body weight well.
[1141] Study 10. In vivo efficacy study of BCY6136 in the Balb / c nude mouse LU-01-0251 PDX model
[1142] (a) Research objectives
[1143] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the Balb / c nude mouse LU-01-0251 PDX model.
[1144] (b) Experimental design
[1145]
[1146] (c) Experimental methods and procedures
[1147] (i) Tumor inoculation
[1148] Each mouse was inoculated subcutaneously on the right flank with tumor fragments of LU-01-0251 (approximately 30 mm 3 ) to form tumors. When the average tumor volume reached 174mm 3 Treatment was started at 4 pm for efficacy study. The test article administration and the number of animals in each group are shown in the experimental design table.
[1149] (ii) Preparation of test article preparations
[1150]
[1151] (d) Results
[1152] (i) Body weight changes and tumor growth curves
[1153] Body weight and tumor growth curves Fig.14 shown.
[1154] (ii) Tumor volume tracking
[1155] Table 31 shows the mean tumor volume on day 28 after the start of treatment in female Balb / c nude mice bearing LU-01-0251 xenografts.
[1156] Table 31: Tumor Volume Tracking Over Time
[1157]
[1158]
[1159] (iii) Tumor growth inhibition analysis
[1160] Tumor growth inhibition rates of BCY6136 and ADC in the LU-01-0251 PDX model were calculated based on tumor volume measurements on day 28 after treatment initiation.
[1161] Table 32: Tumor Growth Inhibition Analysis
[1162]
[1163] a. Mean ± SEM; b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treatment group by the group mean tumor volume of the control group (T / C).
[1164] (e) Summary and discussion of results
[1165] In this study, the therapeutic effects of BCY6136 and ADC were evaluated in the LU-01-0251 PDX model. The body weight and tumor volume measured for all treatment groups at different time points are shown in Fig.14 and Tables 31 and 32.
[1166] In this study, the mean tumor volume of mice treated with empty vector reached 2208 mm on day 28 after the start of treatment. 3 . BCY6136, 1mg / kg, qw (TV=499mm 3 , TGI=84.0%, p<0.001), 2mg / kg, qw (TV=32mm 3 , TGI = 107.0%, p < 0.001) and 3 mg / kg, qw (TV = 0 mm 3 ADC, 3 mg / kg, qw (TV = 39 mm 3 , TGI=106.6%, p<0.001) showed significant anti-tumor activity.
[1167] Study 11: In vivo efficacy study of BCY6136 in the Balb / c nude mouse LU-01-0251 PDX model
[1168] (a) Research objectives
[1169] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the LU-01-0251 PDX model in Balb / c nude mice.
[1170] (b) Experimental design
[1171]
[1172] a. For all mice in this group, the dosing schedule from day 0 to day 70 was maintained, and then BCY6136, 3 mg / kg, qw, was re-administered to mouse 3-2 and mouse 3-4 from day 77, while the treatment was suspended for the other 3 mice. For all mice in this group, the dosing schedule was maintained from day 0 to day 56.
[1173] b. For all mice in this group, the dosing schedule was maintained from day 0 to day 70.
[1174] (c) Experimental methods and procedures
[1175] (i) Tumor inoculation
[1176] Each mouse was inoculated subcutaneously on the right flank with tumor fragments of LU-01-0251 (approximately 30 mm 3 ) to form a tumor. When the average tumor volume reached 960mm 3 Treatment was started at 1:00 pm for efficacy study. The test article administration and the number of animals in each group are shown in the experimental design table.
[1177] (ii) Preparation of test article preparations
[1178]
[1179] (iii) Sample collection
[1180] Tumors from mouse #3-2 were harvested for FFPE on day 94. Tumors from mice #5-2 and 5-3 were harvested on day 140 and embedded in 1 FFPE block.
[1181] (d) Results
[1182] (i) Body weight changes and tumor growth curves
[1183] Body weight and tumor growth curves Fig.15 shown.
[1184] (ii) Tumor volume tracking
[1185] Table 33 shows the mean tumor volumes from day 0 to day 28 after the start of treatment in female Balb / c nude mice bearing LU-01-0251 xenografts.
[1186] Table 33: Tumor Volume Tracking Over Time
[1187]
[1188] (iii) Tumor growth inhibition analysis
[1189] Tumor growth inhibition rates of BCY6136 and ADC in the LU-01-0251 PDX model were calculated based on tumor volume measurements on day 17 after the start of treatment.
[1190] Table 34: Tumor Growth Inhibition Analysis
[1191]
[1192] a. Mean ± SEM;
[1193] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1194] (e) Summary and discussion of results
[1195] In this study, the therapeutic effects of BCY6136 and ADC were evaluated in the LU-01-0251 PDX model. The measured body weight and tumor volume at different time points for all treatment groups are shown in Fig.15 and Tables 33 and 34.
[1196] In this study, when the mean tumor volume reached 960 mm 3 On day 17 after the start of treatment, the average tumor volume of mice treated with empty vector reached 2301mm 3 . BCY6136, 1mg / kg, qw (TV=1672mm 3 , TGI = 47.0%, p > 0.05) did not show significant antitumor activity. BCY6136, 2 mg / kg, qw (TV = 398 mm 3 , TGI = 142.1%, p < 0.001) and 3 mg / kg, qw (TV = 216 mm 3 , TGI=155.6%, p<0.001) produced a dose-dependent antitumor activity on day 17.
[1197] After 70 days of treatment with BCY6136, 2 mg / kg, qw, 3 of the 5 mice showed complete tumor regression, and the other 2 mice showed obvious tumor recurrence from day 42 to day 77. The two recurrent tumors were then further treated with BCY6136, 3 mg / kg, qw starting on day 7, and one of the tumors showed obvious tumor regression, while the other showed resistance to treatment.
[1198] After treatment with BCY6136 at 3 mg / kg, qw for 56 days, all mice in this group showed complete tumor regression.
[1199] ADC, 3 mg / kg, qw (TV = 1143 mm 3 , TGI = 86.3%, p < 0.01) on the 17th day
[1200] Showing significant anti-tumor activity, after another 53 days of treatment, these mice exhibited further tumor regression, but not complete regression.
[1201] In this study, some mice showed sudden weight loss, which may be related to the long-term feeding of immunodeficient mice.
[1202] Study 12: BCY6033, BCY6136, BCY6082 and BCY6031 in LU-01-0046 NSCLC of Balb / c nude mice In vivo efficacy studies in PDX models
[1203] (a) Research objectives
[1204] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6033, BCY6136, BCY6082, and BCY6031 in large LU-01-0046 PDX tumors in Balb / c nude mice.
[1205] (b) Experimental design
[1206]
[1207] (c) Experimental methods and procedures
[1208] (i) Tumor inoculation
[1209] Each mouse was inoculated subcutaneously on the right flank with tumor fragments LU-01-0046 (approximately 30 mm 3 ) to form tumors. For BT17BDC, when the average tumor volume reached 955mm 3 Treatment was initiated when the mean tumor volume reached 1039 mm for the BCY study. 3 The treatment was started at 1 hr. The test article administration and the number of animals in each group are shown in the experimental design table.
[1210] (ii) Preparation of test article preparation
[1211]
[1212] (d) Results
[1213] (i) Body weight changes and tumor growth curves
[1214] Body weight and tumor growth curves Fig.16 shown.
[1215] (ii) Tumor volume tracking
[1216] Table 35 shows the mean tumor volume over time in female Balb / c nude mice bearing LU-01-0046.
[1217] Table 35: Tumor volume tracking over time (BCY selection)
[1218]
[1219]
[1220] Note: For Groups 3, 5, 7, and 9, tumor volume tracking after day 22 is not shown.
[1221] (iii) Tumor growth inhibition analysis
[1222] Tumor growth inhibition of the test articles in the LU-01-0046 PDX model was calculated based on tumor volumes measured on days 22 and 28 after the start of treatment in both parts of the study.
[1223] Table 36: Tumor Growth Inhibition Analysis (BCY Part, on Day 22)
[1224]
[1225] a. Mean ± SEM;
[1226] b. Tumor growth inhibition was calculated by dividing the mean tumor volume of the treated group by the mean tumor volume of the control group (T / C).
[1227] *Some groups were terminated before day 22 and tumor size was calculated using the exponential growth equation as follows:
[1228] Empty vector group: Y = 995.4 × exp (0.1134 × X).
[1229] BCY6082, 1 mpk group: Y = 939.1 × exp (0.1128 × X).
[1230] BCY6033, 1 mpk group: Y = 846.6 × exp (0.0945 × X).
[1231] BCY6136, 1 mpk group: Y = 855.0 × exp (0.0974 × X).
[1232] ADC, 3mpk group: Y = 757.4 × exp (0.1312 × X).
[1233] (e) Summary and discussion of results
[1234] In this study, the therapeutic efficacy of the test article in large LU-01-0046 tumors was evaluated. Fig.16 Tables 35 and 36 show the body weights and tumor volumes measured at various time points for all treatment groups.
[1235] In the BCY study, the mean tumor size of empty vector-treated mice calculated on day 22 was 6186 mm 3 1 mg / kg of BCY6082, BCY6033, BCY6136 and 3 mg / kg of ADC were isolated from tumors with a size of 1000 mm 3 When treatment was initiated, no significant antitumor activity was demonstrated.
[1236] BCY6082(TV=1999mm 3, TGI=81.2%, p<0.01), BCY6033 (TV=88mm 3 ,
[1237] TGI=118.6%, p<0.001), BCY6136 (TV=233mm 3 , TGI=115.6%, p<0.001)
[1238] and BCY6031(TV=115mm 3 , TGI=110.2%, p<0.001) produced significant antitumor activity at 3 mg / kg. Among them, BCY6033 and BCY6136 completely eliminated 2 / 5 and 4 / 5 tumors.
[1239] Study 13: In vivo efficacy of BCY6136 in Balb / c nude mice bearing the LU-01-0046 NSCLC PDX model
[1240] (a) Research objectives
[1241] The aim of this study was to evaluate the in vivo therapeutic efficacy of BCY6136 in Balb / c nude mice bearing the LU-01-0046 NSCLC PDX model.
[1242] (b) Experimental design
[1243]
[1244] Note: When the average tumor volume exceeds 2000mm 3 Each group was terminated and tumors were collected for FFPE: Group 1 at PG-D14, Group 5 at PG-D18, Groups 2&6 at PG-D21, and Groups 3&4 at PG-D31.
[1245] (c) Experimental methods and procedures
[1246] (i) Tumor inoculation
[1247] Each mouse was inoculated subcutaneously on the right flank with a tumor fragment (approximately 30 mm 3 ) was used to form tumors. When the average tumor volume reached about 198 mm 3 The treatment was started at 1 hr. The test article administration and the number of animals in each group are shown in the experimental design table.
[1248] (ii) Preparation of test article preparation
[1249]
[1250]
[1251] NOTE: Dosage preparations are often freshly prepared.
[1252] (iii) Sample collection
[1253] When the average tumor volume exceeds 2000 mm 3 Groups were terminated at PG-D14, and tumors were collected for FFPE after the last measurement: Group 1 at PG-D14, Group 5 at PG-D18, Groups 2&6 at PG-D21, and Groups 3&4 at PG-D31.
[1254] (d) Results
[1255] (i) Body weight changes and tumor growth curves
[1256] Body weight and tumor growth curves Fig.17 shown.
[1257] (ii) Tumor volume tracking
[1258] Table 37 shows the mean tumor volume over time in female Balb / c nude mice bearing the LU-01-0046 NSCLC PDX model.
[1259] Table 37: Tumor volume tracking over time (mm 3 )
[1260]
[1261] (iii) Tumor growth inhibition analysis
[1262] The tumor growth inhibition rate of the test articles in Balb / c nude mice bearing the LU-01-0046 PDX model was calculated based on the tumor volume measured at PG-D14.
[1263] Table 38: Tumor Growth Inhibition Analysis
[1264]
[1265] a. Mean ± SEM.
[1266] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1267] c. Calculate the TGI of each group using the following formula: TGI (%) = [1-(T i -T0) / (V i -V0)]×100
[1268] (e) Summary and discussion of results
[1269] In this study, the therapeutic efficacy of the test article was evaluated in the LU-01-0046 PDX model. Fig.17The measured body weights and tumor volumes for all treatment groups at various time points are shown in Tables 37 and 38.
[1270] The average tumor size of mice treated with empty vector reached 2307 mm at PG-D14. 3 BCY6136 at 1mg / kg (TV = 1058mm 3 , TGI=59.1%, p<0.05), 2mg / kg (TV=264mm 3 , TGI = 97.0%, p < 0.001) and 3 mg / kg (TV = 26 mm 3 ADC showed dose-dependent antitumor activity at 3mg / kg and 5mg / kg (p>0.05). In this study, the body weight of all animals in this group was maintained well.
[1271] Study 14: BCY6033, BCY6136, BCY6082, BCY6173, BCY6175 and BCY6031 in Balb / c nude mice LU-01-0046 In vivo efficacy study in NSCLC PDX models
[1272] (a) Research objectives
[1273] The purpose of this study was to evaluate the in vivo antitumor efficacy of the test article in the LU-01-0046 NSCLC PDX model in Balb / c nude mice.
[1274] (b) Experimental design
[1275]
[1276]
[1277] (c) Experimental methods and procedures
[1278] (i) Tumor inoculation
[1279] Each mouse was inoculated subcutaneously on the right flank with tumor fragments LU-01-0046 (approximately 30 mm 3 ) for tumor formation. When the mean tumor volume in Part 1 reached 200 mm 3 Treatment was started at 14:50 pm, and the mean tumor volume in part 2 reached 192 mm 3 The treatment was started at 1 hr. The experimental design table shows the test article administration and the number of animals in each group.
[1280] (ii) Preparation of test article preparations
[1281]
[1282] (d) Results
[1283] (i) Body weight changes and tumor growth curves
[1284] Body weight and tumor growth curves Figures 18 to 22 shown.
[1285] (ii) Tumor volume tracking
[1286] Tables 39 and 40 show the mean tumor volumes in female Balb / c nude mice bearing LU-01-0046 on day 21 after the start of treatment.
[1287] Table 39: Tumor volume tracking over time (Part 1)
[1288]
[1289] Table 40: Tumor volume tracking over time (Part 2)
[1290]
[1291] (iii) Tumor growth inhibition analysis
[1292] The tumor growth inhibition rate of the test articles in the LU-01-0046 PDX model was calculated based on the tumor volume measurements on day 21 after the start of treatment.
[1293] Table 41: Tumor Growth Inhibition Assay (Part 1)
[1294]
[1295]
[1296] a. Mean ± SEM; b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treatment group by the group mean tumor volume of the control group (T / C).
[1297] Table 42: Tumor Growth Inhibition Assay (Part 2)
[1298]
[1299] a. Mean ± SEM; b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treatment group by the group mean tumor volume of the control group (T / C).
[1300] (e) Summary and discussion of results
[1301] In this study, the therapeutic efficacy of the test article was evaluated in the LU-01-0046 PDX model. Figures 18 to 22 Tables 39 to 42 show the measured body weights and tumor volumes for all treatment groups at various time points.
[1302] In the first part of the study, the mean tumor size of mice treated with empty vector reached 2551 mm on day 21 after the start of treatment. 3 .
[1303] BCY6033, 1 / 2mg / kg, qw (TV=1285mm 3 , TGI = 53.9%, p < 0.001) and
[1304] BCY6136, 1 / 2mg / kg, qw (TV=1285mm 3 , TGI = 53.9%, p < 0.001) produced significant antitumor activity but did not show any tumor regression. BCY6033, 3 mg / kg, qw (TV = 0 mm 3 , TGI = 108.6%, p < 0.001) and BCY6136, 3 mg / kg, qw (TV = 0 mm 3 , TGI = 108.5%, p < 0.001) completely eliminated tumors, and in the 3 mg / kg BCY6033 and BCY6136 groups, 1 out of 5 tumors showed regrowth after dosing was suspended, and when dosing was resumed, the tumors were resistant to BCY6033 or BCY6136 treatment. The remaining tumors in the BCY6033 and BCY6136 groups (4 / 5 in each group) did not regrow after 80 days of dosing.
[1305] BCY6082, 1mg / kg, qw (TV=1826mm 3 , TGI = 30.8%, p < 0.05) and 3 mg / kg,
[1306] qw(TV=1042mm 3 , TGI=64.2%, p<0.001) produced dose-dependent antitumor activity but did not show tumor regression.
[1307] In the second part of the study, the average tumor size of mice treated with empty vector reached 2342 mm on day 21 after the start of treatment. 3 . BCY6173, 1mg / kg, qw (TV=2151mm 3 , TGI = 8.9%, p > 0.05) did not show antitumor activity. BCY6173, 3 mg / kg, qw (TV = 890 mm 3 , TGI=67.5%, p<0.05) produced significant anti-tumor activity.
[1308] BCY6175, 3mg / kg, qw (TV=0mm3 , TGI = 108.9%, p < 0.001) in the 14th
[1309] 4 / 5 tumors were completely eliminated in 24 days. BCY6031, 3 mg / kg, qw (TV = 874 mm 3 , TGI=68.2%, p<0.05) produced significant antitumor activity but did not show any tumor regression.
[1310] Study 15: In vivo efficacy study of BCY6136 in the LU-01-0412 NSCLC PDX model in Balb / c nude mice
[1311] (a) Research objectives
[1312] The aim of this project is to evaluate the in vivo therapeutic efficacy of BCY6136 in the LU-01-0412 NSCLC PDX model in BALB / c nude mice.
[1313] (b) Experimental design
[1314]
[1315] (c) Experimental methods and procedures
[1316] (i) Tumor inoculation
[1317] Each mouse was inoculated subcutaneously on the right flank with LU-01-0412 tumor fragments (approximately 30 mm 3 ) for tumor formation. When the average tumor volume reached 159mm 3 The animals were randomly divided into groups at 1:10. The experimental design table shows the test article administration and the number of animals in each group.
[1318] (ii) Preparation of test article preparations
[1319]
[1320] (iii) Sample collection
[1321] Plasma was collected from 3 additional mice treated with empty vector and BCY6136, BCY8245, and BCY8781 at 30 minutes and 24 hours after dosing. Tumors were collected from 3 additional mice treated with empty vector and BCY6136, BCY8245, and BCY8781 at 24 hours after dosing.
[1322] (d) Results
[1323] (i) Body weight changes and tumor growth curves
[1324] Body weight and tumor growth curves Fig.23 shown.
[1325] (ii) Tumor volume tracking
[1326] Table 43 shows the mean tumor volume over time in female BALB / c nude mice bearing LU-01-0412 xenografts.
[1327] Table 43: Tumor Volume Tracking Over Time
[1328]
[1329] (iii) Tumor growth inhibition analysis
[1330] Tumor growth inhibition rates of BCY6136, BCY8245, and BCY8781 in the LU-01-0412 xenograft model were calculated based on tumor volume measurements on day 32 after the start of treatment.
[1331] Table 44: Tumor Growth Inhibition Analysis
[1332]
[1333] a. Mean ± SEM;
[1334] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1335] (e) Summary and discussion of results
[1336] In this study, the therapeutic effects of BCY6136, BCY8245, and BCY8781 were evaluated in the LU-01-0412 xenograft model. The body weight and tumor volume measured at different time points for all treatment groups are shown in Fig.23 and in Tables 43 and 44.
[1337] On day 32 after the start of treatment, the average tumor volume of mice treated with empty vector reached 1104 mm 3 . BCY6136, 1mg / kg, qw*4 (TV=758mm 3 , TGI = 36.7%, p < 0.05) and 3 mg / kg, qw*4 (TV = 416 mm 3 , TGI = 72.9%, p < 0.001) produced dose-dependent antitumor activity, but did not show any tumor regression. BCY8245, 3 mg / kg, qw*4 (TV = 1 mm 3 , TGI=116.8%, p<0.001) and BCY8781, 3mg / kg, qw*4 (TV=12mm 3, TGI=115.6%, p<0.001) significantly regressed the tumors. On day 32, 5 of 6 tumors treated with BCY8245, 3 mg / kg and 2 of 6 tumors treated with d BCY8781, 3 mg / kg were completely eliminated.
[1338] In this study, animals in all groups maintained good body weight.
[1339] Study 16: In vivo efficacy study of BCY6136 in the LU-01-0486 PDX model of Balb / c nude mice
[1340] (a) Research objectives
[1341] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the LU-01-0486 PDX model in Balb / c nude mice.
[1342] (b) Experimental design
[1343]
[1344] (c) Experimental methods and procedures
[1345] (i) Tumor inoculation
[1346] Each mouse was inoculated subcutaneously on the right flank with tumor fragments LU-01-0486 (approximately 30 mm 3 ) for tumor formation. When the average tumor volume reached 180 mm 3 Treatment was started at 5 ℃ for efficacy study. The test article administration and the number of animals in each group are shown in the experimental design table.
[1347] (ii) Preparation of test article preparations
[1348]
[1349]
[1350] (d) Results
[1351] (i) Body weight changes and tumor growth curves
[1352] Body weight and tumor growth curves Fig.24 shown.
[1353] (ii) Tumor volume tracking
[1354] Table 45 shows the mean tumor volume in female Balb / c nude mice bearing LU-01-0486 xenografts at day 14 after the start of treatment.
[1355] Table 45: Tumor Volume Tracking Over Time
[1356]
[1357] (iii) Tumor growth inhibition analysis
[1358] Tumor growth inhibition by BCY6136 in the LU-01-0486 PDX model was calculated based on tumor volume measurements on day 14 after the start of treatment.
[1359] Table 46: Tumor Growth Inhibition Analysis
[1360]
[1361] a. Mean ± SEM; b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treatment group by the group mean tumor volume of the control group (T / C).
[1362] (e) Summary and discussion of results
[1363] In this study, the therapeutic effect of BCY6136 was evaluated in the LU-01-0486 PDX model. The body weight and tumor volume measured at different time points for all treatment groups are shown in Fig.24 and Tables 45 and 46.
[1364] In this study, the average tumor volume of mice treated with empty vector reached 651 mm on day 14 after the start of treatment. 3 BCY6136 at 1mg / kg, qw(TV=638mm 3 , TGI = 3.0%, p > 0.05) and 2 mg / kg, qw (TV = 645 mm 3 , TGI = 1.2%, p > 0.05) did not show any antitumor activity. BCY6136 at 3 mg / kg, qw (TV = 449 mm 3 , TGI=43.1%, p>0.05) produced a slight antitumor activity, which was not statistically significant.
[1365] Study 17: Effects of BCY6033, BCY6136, and BCY6082 on the treatment of MDA-MB-231-luc xenografts in Balb / c nude mice In vivo efficacy testing in plants
[1366] (a) Research objectives
[1367] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6033, BCY6136, and BCY6082 in the treatment of the MDA-MB-231-luc xenograft model in Balb / c nude mice.
[1368] (b) Experimental design
[1369]
[1370] (c) Experimental methods and procedures
[1371] (i) Cell culture
[1372] Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1373] (ii) Tumor inoculation
[1374] Each mouse was subcutaneously inoculated on the right side with 0.1 ml of PBS (containing 0.1 ml of matrigel) containing MDA-MB-231-luc tumor cells (10×10^6) to form tumors. When the average tumor volume reached 159 mm 3 At 1 , 36 animals were randomly divided into groups. The experimental design table shows the test article administration and the number of animals in each group.
[1375] (iii) Preparation of test article preparation
[1376]
[1377]
[1378] (iv) Sample collection
[1379] On PG-D24, we collected and fixed tumors from groups 1, 8, and 9 for FFPE.
[1380] At PG-D33, we collected and fixed tumors from groups 2 and 5 for FFPE.
[1381] At the end of the study, we collected and fixed tumors from groups 3, 4, 6, and 7 for FFPE.
[1382] (d) Results
[1383] (i) Body weight changes and tumor growth curves
[1384] Body weight and tumor growth Figure 25 to Figure 27 shown.
[1385] (ii) Tumor volume tracking
[1386] Tables 47-49 show the mean tumor volume over time in female Balb / c nude mice bearing MDA-MB-231-luc xenografts.
[1387] Table 47: Tumor Volume Tracking (PG-D0 to PG-D17)
[1388]
[1389] Table 48: Tumor Volume Tracking (PG-D19 to PG-D33)
[1390]
[1391]
[1392] Table 49: Tumor Volume Tracking (PG-D35 to PG-D47)
[1393]
[1394] (iii) Tumor growth inhibition analysis
[1395] Tumor growth inhibition rates of BCY6033, BCY6136, and BCY6082 in the MDA-MB-231-luc xenograft model were calculated based on tumor volume measurements on day 21 after the start of treatment.
[1396] Table 50: Tumor Growth Inhibition Analysis
[1397]
[1398]
[1399] a. Mean ± SEM.
[1400] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1401] (e) Summary and discussion of results
[1402] In this study, the therapeutic efficacy of BCY6033, BCY6136, and BCY6082 was evaluated in the MDA-MB-231-luc xenograft model. Figures 25 to 27 Tables 47 to 50 show the body weights and tumor volumes measured at various time points for all treatment groups.
[1403] On day 21, the average tumor size of empty vector-treated mice reached 1661 mm 3 . BCY6033, 1mg / kg (TV=880mm 3 , TGI=52.0%, p<0.001), 2mg / kg (TV=67mm 3 , TGI = 106.1%, p < 0.001) and 3 mg / kg (TV = 22 mm 3, TGI = 109.1%, p < 0.001) produced a dose-dependent antitumor activity. BCY6033, 2 mg / kg and 3 mg / kg, was effective in regressing tumors, but from day 21 onwards, the tumors showed significant regrowth.
[1404] BCY6136, 1 mg / kg (TV = 994 mm 3 , TGI = 44.4%, p < 0.01) showed moderate antitumor activity, BCY6136, 2 mg / kg (TV = 33 mm 3 , TGI = 108.4%, p < 0.001) and 3 mg / kg (TV = 132 mm 3 , TGI=101.1%, p<0.001) produced effective antitumor activity, but the tumors showed significant regrowth from day 28 onwards.
[1405] BCY6082, 2 mg / kg (TV=1287 mm3, TGI=24.9%, p>0.05) did not show obvious antitumor activity, while BCY6082, 5 mg / kg (TV=218 mm3, TGI=96.1%, p<0.001) produced significant antitumor activity.
[1406] In this study, one mouse treated with 2 mg / kg BCY6136 lost more than 15% of its body weight during treatment, while the other mice maintained their weight well.
[1407] Study 18: In vivo efficacy testing of BCY6136 in the EMT-6 syngeneic model of BALB / c mice
[1408] (a) Research objectives
[1409] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the EMT-6 syngeneic model of BALB / c mice.
[1410] (b) Experimental design
[1411]
[1412] a. The injection volume for each mouse was 10 ml / kg.
[1413] b. From day 14, the dose of Group 3 and Group 4 was changed to 5 mpk and 3 mpk.
[1414] (c) Experimental methods and procedures
[1415] (i) Cell culture
[1416] EMT-6 tumor cells were maintained in vitro in EMEM medium supplemented with 10% heat-inactivated fetal bovine serum in a monolayer culture at 37°C in an atmosphere of 5% CO2 in air. Tumor cells were routinely subcultured twice a week by trypsin-EDTA treatment. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1417] (ii) Tumor inoculation
[1418] Each mouse was inoculated subcutaneously on the right side of the uterus with 0.1 ml of EMT-6 tumor cells (5 x 10 6 )PBS was used to form tumors. When the average tumor volume reached 75 mm 3 At 44 times, 44 animals were randomly divided into groups. The experimental design table shows the test article administration and the number of animals in each group.
[1419] (iii) Preparation of test article preparation
[1420]
[1421] (iv) Sample collection
[1422] Three tumors were collected from spare mice for FACS on day 11. Data provided by the Biological Group.
[1423] (d) Results
[1424] (i) Body weight changes and tumor growth curves
[1425] Body weight and tumor growth curves Fig.28 shown.
[1426] (ii) Tumor volume tracking
[1427] Table 51 shows the mean tumor volume over time in female BALB / c mice bearing the EMT-6 syngeneic gene.
[1428] Table 51: Tumor Volume Tracking Over Time
[1429]
[1430] From day 14, the doses of groups 3 and 4 were changed to 5 mpk and 3 mpk.
[1431] (iii) Tumor growth inhibition analysis
[1432] Tumor growth inhibition rate of BCY6136 in the EMT-6 syngeneic model was calculated based on tumor volume measurements on day 21 after the start of treatment.
[1433] Table 52: Tumor Growth Inhibition Analysis
[1434]
[1435] a. Mean ± SEM.
[1436] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1437] c. From day 14, the dose of groups 3 and 4 was changed to 5 mpk and 3 mpk.
[1438] (e) Summary and discussion of results
[1439] In this study, the therapeutic efficacy of BCY6136 was evaluated in the EMT-6 syngeneic model. Fig.28 Tables 51 and 52 show the body weights and tumor volumes measured at various time points for all treatment groups.
[1440] The average tumor size of empty vector-treated mice reached 1499 mm on day 21. 3 . BCY6136, 3mg / kg, qw (TV=561mm 3 , TGI = 66.2%, p < 0.05) showed significant antitumor activity. BCY6136, 1 / 5 mg / kg, qw (TV = 1272 mm 3 , TGI = 16.1%, p>0.05) and BCY6136, 0.3 / 3 mg / kg, qw (TV = 1394 mm 3 , TGI=7.4%, p>0.05) did not show any antitumor activity.
[1441] The dose was changed to 5 mpk and 3 mpk for groups 3 and 4 from day 14. Tumor ulcers were found on day 14 in mice 3-5 and antibiotic cream was applied to the mice. All mice maintained good body weight in this study.
[1442] Study 19: In vivo efficacy study of BCY6136 in treating NCI-N87 xenografts in Balb / c nude mice
[1443] (a) Research objectives
[1444] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the treatment of NCI-N87 xenografts in Balb / c nude mice.
[1445] (b) Experimental design
[1446]
[1447] (c) Experimental methods and procedures
[1448] (i) Cell culture
[1449] NCI-N87 tumor cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in an atmosphere of 5% CO2 in air. Tumor cells were routinely subcultured twice a week. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1450] (ii) Tumor inoculation
[1451] Each mouse was inoculated subcutaneously on the right side of the lung with 0.2 ml of NCI-N87 tumor cells (10 x 10 6 ) and Matrigel (1:1) in PBS were used to form tumors. When the average tumor volume reached approximately 176 mm 3 At 14:00, animals were randomized and treatment started. The experimental design table shows the test article administration and the number of animals in each group.
[1452] (iii) Preparation of test article preparation
[1453]
[1454] (d) Results
[1455] (i) Body weight changes and tumor growth curves
[1456] Body weight and tumor growth curves Fig.29 shown.
[1457] (ii) Tumor volume tracking
[1458] Table 53 shows the mean tumor volume over time in female Balb / c nude mice bearing NCI-N87 xenografts.
[1459] Table 53: Tumor Volume Tracking Over Time
[1460]
[1461] (iii) Tumor growth inhibition analysis
[1462] Tumor growth inhibition by BCY6136 in NCI-N87 xenografts was calculated based on tumor volume measurements at day 30 after the start of treatment.
[1463] Table 54: Tumor Growth Inhibition Analysis
[1464]
[1465] a. Mean ± SEM.
[1466] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1467] (e) Summary and discussion of results
[1468] In this study, the therapeutic effect of BCY6136 was evaluated in the NCI-N87 model. The body weight and tumor volume measured at different time points for all treatment groups are shown in Fig.29 and in Tables 53 and 54.
[1469] The mean tumor size of the mice treated with the vehicle-free medium reached 1465 mm on day 30. 3 . BCY6136, 1mg / kg, qw (TV=425mm 3 , TGI=80.7%, p<0.001) and 2mg / kg, qw (TV=210mm 3 , TGI = 97.4%, p < 0.001) produced significant antitumor activity in a dose-dependent manner, BCY6136, 3 mg / kg, qw (TV = 201 mm 3 , TGI=98.1%, p<0.001) showed an antitumor activity comparable to that of 2 mpk of BCY6136.
[1470] In this study, no significant weight loss was observed in any of the groups during treatment.
[1471] Study 20: In vivo efficacy study of BCY6136 in the treatment of SK-OV-3 xenografts in Balb / c nude mice
[1472] (a) Research objectives
[1473] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the treatment of SK-OV-3 xenografts in Balb / c nude mice.
[1474] (b) Experimental design
[1475]
[1476] (c) Experimental methods and procedures
[1477] (i) Cell culture
[1478] SK-OV-3 tumor cells were maintained in McCoy 5a medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in an atmosphere of 5% CO2 in air. Tumor cells were routinely subcultured twice a week. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1479] (ii) Tumor inoculation
[1480] Each mouse was inoculated subcutaneously on the right side of the lung with 0.2 ml of SK-OV-3 tumor cells (10 x 10 6 ) and Matrigel (1:1) in PBS were used to form tumors. When the average tumor volume reached approximately 186 mm 3 At 14:00, animals were randomized and treatment started. The experimental design table shows the test article administration and the number of animals in each group.
[1481] (iii) Preparation of test article preparation
[1482]
[1483] (d) Results
[1484] (i) Body weight changes and tumor growth curves
[1485] Body weight and tumor growth curves Fig.30 shown.
[1486] (ii) Tumor volume tracking
[1487] Table 55 shows the mean tumor volume over time in female Balb / c nude mice bearing SK-OV-3 xenografts.
[1488] Table 55: Tumor Volume Tracking Over Time
[1489]
[1490] (iii) Tumor growth inhibition analysis
[1491] Tumor growth inhibition by BCY6136 in SK-OV-3 xenografts was calculated based on tumor volume measurements on day 28 after the start of treatment.
[1492] Table 56: Tumor Growth Inhibition Analysis
[1493]
[1494] a. Mean ± SEM.
[1495] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1496] (e) Summary and discussion of results
[1497] In this study, the therapeutic efficacy of BCY6136 was evaluated in the SK-OV-3 model. Fig.30Tables 55 and 56 show the body weight and tumor volume measured at different time points for all treatment groups.
[1498] The average tumor size of the vector-treated mice reached 1560 mm on day 28. 3 . ADC, 3mg / kg, qw (TV=684mm 3 , TGI = 63.8%, p < 0.01) showed moderate antitumor efficacy. BCY6136, 1 mg / kg, qw (TV = 1035 mm 3 , TGI = 38.1%, p>0.05) did not show significant antitumor activity. BCY6136, 2 mg / kg, qw (TV = 277 mm 3 , TGI = 93.3%, p < 0.001) and 3 mg / kg, qw (TV = 254 mm 3 , TGI=95.0%, p<0.001) produced significant antitumor activity.
[1499] In this study, no significant weight loss was found in any group during treatment.
[1500] Study 21: In vivo efficacy study of BCY6136 in the treatment of OE21 xenografts in Balb / c nude mice
[1501] (a) Research objectives
[1502] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 in the treatment of OE21 xenografts in Balb / c nude mice.
[1503] (b) Experimental design
[1504]
[1505] (c) Experimental methods and procedures
[1506] (i) Cell culture
[1507] OE21 tumor cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in an atmosphere of 5% CO2 in air. Tumor cells were routinely subcultured twice a week. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1508] (ii) Tumor inoculation
[1509] Each mouse was inoculated subcutaneously on the right flank with 0.2 ml of OE21 tumor cells (5 x 10 6 ) and Matrigel (1:1) in PBS were used to form tumors. When the average tumor volume reached approximately 157 mm3 At 14:00, animals were randomized and treatment started. The experimental design table shows the test article administration and the number of animals in each group.
[1510] (iii) Preparation of test article preparation
[1511]
[1512] (d) Results
[1513] (i) Body weight changes and tumor growth curves
[1514] Body weight and tumor growth curves Fig.31 shown.
[1515] (ii) Tumor volume tracking
[1516] Table 57 shows the mean tumor volume over time in female Balb / c nude mice bearing OE21 xenografts.
[1517] Table 57: Tumor Volume Tracking Over Time
[1518]
[1519] (iii) Tumor growth inhibition analysis
[1520] Tumor growth inhibition rate of BCY6136 in OE21 xenografts was calculated based on tumor volume measurements on day 23 after the start of treatment.
[1521] Table 58: Tumor Growth Inhibition Analysis
[1522]
[1523] a. Mean ± SEM.
[1524] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1525] (e) Summary and discussion of results
[1526] In this study, the therapeutic effect of BCY6136 was evaluated in the OE21 model. The body weight and tumor volume measured at different time points for all treatment groups are shown in Fig.31 and Tables 57 and 58.
[1527] On day 23, the average tumor size of empty vector-treated mice reached 1586 mm 3 . BCY6136, 1mg / kg, qw (TV=1155mm 3, TGI = 30.4%, p < 0.05) showed slight antitumor activity. BCY6136, 2 mg / kg, qw (TV = 537 mm 3 , TGI=73.4%, p<0.001) and 3mg / kg, qw (TV=489mm 3 , TGI=76.7%, p<0.001) produced significant antitumor activity.
[1528] In this study, no significant weight loss was observed in any of the groups during treatment.
[1529] Study 22: In vivo efficacy of BCY6136 and BCY6082 in treating MOLP-8 xenografts in CB17-SCID mice Effectiveness Test
[1530] (a) Research objectives
[1531] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY6136 and BCY6082 in the treatment of MOLP-8 xenografts in CB17-SCID mice.
[1532] (b) Experimental design
[1533]
[1534] (c) Experimental methods and procedures
[1535] (i) Cell culture
[1536] MOLP-8 tumor cells were maintained in RPMI-1640 as monolayer cultures in vitro at 37°C in an atmosphere of 5% CO2 in air, supplemented with 20% heat-inactivated fetal bovine serum. Tumor cells were routinely subcultured by trypsin-EDTA treatment. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1537] (ii) Tumor inoculation
[1538] Each mouse was inoculated subcutaneously on the right side of the lung with 0.2 ml of MOLP-8 tumor cells (10 x 10 6 ) in PBS (containing 50% Matrigel) for tumor formation. When the average tumor volume reached approximately 141 mm 3 At 1 , 36 animals were randomly divided into groups. The experimental design table shows the test article administration and the number of animals in each group.
[1539] (iii) Preparation of test article preparation
[1540]
[1541] (d) Results
[1542] (i) Body weight changes and tumor growth curves
[1543] Body weight and tumor growth curves Fig.32 and 33 shown.
[1544] (ii) Tumor volume tracking
[1545] Table 59 shows the mean tumor volume over time in female CB17-SCID mice bearing MOLP-8 xenografts.
[1546] Table 59: Tumor Volume Tracking Over Time
[1547]
[1548] (iii) Tumor growth inhibition analysis
[1549] The tumor growth inhibition rate of BCY6136 and BCY6082 in the MOLP-8 xenograft model was calculated based on the tumor volume measurements on day 14 after the start of treatment.
[1550] Table 60: Tumor Growth Inhibition Analysis
[1551]
[1552] a. Mean ± SEM.
[1553] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1554] (e) Summary and discussion of results
[1555] In this study, the therapeutic effects of BCY6136 and BCY6082 were evaluated in the MOLP-8 xenograft model. Fig.32 and 33 Tables 59 and 60 show the body weight and tumor volume measured at various time points for all treatment groups.
[1556] The average tumor size of the vector-free mice reached 2528 mm on day 14. 3 . BCY6136, 1mg / kg (TV=1146mm 3 , TGI=45.5%, p>0.05), 2mg / kg (TV=1218mm 3 , TGI = 54.9%, p < 0.05) and 3 mg / kg (TV = 938 mm 3, TGI=66.7%, p<0.01) produced a dose-dependent antitumor activity, but all doses failed to induce regression of MOLP-8 xenograft tumors.
[1557] BCY6082, 1 mg / kg (TV = 2296 mm 3 , TGI=9.8%,p>0.05) and 2mg / kg (TV
[1558] =1554mm 3 , TGI = 40.8%, p>0.05) did not show significant antitumor activity. BCY6082, 3 mg / kg, significantly inhibited tumor growth (TV = 1321 mm 3 , TGI=50.6%, p<0.05), but did not cause tumor regression in MOLP-8 xenografts.
[1559] In this study, all mice maintained good body weight.
[1560] Study 23: In vivo efficacy testing of BCY in treating HT1080 xenografts in BALB / c nude mice
[1561] (a) Research objectives
[1562] The aim of this study was to evaluate the in vivo antitumor efficacy of BCY in the HT1080 xenograft model in BALB / c nude mice.
[1563] (b) Experimental design
[1564]
[1565]
[1566] Note: n: number of animals; Dosing volume: adjusted according to body weight to 10 μl / g.
[1567] (c) Experimental methods and procedures
[1568] (i) Cell culture
[1569] HT1080 tumor cells were maintained in culture medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in an atmosphere of 5% CO2 in air. Tumor cells were routinely subcultured twice a week. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.
[1570] (ii) Tumor inoculation
[1571] Each mouse was inoculated subcutaneously on the right flank with HT1080 tumor cells (5 x 10 6 ) for tumor formation. When the average tumor volume reaches about 150-200mm3 At 14:00, animals were randomized into groups and treatment was started. The experimental design table shows the test article administration and the number of animals in each group.
[1572] (iii) Preparation of test article preparation
[1573]
[1574]
[1575] (d) Results
[1576] (i) Body weight changes and tumor growth curves
[1577] Body weight and tumor growth curves Figures 34 to 42 shown.
[1578] (ii) Tumor volume tracking
[1579] Table 61 shows the mean tumor volume over time in female Balb / c nude mice bearing HT1080 xenografts.
[1580] Table 61: Tumor Volume Tracking Over Time
[1581]
[1582]
[1583] (iii) Tumor growth inhibition analysis
[1584] The tumor growth inhibition rate of BCY in the HT1080 xenograft model was calculated based on the tumor volume measurements on day 14 after the start of treatment.
[1585] Table 62: Tumor Growth Inhibition Analysis
[1586]
[1587]
[1588] a. Mean ± SEM.
[1589] b. Tumor growth inhibition was calculated by dividing the group mean tumor volume of the treated group by the group mean tumor volume of the control group (T / C).
[1590] (e) Summary and discussion of results
[1591] In this study, the therapeutic effect of BCY was evaluated in the HT1080 xenograft model. Figures 34 to 42 Tables 61 and 62 show the body weight and tumor volume measured at various time points for all treatment groups.
[1592] On day 14, the average tumor size of empty vector-treated mice reached 1737 mm 3 .
[1593] BCY6082, 2mg / kg, qw (TV=5mm 3 , TGI=111.1%, p<0.01) and BCY6031,
[1594] 2mg / kg, qw(TV=7mm 3 , TGI=106.8%, p<0.01) showed effective anti-tumor activity.
[1595] BCY6173, 1mg / kg, qw (TV=1074mm 3 , TGI=42.5%, p>0.05), 2mg / kg,
[1596] qw(TV=480mm 3 , TGI=80.6%, p<0.05) and 3mg / kg, qw (TV=7mm 3 , TGI=108.4%, p<0.01) produced dose-dependent antitumor activity.
[1597] BCY6135, 1mg / kg, qw (TV=871mm 3 , TGI=55.5%, p<0.01), 2mg / kg,
[1598] qw(TV=62mm 3 , TGI=107.5%, p<0.001) and 3mg / kg, qw (TV=44mm 3 , TGI=108.6%, p<0.001) produced dose-dependent antitumor activity.
[1599] BCY6033, 3mg / kg, qw (TV=9mm 3 , TGI=110.8%, p<0.001) and 5 mg / kg,
[1600] qw(TV=0mm 3 , TGI=111.4%, p<0.001) showed effective antitumor activity, and 5 mg / kg completely eliminated the tumor on day 14.
[1601] BCY6136, 2mg / kg, qw (TV=345mm 3 , TGI=95.7%, p<0.001), 3mg / kg,
[1602] qw(TV=3mm 3 , TGI=111.2%, p<0.001) and 5mg / kg, qw (TV=2mm 3 , TGI=111.3%, p<0.001) showed effective anti-tumor activity.
[1603] BCY6174, 1mg / kg, qw (TV=1066mm 3 , TGI=43.1%, p<0.05), 2mg / kg,
[1604] qw(TV=532mm 3 , TGI=77.3%, p<0.01) and 3mg / kg, qw (TV=11mm 3 , TGI=110.7%, p<0.001) produced dose-dependent antitumor activity.
[1605] BCY6175, 1mg / kg, qw (TV=769mm 3 , TGI=62.1%, p<0.01), 2mg / kg,
[1606] qw(TV=295mm 3 , TGI=92.5%, p<0.001) and 3mg / kg, qw (TV=11mm 3 , TGI
[1607] =110.8%, p<0.001) produced dose-dependent antitumor activity.
[1608] ADC, 3 mg / kg, qw(TV=0 mm 3 , TGI=111.5%) completely eliminated the tumor on the 14th day.
[1609] Study 24: Correlation between copy number variations (CNVs) and gene expression of EphA2 from multiple tumor types Research
[1610] method
[1611] 1. In cBioPortal( http: / / www.cbioportal.org / ) and search for EPHA2.
[1612] (a) Delete temporary studies.
[1613] (b) Deselect studies with overlapping samples to prevent sampling bias (based on warnings in cBioPortal)—if this is possible, the PanCancer study is generally retained.
[1614] (c) Studies selected for analysis (Table 63).
[1615] Table 63: Studies and units included in the studies analyzed by cBioPortal
[1616]
[1617]
[1618] 2. Export CNV and RNA expression data from cBioPortal.
[1619] 3. Test whether CNVs are statistically significantly associated with changes in EphA2 mRNA expression (log2 not applied).
[1620] (a) Nonparametric Kruskal-Wallis test was run in GraphPad Prism (7.04) and R / R Studio (threshold for significance: p<0.01).
[1621] (i) GraphPad Prism: Set up lists and run unmatched or paired nonparametric tests without assuming a Gaussian distribution.
[1622] (ii) Software packages used in R:
[1623] 1.XLConnect
[1624] 2. dplyr
[1625] 3. Kruskal-Wallis rank sum test: Kruskal.test.
[1626] 4. Multiple comparisons were adjusted in R / Rstudio using Dunn's test (all possible comparisons were included even if n=1 within a group) (significance threshold: p<0.025).
[1627] (a) dunn.test = "bonferonni" using the multiple comparison method.
[1628] result
[1629] The results are shown in Table 64 below. In 41 publicly available datasets collected in cBioPortal, copy number variations (CNVs) and mRNA gene expression of EphA2 were reported, with many cancer types reporting cases with EphA2 shallow-deletion (<2 copies). Although less common, in these same cancer types, a subset of tumors had EphA2 deep deletion (>1 copy deletion or biallelic deletion), EphA2 gain (2-3 copies), or EphA2 amplification (>3 copies). Indications where more than 33% of tumors had shallow or deep deletions of EphA2 included: renal chromophobe cell carcinoma, cholangiocarcinoma, pheochromocytoma and paraganglioma, lung squamous cell carcinoma, breast cancer, rectal cancer, brain low-grade glioma, liver cancer, adrenocortical carcinoma, mesothelioma, esophageal adenocarcinoma, and colon cancer. In contrast, no study showed that >33% of samples had gain or amplification of EphA2. Together these results suggest that loss of EphA2 DNA is present in a variety of indications.
[1630] Approximately one-third of all samples analyzed in the 41 studies harbored an EphA2 CNV. Based on the high percentage of CNVs across the studies, as well as the high percentage of mild deletions in specific tumor types, statistical tests were performed to identify possible correlations between copy number changes and RNA expression. Tumors for each indication were assigned to 1 of 5 categories:
[1631] a) Depth loss;
[1632] b) Mild deficiency;
[1633] c) diploid;
[1634] d) gain; or
[1635] e) Amplification.
[1636] Kruskall-Wallis tests were then performed to test whether the distribution of mRNA expression values for each category differed between categories (P<0.01). For those TCGA datasets with P<0.01, post-hoc testing was performed by calculating the Z statistic and adjusting the P value (Bonferroni) to determine which categories differed from each other. To simplify interpretation, the pairwise comparisons for each indication were reviewed with the comparisons for diploids (although all pairwise P values were calculated). The Kruskall-Wallis p value for 19 / 41 of these studies was less than 0.01, indicating that copy number was statistically significantly associated with RNA expression. Of these 19 studies, 17 had a Bonferroni adjusted P<0.025 for diploids versus mild deletions, indicating that decreased EphA2 mRNA expression was associated with decreased EphA2 copy number. Of these 19 studies, only two had a Bonferroni adjusted P<0.025 for diploids versus gains, and both were breast cancer studies. Furthermore, in one of these breast cancer studies (invasive breast carcinoma (TCGA, PanCancer Atlas)), the Bonferroni-adjusted P < 0.025 for both diploidy versus mild loss and diploidy versus gain, suggesting that copy number variation may have a strong effect on EphA2 RNA expression in breast cancer.
[1637] The central dogma of genetics suggests that a reduction in EphA2 copy number leads to a reduction in RNA and protein expression. Therefore, the correlation between EphA2 copy number loss and reduced mRNA expression observed in multiple tumor types suggests that EphA2 protein expression may also be reduced. Similarly, the gain in EphA2 copy number in breast cancer associated with increased mRNA expression may also imply an increase in EphA2 protein expression. In addition, in preclinical in vivo models, higher EphA2 protein expression (measured by FACS) was associated with increased efficacy (measured by tumor volume) of certain EphA2 bicyclic drug conjugates of the present invention. In summary, if copy number changes associated with changes in mRNA expression do predict protein expression levels, tumor patients with EphA2 copy number loss may be less likely to respond to the EphA2 bicyclic drug conjugates of the present invention. Similarly, if tumor patients have a copy number gain of EphA2 (e.g., breast cancer), these patients are more likely to respond to the EphA2 bicyclic drug conjugates of the present invention. Therefore, if patients are stratified by EphA2 copy number status, this information can be used to exclude and select patients for treatment with the EphA2 bicyclic drug conjugates of the invention to increase efficacy.
[1638]
[1639]
[1640]
[1641]
[1642]
[1643]
[1644]
[1645]
[1646]
Claims
1. A peptide ligand specific for EphA2, comprising a polypeptide and a non-aromatic molecular scaffold, wherein the polypeptide comprises at least three cysteine residues separated by at least two ring sequences, and the non-aromatic molecular scaffold forms covalent bonds with the cysteine residues of the polypeptide to form at least two polypeptide rings on the molecular scaffold.
2. The peptide ligand of claim 1, wherein the loop sequence comprises 2, 3, 5, 6 or 7 amino acids.
3. A peptide ligand according to claim 1 or 2, wherein the loop sequence comprises three cysteine residues separated by two loop sequences, one of which consists of 2 amino acids and the other of which consists of 7 amino acids (such as those listed in Table 4).
4. The peptide ligand according to claim 1 or 2, wherein the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 5 amino acids (such as those listed in Tables 3 and 4).
5. The peptide ligand according to claim 1 or 2, wherein the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 6 amino acids (such as those listed in Tables 3 to 5 and Table 10).
6. A peptide ligand according to claim 1 or 2, wherein the loop sequence comprises three cysteine residues separated by two loop sequences, one of which consists of 7 amino acids and the other of which consists of 3 amino acids (such as those listed in Table 4).
7. A peptide ligand according to claim 1 or 2, wherein the loop sequence comprises three cysteine residues separated by two loop sequences, one of which consists of 6 amino acids and the other of which consists of 7 amino acids (such as those listed in Table 5).
8. The peptide ligand according to any one of claims 1 to 7, wherein the peptide ligand comprises an amino acid sequence selected from the group consisting of: C i -X1-C ii -X2-C iii , wherein X1 and X2 represent amino acid residues between the cysteine residues listed in Tables 3 to 5 and 10, C i , C ii and C iii represent the first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.
9. The peptide ligand according to any one of claims 1 to 8, wherein the peptide ligand comprises an amino acid sequence of one or more peptide ligands listed in one or more of Tables 3 to 5 and Table 10.
10. The peptide ligand according to any one of claims 1 to 8, wherein the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 6 amino acids, and the peptide ligand has the following amino acid sequence: C i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 1); and C i PLVNPLC ii LHPGWTC iii (SEQ ID NO:97); For example: Ci(HyP)LVNPLCiiLHP(D-Asp)W(HArg)Ciii (SEQ ID NO: 1); wherein HyP is hydroxyproline, HArg is homoarginine, Ci, Cii and Ciii represent the first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.
11. The peptide ligand according to claim 10, wherein the loop sequence comprises three cysteine residues separated by two loop sequences, each of which consists of 6 amino acids, and the peptide ligand has the following amino acid sequence: (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 2) (BCY6099; Compound 66); and (β-Ala)-Sar 10 -A(HArg)DC i PLVNPLC ii LHPGWTC iii ((β-Ala)-Sar 10 -(SEQ ID NO:11))(BCY6014;Zone67)! For example: (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO:2)(BCY6099;ZO66); in, Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline.
12. A peptide ligand according to any one of claims 1 to 11, wherein the molecular scaffold is selected from 1,1′,1″″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA), and the peptide ligand is selected from any one of the peptide ligands listed in Table 3, Table 4, Table 5 and Table 10.
13. The peptide ligand according to any one of claims 1 to 11, wherein the molecular scaffold is selected from 1,1′,1″″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA), the peptide ligand is (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO: 2) (BCY6099; Compound 66); and (β-Ala)-Sar 10 -A(HArg)DC i PLVNPLC ii LHPGWTC iii ((β-Ala)-Sar 10 -(SEQ ID NO:11))(BCY6014;Zone67)! For example: (β-Ala)-Sar 10 -A(HArg)DC i (HyP)LVNPLC ii LHP(D-Asp)W(HArg)C iii (SEQ ID NO:2)(BCY6099;ZO66); in, Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline.
14. The peptide ligand according to any one of claims 1 to 13, which is selected from any one of Compounds 1-113 or a pharmaceutically acceptable salt thereof.
15. The peptide ligand according to any one of claims 1 to 13, which is Compound 66 (BCY6099) or Compound 67 (BCY6014), or a pharmaceutically acceptable salt thereof, such as Compound 66 (BCY6099) or a pharmaceutically acceptable salt thereof.
16. The peptide ligand according to any one of claims 1 to 15, wherein the pharmaceutically acceptable salt is selected from the free acid or sodium, potassium, calcium, ammonium salts.
17. The peptide ligand according to any one of claims 1 to 16, wherein the EphA2 is human EphA2.
18. A drug conjugate comprising a peptide ligand according to any one of claims 1 to 17 conjugated to one or more effectors and / or functional groups.
19. The drug conjugate according to claim 18, wherein the cytotoxic agent is selected from DM1 or MMAE.
20. The drug conjugate according to claim 18 or claim 19, further comprising a linker between the peptide ligand and the cytotoxic agent.
21. The drug conjugate of claim 20, wherein the cytotoxic agent is MMAE and the linker is selected from: -Val-Cit-, -Trp-Cit-, -Val-Lys-, -D-Trp-Cit-, -Ala-Ala-Asn-, D-Ala-Phe-Lys- or -Glu-Pro-Cit-Gly-hPhe-Tyr-Leu- (SEQ ID NO: 98).
22. The drug conjugate of claim 21, wherein the cytotoxic agent is MMAE and the linker is -Val-Cit-.
23. The drug conjugate of claim 20, wherein the cytotoxic agent is DM1 and the linker is selected from: -SS-, -SS(SO3H)-, -SS-(Me)-, -(Me)-SS-(Me)-, -SS-(Me2)-, or -SS-(Me)-SO3H-.
24. The drug conjugate according to any one of claims 18 to 23, which is selected from BCY6027, BCY6028, BCY6031 and BCY6032; the BDCs listed in Table 11 or Table 13; or any one of BCY6033, BCY6082, BCY6136 and BCY6173.
25. The drug conjugate according to claim 24, which is selected from any one of BCY6031, BCY6033, BCY6082, BCY6135, BCY6136, BCY6173, BCY6174 and BCY6175.
26. The drug conjugate according to claim 24 or 25, which is BCY6136.
27. A pharmaceutical composition comprising the peptide ligand of any one of claims 1 to 17 or the drug conjugate of any one of claims 18 to 26, and one or more pharmaceutically acceptable excipients.
28. The drug conjugate according to any one of claims 18 to 26, for use in preventing, inhibiting or treating a disease or disorder characterized by overexpression of EphA2 in diseased tissue.
29. The drug conjugate according to any one of claims 18 to 26, for use in preventing, inhibiting or treating cancer.
30. Use of the drug conjugate according to claim 29, wherein the cancer is selected from: prostate cancer, lung cancer (e.g. non-small cell lung cancer (NSCLC)), breast cancer (e.g. triple-negative breast cancer), gastric cancer, ovarian cancer, esophageal cancer, multiple myeloma and fibrosarcoma.
31. A method for preventing, inhibiting or treating cancer, comprising administering the drug conjugate of any one of claims 18 to 26 to a patient in need thereof, wherein the patient is identified as having an increased EphA2 copy number variation (CNV).
